

US012152279B2

(12) United States Patent

Rajasekaran

(10) Patent No.: US 12,152,279 B2

(45) **Date of Patent:** *Nov. 26, 2024

(54) PHOTOACTIVE COMPOUNDS AND METHODS FOR BIOMOLECULE DETECTION AND SEQUENCING

(71) Applicant: Vibrant Holdings LLC, San Carlos,

CA (US)

(72) Inventor: John J. Rajasekaran, Hillsborough,

CA (US)

(73) Assignee: Vibrant Holdings, LLC, Santa Clara,

CA (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 519 days.

This patent is subject to a terminal dis-

claimer.

- (21) Appl. No.: 17/492,189
- (22) Filed: Oct. 1, 2021

(65) Prior Publication Data

US 2022/0162698 A1 May 26, 2022

Related U.S. Application Data

- (60) Continuation of application No. 16/709,423, filed on Dec. 10, 2019, which is a division of application No. 15/991,706, filed on May 29, 2018, now Pat. No. 10,538,808.
- (60) Provisional application No. 62/511,786, filed on May 26, 2017.
- (51) Int. Cl. C12Q 1/6876 (2018.01) C12Q 1/6837 (2018.01) C12Q 1/6874 (2018.01) C40B 30/04 (2006.01)
- (52) U.S. Cl.

CPC C12Q 1/6876 (2013.01); C12Q 1/6837 (2013.01); C12Q 1/6874 (2013.01); C40B 30/04 (2013.01)

(58) Field of Classification Search

CPC .. C12Q 1/6876; C12Q 1/6837; C12Q 1/6874; C12Q 2523/319; C12Q 2527/119; C12Q 2535/101; C12Q 2565/607; C40B 30/04 See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

4,780,405 A	10/1988	Kaiser et al.
5,069,996 A	12/1991	Rogler
5,143,854 A	9/1992	Pinrung et al.
5,240,811 A	8/1993	Taylor et al.
5,310,687 A	5/1994	Bard et al.
5,866,434 A	2/1999	Massey et al.
5,919,523 A	7/1999	Sundberg et al.
5,945,286 A	8/1999	Krihak et al.
6,017,696 A	1/2000	Heller
6,040,138 A	3/2000	Lockhart et al.
6,083,697 A	7/2000	Beecher et al.

6 1 40 0 45 4	10/2000	*** 11 . 1 1
6,140,045 A	10/2000	Wohlstadter et al.
6,316,230 B1	11/2001	Egholm et al.
6,319,726 B1	11/2001	Schuppan et al.
6,359,125 B1	3/2002	Kim et al.
6,395,474 B1	5/2002	Buchardt et al.
6,469,151 B1	10/2002	Egholm et al.
6,506,558 B1	1/2003	Fodor et al.
6,521,181 B1	2/2003	Northrup et al.
6,861,216 B2	3/2005	Neriishi et al.
6,943,034 B1	9/2005	Winkler et al.
6,969,766 B2	11/2005	Kim et al.
7,022,851 B2	4/2006	Kim et al.
7,041,453 B2	5/2006	Yang
7,125,994 B2	10/2006	Kim et al.
7,145,006 B2	12/2006	Kim et al.
7,179,896 B2	2/2007	Kim et al.
7,211,668 B2	5/2007	Kim et al.
7,320,864 B2	1/2008	Yang
7,476,504 B2	1/2009	Turner
7,510,841 B2	3/2009	Stuelpnagel et al.
7,527,912 B2	5/2009	Ohsawa et al.
7,544,638 B2	6/2009	Gao et al.
7,553,943 B2	6/2009	Ellis et al.
7,608,397 B2	10/2009	Densham
7,622,279 B2	11/2009	Ju
7,659,064 B2	2/2010	Park et al.
7,862,996 B2	1/2011	Kuimelis et al.
7,956,011 B2	6/2011	Serafinowski et al.
8,128,908 B2	3/2012	Santra et al.
8,133,985 B2	3/2012	Lee et al.
8,252,533 B2	8/2012	Park et al.
	(Con	tinued)
	(Con	illiaca,

FOREIGN PATENT DOCUMENTS

CN 103234948 8/2013 CN 103675291 A 3/2014 (Continued)

OTHER PUBLICATIONS

US 6,200,755 B1, 08/2006, Gordon et al. (withdrawn) (Continued)

Primary Examiner - Narayan K Bhat

(74) Attorney, Agent, or Firm — Goodwin Procter LLP

(57) ABSTRACT

Disclosed herein are compositions, probes, devices, and processes useful for detecting specific reactions and binding interactions with biological molecules. In certain embodiments, methods of binding one or more biomolecules to a solid support are disclosed. Methods of generating site-specific sequences for one or more biomolecules from a solid support are also disclosed. Biological complexes generated by these methods are also disclosed.

29 Claims, 23 Drawing Sheets

Specification includes a Sequence Listing.

S. PATENT DOCUMENTS	(56)	Referen	ces Cited		FOREIGN PATEN	NT DOCUMENTS
8,546,437 B2 10/2015 Quart et al. EP	U.S.	PATENT	DOCUMENTS	EP	1077264 A2	2/2001
8.969.002 B2 32.015 Safandyarpour et al.				EP	1517178 A1	
9.216,399 B2 12.2015 Rajissekaran et al. EP 1470114 B1 82,000 9.417,236 B2 82016 Rajissekaran et al. EP 1501812 B1 112,000 9.631,231 B2 42017 Shaffer et al. EP 1501812 B1 112,000 9.631,231 B2 42017 Shaffer et al. EP 1501812 B1 112,000 9.631,231 B2 42017 Shaffer et al. EP 1501812 B1 12,000 9.631,231 B2 92017 Tournezor et al. EP 2003510 B1 10,000 9.631 B1 10,000 9.6						
9.417,236 B2 82 (2016) Rajasekaran et al. EP 1651642 B1 11/2009 9.631,231 B2 4-2017 Journagous et al. EP 151812 B1 11/2009 9.766,200 B2 9.2017 Journagous et al. EP 21/14/30 A1 4/2010 10.006,909 B2 6-2018 Rajasekaran et al. EP 21/14/30 A1 4/2010 10.006,909 B2 6-2018 Rajasekaran et al. EP 21/14/30 A1 4/2010 10.006,909 B2 6-2018 Rajasekaran et al. EP 21/14/30 A1 4/2010 10.006,909 B2 6-2018 Rajasekaran et al. EP 21/14/30 A1 1/2002 10.0076834 A1 6/2002 Delief et al. EP 20/04/30 B1 10/2014 10.538 A8 B2 12/2029 A1 7/2002 Rajasekaran EP 20/04/30 B1 10/2014 10.006,909 A1 4 7/2002 Rajasekaran EP 20/04/30 B1 10/2014 10.006,909 A1 4 7/2003 Mirkin et al. PP 1005/2009 A 11/19/3 10.003/03/08/24 A1 5/2003 Parlinh et al. PP 20/01/50/386 A 3/2001 10.003/03/03/24 A1 5/2003 Parlinh et al. PP 20/01/50/386 A 3/2001 10.003/03/24/24 A1 5/2003 Parlinh et al. PP 20/03/25/03/68 A 1/2002 10.003/03/24/24 A1 5/2003 Rajasekaran et al. PP 20/03/25/03/68 A 1/2002 10.003/03/24/24 A1 5/2003 Rajasekaran et al. PP 20/03/25/03/68 A 1/2002 10.003/03/24/24 A1 5/2003 Rajasekaran et al. PP 20/03/25/03/68 A 1/2002 10.003/03/24/24 A1 5/2003 Rajasekaran et al. PP 20/03/25/03/49 A 5/2003 10.004/03/23/88 A1 2/2004 Varianto et al. PP 20/03/25/14/9 A 5/2003 10.004/03/23/88 A1 2/2004 Varianto et al. PP 20/03/25/14/9 A 5/2003 10.005/03/24/86 A1 1/2005 10.005/03/24/86 A1 1/						
9,631,231 B2 4,2017 Shaffer et al. EP 1501812 B1 122009 9,765,200 B2 9,2017 Toumazou et al. EP 1025120 B1 8,2010 10,040,818 B2 8,2018 Rajasecharan et al. EP 1025120 B1 8,2010 10,404,818 B2 8,2018 Rajasecharan et al. EP 20045463 B1 8,2014 10,538,848 B1 120,30 Rajasecharan et al. EP 20045463 B1 8,2014 10,538,848 B1 120,30 Rajasecharan et al. EP 20045463 B1 8,2014 10,538,848 B1 120,30 Rajasecharan et al. EP 100510,00 Rajasecharan et al. EP 100510,00 Rajasecharan et al. EP 100500,00 Rajasecharan et al. EP 2004500,00 Rajasecharan et al. EP 2004500,00 Rajasecharan et al. EP 200500,00 Rajasecha						
9,766,200 B2 6/2018 Rajasekaran et al. EP 2174936 A1 4/2010 10,040,818 B2 8/2018 Jayaraman EP 2003501 B1 10,2010 10,316,363 B2 6/2019 Ansari et al. EP 2003501 B1 10,2010 10,316,363 B2 6/2019 Ansari et al. EP 2004503 B1 8/2014 10,538,808 B2 1/2020 Rajasekaran EP 3790,885 A1 3/2021 10,303,808 A1 6/2002 Detlef et al. PP 80529999 A1 11,1993 2002/0907833 A1 6/2002 Detlef et al. PP 80529999 A1 11,1993 2003/08334 A1 7/2003 Ellson et al. PP 2001503856 A 3/2001 2003/08340 A1 7/2003 Blubn et al. PP 2001503856 A 3/2001 2003/08340 A1 7/2003 Webb et al. PP 200250068 A 11,2902 2003/08400 A1 5/2003 Rubn et al. PP 2002502098 A 11,2902 2003/08400 A1 5/2003 Agrawal et al. PP 2002502098 A 11,2902 2003/083014029 A1 5/2003 Slootsta et al. PP 2002502098 A 12,2004 2004/0907309 A1 2/2004 Tashiro et al. PP 200253018 A 7/2002 2004/0907309 A1 2/2004 Tashiro et al. PP 200253018 A 7/2003 2004/0907309 A1 2/2004 Tashiro et al. PP 200353149 A 5/2003 2004/0907309 A1 2/2004 Tashiro et al. PP 2003532439 A 8/2003 2004/0907309 A1 2/2004 Tashiro et al. PP 2003532439 A 8/2003 2004/0907309 A1 2/2004 Tashiro et al. PP 2003532439 A 8/2003 2004/0907309 A1 2/2004 Tashiro et al. PP 2003532439 A 8/2003 2005/0908363 A1 4/2006 Kyu et al. PP 2005352439 A 8/2003 2005/0908361 A1 10/2005 Sufford et al. PP 2005352439 A 8/2003 2005/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005512035 A 4/2005 2006/0908363 A1 4/2006 Wang et al. PP 2005054004 A 7/2008 2006/0908363 A1 4/2006 Wang et al. PP 200551203						
10,006,909 B2 6/2018 Rajasekaran et al. EP 1025120 B1 8/2010						
10.518.03 B2 20.00 Ansari et al. EP 2094803 B1 82.014 10.518.08 B2 12.020 Rajasekaran EP 379085 A1 37.0201 2002/006314 A1 6/2002 Detlef et al. JP H0529395 A1 11/1993 2003/0068446 A1 47.003 Mirkin et al. JP 200150386 A 37.000 2003/0068446 A1 47.003 Mirkin et al. JP 200150386 A 17.000 2003/00124029 A1 72.003 Mirkin et al. JP 2002503608 A 17.000 2003/00124029 A1 72.003 Webb et al. JP 2002503608 A 17.000 2003/00124029 A1 72.003 Webb et al. JP 2002503608 A 72.000 2004/0012403 A1 12.003 Webb et al. JP 2002503608 A 72.000 2004/0012403 A1 12.003 Servival et al. JP 200351749 A 57.000 2004/0012508 A1 12.003 Servival et al. JP 200551749 A 57.000 2004/0012508 A1 12.003 Servival et al. JP 200551749 A 57.000 2004/0012508 A1 12.005 Servival et al. JP 200551749 A 57.000 2004/0012518 A1 10.0005 Servi JP 200551749 A 57.000 2005/002451 A1 10.0005 Servi JP 200551749 A 57.000 2005/002451 A1 10.0005 Servi JP 200551749 A 10.000 2005/002451 A1 11.0005 Servi JP 200551749 A 10.000 2005/002450 A1 A1 17.0005 Servi JP 200551203 A 42.000 2005/002450 A1 A1 17.0005 Servi JP 200551203 A 42.000 2005/002450 A1 A1 17.0005 Servi JP 200551203 A 42.000 2005/002450 A1 A1 17.0005 Servi JP 200551203 A 42.000 2005/002450 A1 A1 17.0005 Servi JP 200551203 A 42.000 2005/002450 A1 A1 17.0005 Servi JP 200551203 A 42.000 2005/002450 A1 A1 17.0005 Servi JP 200551203 A 42.000 2006/002550 A1 A1 20.0007 Servi Se		6/2018				
10,538,380 B						
2002/096819 Al 7/2002 Delte et al. PP H05294995 A 11/1993						
2002/0086319 Al 7,2002 Ellson et al. JP H06500308 A 11994	, ,					
2003-00082294 Al 5-2003 Sanha et al. JP 2002500362 A 172002 2003-012402 Al 7-2003 Webb et al. JP 2002520618 A 7-2002 2003-0124805 Al 122003 Schostrat et al. JP 200252057 A 8-2003 2004-0038388 Al 22004 Tashiro et al. JP 200352757 A 8-2003 2004-0038388 Al 22004 Tashiro et al. JP 2003527334 A 8-2003 2004-0010333 Al 10-2005 Sanford et al. JP 2003527334 A 8-2003 2005-021351 Al 10-2005 Sanford et al. JP 2003524193 A 8-2003 2005-021351 Al 10-2005 Sanford et al. JP 2003524193 A 8-2003 2005-021351 Al 11-2005 Sanford et al. JP 200519285 9-2004 2005-0214081 Al 11-2005 Sanford et al. JP 200519285 9-2004 2005-0214081 Al 11-2005 Sanford et al. JP 200551203 A 4-2005 A 4-200						
2003-0124029 Al 7,2003 Webb et al. JP 2002502698 A 7,2002 2003-014401 Al 8,2003 Agrawal et al. JP 2002525577 A 8,2002 2004-0007303 Al 2,2004 Tashiro et al. JP 2003523148 A 8,2003 2004-00103388 Al 2,2004 Tashiro et al. JP 2003523148 A 8,2003 2004-010133 Al 6,2004 Carlos Carlos Carlos Al 2,2004 Carlos Carlo	2003/0068446 A1					
2003-0148401 Al x 2003 Agrawal et al. JP 2002520618 A 7/2002 20040027093 Al 2/2004 Tashiro et al. JP 2003517149 A 5/2003 2004003888 Al 2/2004 Vanamoto et al. JP 2003527348 A 8/2003 2004-003888 Al 2/2004 Vanamoto et al. JP 2003527438 A 8/2003 2005-021351 Al 1/2005 Ryu JP 20035274193 A 8/2003 2005-021351 Al 1/2005 Ryu JP 20035274193 A 8/2003 2005-0240811 Al 1/2005 Safford et al. JP 20053274354 A 1/22003 2005-024081 Al 1/2005 Safford et al. JP 200541226 A 1/22003 2005-024081 Al 1/2005 Mir JP 2005512032 A 4/2005 2005-0240881 Al 1/2005 Mir JP 2005512032 A 4/2005 2006-0038863 Al 4/2005 Vanamoto et al. JP 2005512032 A 4/2005 2006-00147949 Al 7/2006 Ha et al. JP 2005512032 A 7/2005 2006-00147949 Al 7/2006 Ha et al. JP 2005512032 A 4/2005 2007-0122841 Al 5/2007 Rajasekaran et al. JP 2005512033 A 4/2006 2007-0122842 Al 5/2007 Rajasekaran et al. JP 2005512033 A 4/2006 2007-0125494 Al 1/2007 Rajasekaran et al. JP 2005512033 A 4/2006 2007-0154946 Al 7/2007 Rajasekaran et al. JP 200551203 A 4/2006 2007-0154946 Al 7/2007 Rajasekaran et al. JP 2005704462 A 3/2007 2007-0231794 Al 10/2007 Dil et al. JP 200512093 A 4/2006 2009-0311727 Al 1/2009 Sundararajan et al. JP 200517049 A 7/2008 2009-0311727 Al 1/2009 Varian et al. JP 200517049 A 7/2008 2009-0311727 Al 1/2009 Varian et al. JP 200517049 A 7/2008 2009-0311727 Al 1/2009 Varian et al. JP 200515108 A 7/2008 2009-0311727 Al 1/2009 Varian et al. JP 200517049 A 7/2008 2009-0311727 Al 1/2009 Varian et al. JP 200515108 A 7/2008 2009-0311727 Al 1/2009 Varian et al. JP 200515108 A 7/2008 2009-0311727 Al 1/2009 Varian et al. JP 200515108 A 7/2008 A 7/200						
2003/0228605 Al 1 2/2003 Slootstra et al.						
2004-00338 A 2.2004 Tashiro et al. JP 2003\$17149 3 5.2003 2004-00388 A 2.2004 Yamunoto et al. JP 2003\$2348 A 8.2003 2004-001383 A 6.2004 Yamunoto et al. JP 2003\$2348 A 8.2003 2005*02131 A 10.2005 Ryu JP 2003\$24193 A 8.2003 2005*02131 A 10.2005 Ryu JP 2003\$24193 A 8.2003 2005*02131 A 10.2005 Ryu JP 2005*024886 A 11.2005 Mir JP 2005*024886 A 11.2005 Mir JP 2005*024886 A 11.2005 Mir JP 2005*12032 A 4.2005 2006*014794 A 7.2006 Ha et al. JP 2005*12032 A 4.2005 2006*014794 A 7.2006 Ha et al. JP 2005*21032 A 7.2005 2006*014794 A 7.2006 Ha et al. JP 2005*21032 A 7.2005 2006*0172340 A 8.2006 Walstadter et al. JP 2005*30983 A 10.2005 2007*0123842 A \$.2007 Rajasekaran et al. JP 2005*30983 A 4.2006 2007*012484 A 7.2007 Rajasekaran et al. JP 2006*015*293 A 4.2006 2007*016*178 A 7.2007 Rajasekaran et al. JP 2006*075*1283 A 4.2006 2007*02174 A 10.2007 Dill et al. JP 2008*15*7952 A 7.2008 2008*031177 A 1 2.2009 Walkins et al. JP 2008*15*7952 A 7.2008 2008*031177 A 1 2.2009 Walkins et al. JP 2009*15*136 A 3.2009 2009*031177 A 1 2.2009 Walkins et al. JP 2009*15*136 A 4.2010 2010*0235*34 A 4.2010 Cha JP 2010*03*131 A 4.2010 2010*02405*5 A 2.2010 Walkins et al. JP 2010*15*131 A 4.2011 2010*02405*5 A 9.2010 Chamarti et al. JP 2010*15*131 A 4.2011 2010*02405*5 A 9.2010 Valuar et al. JP 2010*15*131 A 4.2011 2010*02405*5 A 9.2010 Chamarti et al. JP 2010*15*131 A 4.2011 2010*02405*5 A 9.2010 Chamarti et al. JP 2011*15*18 A 6.2011 2010*02405*5 A 9.2010 Chamarti et al. JP 2011*15*18 A 7.2011 2010*03027 A 4.2011 A 4.2011 A 4.2011 A 4.2010 A 4.2011 A 4.2010 A 4.2010 A 4.2010 A 4.2010 A 4.2010 A						
2004/01013838 Al 2/2004 Yamamoto et al. JP 2003523348 A 8/2003						
1005/022135 Al 10/2005 Ryu Cal. JP 2006342354 Al 12/2003 2005/024801 Al 10/2005 Ryu JP 200651285 9/2004 2005/024863 Al 11/2005 Mir JP 200651285 Al 4/2005 2005/024863 Al 11/2005 Mir JP 2005512032 Al 4/2005 2006/008863 Al 4/2006 Yamamoto et al. JP 2005512032 Ar/2005 2006/008863 Al 4/2006 Yamamoto et al. JP 2005521032 Ar/2005 2006/0147949 Al 7/2006 Ha et al. JP 2005521032 Ar/2005 2006/017234 Al 8/2006 Wohlstadter et al. JP 2005520382 Ar/2005 2007/0122841 Al 5/2007 Rajasekaran et al. JP 2005521893 Ar/2006 2007/0122842 Al 5/2007 Rajasekaran et al. JP 2006512893 Ar/2006 2007/0154946 Al 7/2007 Rajasekaran et al. JP 2006575152 Al 10/2006 2007/0154944 Al 5/2007 Rajasekaran et al. JP 2008170446 Al 7/2007 Rajasekaran et al. JP 2008170449 Al 7/2008 2009/0311727 Al 10/2007 Dill et al. JP 2008170449 Al 7/2008 Sundaranjan et al. JP 2008170449 Al 7/2008 Sundaranjan et al. JP 20098170449 Al 7/2008 Sundaranjan et al. JP 20098170449 Al 7/2008 Sundaranjan et al. JP 2009873110 Al 4/2009 2010/00023559 Al 2/2010 Yan et al. JP 20098731281 Al 4/2009 2010/00023559 Al 2/2010 Yan et al. JP 201057099 Al 3/2010 2010/0023554 Al 4/2010 China JP 2010151816 Al 2/2010 2010/024555 Al 2/2010 Rajasepalna et al. JP 2010151816 Al 2/2010 2010/034555 Al 2/2010 Rajasepalna et al. JP 2011051816 Al 2/2010 Al 2/2011 Al Al Al Al Al Al Al						
2005/024863 1 10/2005 3afford et al. JP 2004534226 11/2005 2005/024863 11/2005 3afford et al. JP 2004534226 11/2005 2005/026611 11/2005 Vang et al. JP 2005512032 A 4/2006 2006/04/394 A 7/2005 2006/04/394 A 7/2005 Mang et al. JP 2005512032 A 7/2005 2006/04/394 A 7/2006 Ha et al. JP 2005512032 A 7/2005 2006/04/394 A 7/2006 Ha et al. JP 200552032 A 7/2005 2006/01/2340 A 8/2006 Ha et al. JP 200552032 A 7/2005 2007/01/22842 A 5/2007 Rajasekaran et al. JP 2005530983 A 10/2005 2007/01/22844 A 5/2007 Rajasekaran et al. JP 2006512893 A 4/2006 2007/01/2494 A 7/2007 Rajasekaran et al. JP 2006751512 A 10/2006 2007/01/2494 A 7/2007 Rajasekaran et al. JP 2008157952 A 7/2008 2007/02/3194 A 10/2007 Dill et al. JP 2008170449 A 7/2008 2008/03/11727 A 11/2009 Warkins et al. JP 20095170442 A 7/2008 2009/03/1274 A 10/2009 Warkins et al. JP 2009517046 A 7/2008 2009/03/1274 A 10/2009 Warkins et al. JP 2009517046 A 7/2008 2009/03/1274 A 10/2009 Warkins et al. JP 2009517046 A 7/2008 2009/03/1274 A 10/2009 Warkins et al. JP 2009517046 A 7/2009 2009/03/25816 A 12/2010 Warkins et al. JP 2009517046 A 7/2009 2009/03/25816 A 12/2010 Warkins et al. JP 2009517040 A 9/2010 2010/0024555 A 2/2010 Chamari et al. JP 2010/15716 A 7/2011 2010/0245057 A 9/2010 Rajagopalan et al. JP 2011/3116 A 9/2010 2010/034057 A 9/2010 Rajagopalan et al. JP 2011/3116 A 9/2011 2010/034057 A 9/2011 Rajagopalan et al. JP 2011/3116 A 9/2011 2011/020764 A 8/2011 Coper Wo 98/0357 A 1/2011 Coper Wo 98/0357 A 1/2011 Coper Wo 98/0357 A 1/2011 Coper Wo 98/03573 A 1/2012 Coper Wo 98/03573 A 1/2012 Coper Wo 98/03573 A 1/2010 Coper Wo 98/03573 A	2004/0110133 A1	6/2004	Xu et al.			
2005/0244863 Al 11/2005 Mir JP 200453426 A 11/2004			,			
2005/02466611 A1 11/2005 Vang et al. JP 2005513093 A 4/2005 2006/0047949 A1 7/2005 Wang et al. JP 2005513093 A 5/2005 2006/0147949 A1 7/2006 Ha et al. JP 200552032 A 7/2005 2006/0147949 A1 7/2006 Ha et al. JP 200552032 A 7/2005 2006/0147949 A1 7/2006 Ha et al. JP 2005520383 A 10/2005 2007/0122842 A1 5/2007 Rajasekaran et al. JP 2006512893 A 4/2006 2007/0122842 A1 5/2007 Rajasekaran et al. JP 20065275152 A1 10/2006 2007/0161778 A1 7/2007 Rajasekaran et al. JP 2006751512 A1 10/2006 2007/0161778 A1 7/2007 Rajasekaran et al. JP 2008157952 A 7/2008 2007/021749 A1 10/2007 Dill et al. JP 2008157952 A 7/2008 2009/031274 A1 10/2009 Dill et al. JP 2008157952 A 7/2008 2009/031274 A1 10/2009 Watkins et al. JP 2009510786 A 3/2009 2009/031274 A1 10/2009 Watkins et al. JP 2009510786 A 3/2009 2009/031274 A1 10/2009 Watkins et al. JP 2009510786 A 3/2010 2010/0028559 A1 2/2010 Watkins et al. JP 2009510786 A 3/2010 2010/0028559 A1 2/2010 Watkins et al. JP 201057099 A 3/2010 2010/0028559 A1 2/2010 Rajasopalan et al. JP 2010157104 A 2/2011 2010/00240575 A1 2/2010 Rajasopalan et al. JP 201103118 A 2/2011 2010/00240575 A1 2/2011 Rajasopalan et al. JP 201103118 A 2/2011 2010/0034057 A1 2/2011 Rajasopalan et al. JP 2011151168 A 2/2011 2010/0034057 A1 2/2011 Campart et al. JP 2011251631 A 2/2011 2/2011/00304303 A1 1/2011 Campart et al. JP 2011251631 A 2/2011 2/2011/00304303 A1 1/2011 Campart et al. JP 2011251631 A 2/2011 2/2011/00304303 A1 1/2011 Campart et al. JP 2011251634 A 2/2012 2/2011/00304303 A1 1/2012 Campart et al. JP 2011251634 A 2/2012 2/2012 A 2/						
2006/0088863 Al 4/2006 Amammoto et al. JP 2005521025 A 7/2005						
2006/0147949 A.1 7/2006 Ha et al JP 2005264156 A 9/2005						
2006/01/2349 Al 82/006 Wohlstadter et al. JP 2005/30/83 A 0/2005 2007/01/2841 Al 5/2007 Rajasekaran et al. JP 2006/51/83 A 4/2006 2007/01/54946 Al 7/2007 Rajasekaran et al. JP 2006/51/85 Al 10/2006 2007/01/54946 Al 7/2007 Rajasekaran et al. JP 2006/57/51 Al 7/2007 Rajasekaran et al. JP 2007/01/61/78 Al 7/2007 Rajasekaran et al. JP 2007/01/61/78 Al 7/2007 Rajasekaran et al. JP 2008/15/795 Al 7/2008 2007/01/78 Al 7/2008 2007/0231/794 Al 10/2007 Dill et al. JP 2008/15/795 Al 7/2008 2009/0301/727 Al 12/2009 Watkins et al. JP 2009/51/704 Al 7/2008 2009/031/727 Al 12/2009 Watkins et al. JP 2009/51/31 Al 4/2009 2009/0325816 Al 12/2009 Watkins et al. JP 2009/51/31 Al 4/2009 2009/0325816 Al 12/2009 Watkins et al. JP 2009/51/31 Al 4/2009 2010/0026589 Al 2/2010 Yan et al. JP 2010/51/86 Al 9/2010 2010/00205859 Al 2/2010 Yan et al. JP 2011/51/816 Al 9/2010 2010/0020585 Al 9/2010 Rajagopalan et al. JP 2011/51/816 Al 9/2011 2010/0020555 Al 9/2010 Chamarti et al. JP 2011/51/816 Al 9/2011 2011/0020555 Al 9/2010 Chamarti et al. JP 2011/51/816 Al 9/2011 2011/00304303 Al 1/2011 Gooper Woo 9/2013/4723 Al 1/2011 2011/00304303 Al 1/2011 Gooper Woo 9/2013/473 Al 1/2011 2011/0030440 Al 1/2011 Cooper Woo 9/2013/4870 Al 8/2012 2011/0030464 Al 1/2011 Cooper Woo 9/2013/4870 Al 2/2011 Shirazi et al. Woo 1/2013/4870 Al 2/2011 Shirazi et al. Woo 1/2013/4870 Al 2/2011 Shirazi et al. Woo 2/2013/4870 Al 2/2013 Shirazi et al. Woo 2/2013/4870 Al 2/2003 2/2013/4870 Al 2/2013 Shirazi et al. Woo 2/203/3080 Al 2/2003 2/2003/3080 Al 2/2003 Al 2/2						
2007/0122841 Al 5/2007 Agjasekaran et al. JP 2006512893 A 4/2006						
2007/0122842 Al 5/2007 Rajasekaran et al. JP 2006275152 Al 10/2006						
2007/0161778 Al			3			
2007/0231794 Al 10/2007 Dill et al. JP 2008170449 A 7/2008 2008/031777 Al 12/2009 Sundararajan et al. JP 2009975131 A 4/2009 2009/031777 Al 12/2009 Mirkin et al. JP 2009534200 A 9/2009 2010/0028559 Al 2/2010 Yan et al. JP 201057099 A 3/2010 2010/0028559 Al 4/2010 Chu JP 2010215816 A 9/2010 2010/0023554 Al 4/2010 Chu JP 2010215816 A 9/2010 2010/0023554 Al 4/2010 Chu JP 201015181 A 1/2011 2010/00240555 Al 9/2010 Rajagopalan et al. JP 2011017711 A 1/2011 2010/00240555 Al 9/2010 Sundararajan et al. JP 201113711 A 1/2011 2010/00240555 Al 9/2010 Sundararajan et al. JP 2011234723 A 11/2011 2010/0304303 Al 1/2010 Maeda et al. JP 2011234723 A 11/2011 2010/0304303 Al 1/2011 Maeda et al. JP 2011234723 A 11/2011 2010/0304303 Al 1/2011 Maeda et al. JP 20112510451 A 5/2012 2011/0997762 Al 4/2011 Gao et al. JP 2011258294 A 8/2012 2011/098764 Al 12/2011 Adini et al. WO 1994/28075 Al 12/1994 2011/0281766 Al 11/2011 Cooper WO 98/03872 Al 1/1998 2011/0230944 Al 12/2011 Shirazi et al. WO 1999/41007 A2 8/1999 2012/0173309 Al 7/2012 Dal Farra et al. WO 2000/16089 A2 3/2000 2012/0183881 Al 7/2012 Norman et al. WO 2001/43870 A2 6/2001 2012/0238477 Al 9/2012 Albert et al. WO 2003/038033 A2 5/2003 2013/0084532 Al 4/2013 Wi et al. WO 2003/038033 A2 5/2003 2013/0084532 Al 4/2014 Kotsbak WO 2003/038033 A2 5/2003 2014/0073219 Al 1/2014 Kotsbak WO 2003/038033 A2 5/2003 2014/0073219 Al 1/2014 Rajasekaran et al. WO 2008/18166 Al 7/2010 2016/010868 Al 7/2016 Bamyai et al. WO 2008/18166 Al 7/2007 2016/010868 Al 7/2016 Bamyai et al. WO 2008/18166 Al 7/2007 2016/0108622 Al 6/2016 Bamyai et al. WO 2008/18166 Al 7/2007 2016/0108623 Al 5/2016 Bamyai et al. WO 2008/01696 Al 7/2008 2016/0108623 Al 7/2016 Bamyai et						
2008/0108149 A1 5/2008 Sundararajan et al. IP 2009510786 A 3/2009 2009/031727 A1 12/2009 Watkins et al. IP 2009534200 A 9/2009 2010/0028559 A1 2/2010 Yan et al. IP 2010507099 A 3/2010 2010/0028554 A1 4/2010 Chu IP 2010151816 A 9/2010 2010/0028554 A1 4/2010 Chu IP 2010151816 A 9/2010 2010/0022547 A1 9/2010 Huang et al. IP 2010151816 A 9/2010 2010/0024555 A1 9/2010 Rajagopalan et al. IP 2011013118 A 1/2011 2010/024055 A1 9/2010 Sundararajan et al. IP 2011519168 A 6/2011 2010/0245057 A1 9/2010 Sundararajan et al. IP 2011234723 A 11/2011 2010/034030 A1 12/2010 Chamarti et al. IP 2011234723 A 11/2011 2010/034030 A1 12/2010 Maeda et al. IP 20112163491 A 8/2012 2011/0097762 A1 4/2011 Gao et al. IP 2011218394 A 8/2012 2011/0293644 A1 12/2011 Adini et al. WO 1994/28075 A1 12/1994 2011/0293644 A1 12/2011 Anderson et al. WO 98/12539 A1 3/1998 2011/0303027 A1 12/2011 Shirazi et al. WO 2003/3872 A2 1/1998 2012/0133981 A1 7/2012 Dal Farra et al. WO 2001/43870 A2 8/1999 2012/0133871 A1 7/2012 Norman et al. WO 2003/03303 A2 5/2003 2013/0084532 A1 4/2013 Wu et al. WO 2003/03303 A2 5/2003 2014/0072963 A1 3/2014 Ohn WO 2003/03303 A2 5/2003 2014/0073963 A1 3/2014 Ohn WO 2003/03303 A2 5/2003 2014/0073963 A1 3/2014 Ohn WO 2003/03803 A2 5/2003 2014/0073963 A1 3/2014 Ohn WO 2003/03803 A2 5/2003 2014/0073963 A1 3/2014 Ohn WO 2003/03803 A2 5/2003 2014/0073963 A1 3/2014 Ohn WO 2003/03608 A1 4/2004 Ohn WO 2003/03803 A2 5/2003 2016/004868 A1 5/2016 Esfandyapour et al. WO 2003/03803 A2 5/2003 2016/004868 A1 5/2016 Esfandyapour et al. WO 2003/03667 A1 2/2005 Esfandyapour et al. WO 2003/03667 A1 3/2014 Ohn 2016/014466 A1 5/2016 Esfandyapour et al. WO 2010/038693 A1 7/2010 2016/014466 A1 5/2016 Esfandy						
2009/0311727 Al 12/2009 Watkins et al. JP 2009075131 A 4/2009 2009/0325816 Al 12/2009 Mirkin et al. JP 2009534200 A 9/2009 2010/0028559 Al 2/2010 Yan et al. JP 20105307099 A 3/2010 2010/0029555 Al 4/2010 Chu JP 2010215816 A 9/2010 2010/0120630 Al 5/2010 Huang et al. JP 2011017111 A 1/2011 2010/022547 Al 9/2010 Rajagopalan et al. JP 2011017711 A 1/2011 2010/0240555 Al 9/2010 Sundararajan et al. JP 2011519168 A 6/2011 2010/0240557 Al 9/2010 Chamarti et al. JP 2011234723 A 11/2011 2010/0304303 Al 12/2010 Maeda et al. JP 2012510431 A 5/2012 2011/0097762 Al 4/2011 Gao et al. JP 2012516349 A 8/2012 2011/0281766 Al 11/2011 Cooper WO 1994/28075 Al 12/2011 Anderson et al. WO 1994/28075 Al 12/2011 Anderson et al. WO 98/03872 A2 11/1998 2011/0239344 Al 12/2011 Anderson et al. WO 298/12539 Al 3/1998 2011/0303027 Al 12/2011 Shirazi et al. WO 2000/16089 A2 3/2000 2012/018398 Al 7/2012 Dal Farra et al. WO 2000/16089 A2 3/2000 2012/018398 Al 7/2012 Albert et al. WO 2003/001889 A2 1/2003 2014/0031239 Al 7/2012 Albert et al. WO 2003/003803 A2 5/2003 2014/0031239 Al 1/2014 Kotsbak WO 2003/003803 A2 5/2003 2014/007351 Al 3/2014 Kotsbak WO 2003/004865 Al 4/2004 Albert et al. WO 2003/004865 Al 4/2004 Albert et al. WO 2003/004865 Al 4/2004 Albert et al. WO 2003/004666 Al 2/2005 2016/003737 Al 1/2015 Somoza et al. WO 2000/104606 Al 2/2005 2016/003737 Al 1/2015 Somoza et al. WO 2000/0080633 Al 2/2005 2016/003737 Al 1/2015 Somoza et al. WO 2000/008065 Al 2/2005 2016/018605 Al 3/2016 Albert et al. WO 2000/008065 Al 2/2005 2016/018605 Al 3/2016 Albert et al. WO 2000/008065 Al 2/2005 2016/018605 Al 3/2016 Albert et al. WO						
2009/0325816 Al 12/2009 Mirkin et al. JP 2010507099 A 3/2010 2010/0028559 Al 2/2010 Yan et al. JP 2010507099 A 3/2010 2010/0033554 Al 4/2010 Chu JP 2010507099 A 3/2010 2010/01205355 Al 4/2010 Huang et al. JP 2011013118 A 1/2011 2010/0240555 Al 9/2010 Huang et al. JP 2011017711 A 1/2011 2010/0240555 Al 9/2010 Chamarti et al. JP 2011519168 A 6/2011 2010/034033 Al 2/2010 Chamarti et al. JP 2011519168 A 6/2011 2010/034033 Al 2/2010 Chamarti et al. JP 2012510431 A 5/2012 2011/0097762 Al 4/2011 Gao et al. JP 2012510431 A 5/2012 2011/09097762 Al 4/2011 Gao et al. JP 2012518294 A 8/2012 2011/09281766 Al 11/2011 Cooper WO 1994/28075 Al 12/2019 Addini et al. WO 1994/28075 Al 12/2019 Al 2/2011 Addini et al. WO 98/12539 Al 3/1998 2011/0293644 Al 12/2011 Adderson et al. WO 98/12539 Al 3/1998 2011/0293644 Al 12/2011 Anderson et al. WO 98/12539 Al 3/1998 2012/0172309 Al 7/2012 Dal Farra et al. WO 2000/16089 A2 3/2000 2012/0183981 Al 7/2012 Dal Farra et al. WO 2000/16089 A2 3/2000 2012/0183981 Al 7/2012 Albert et al. WO 2003/003803 A2 3/2003 2012/0245057 Al 9/2012 Albert et al. WO 2003/003803 A2 3/2003 2013/0084532 Al 4/2013 Wu et al. WO 2003/03803 A2 3/2003 2014/0031239 Al 1/2014 Kotsbak WO 2003/03803 A2 3/2003 2014/0072963 Al 3/2014 Wong et al. WO 2005/014696 Al 2/2005 2016/0098737 Al 1/2014 Rajasekaran et al. WO 2008/07370 Al 2/2005 2016/0186252 Al 6/2016 Esfandyarpour et al. WO 2008/07370 Al 2/2005 2016/0193608 Al 7/2016 Esfandyarpour et al. WO 2011/038167 Al 1/2010 2016/0193608 Al 7/2016 Esfandyarpour et al. WO 2011/038163 Al 7/2010 2016/0193608 Al 7/2016 Esfandyarpour et al. WO 2011/038162 Al 3/2014 2016/0144368 Al 3/201			3			
2010/0033554 Al						
2010/01/20630 Al 4/2010 Chi JP 2011013118 A 1/2011 2010/01/20630 Al 5/2010 Huang et al. JP 2011017711 A 1/2011 2010/02245057 Al 9/2010 Sundararajan et al. JP 2011234723 A 11/2011 2010/0245055 Al 9/2010 Chamarti et al. JP 2011234723 A 11/2011 2010/0304303 Al 12/2010 Maeda et al. JP 20112510431 A 5/2012 2011/0097762 Al 4/2011 Gao et al. JP 20112510431 A 5/2012 2011/01907762 Al 4/2011 Gao et al. JP 20112518294 A 8/2012 2011/0190210 Al 8/2011 Adini et al. WO 1994/28075 Al 12/1994 2011/0281766 Al 11/2011 Cooper WO 98/03872 A2 1/1998 2011/0281766 Al 11/2011 Anderson et al. WO 99/03872 A2 1/1998 2011/0303027 Al 12/2011 Shirazi et al. WO 1999/41007 A2 8/1999 2012/0172309 Al 7/2012 Dal Farra et al. WO 2000/16089 A2 3/2000 2012/0238477 Al 9/2012 Albert et al. WO 2003/01889 A2 1/2003 2011/02045057 Al 9/2012 Albert et al. WO 2003/038033 A2 5/2003 2014/0031239 Al 1/2014 Kotsbak WO 2003/038033 A2 5/2003 2014/007293 Al 1/2014 Kotsbak WO 2004/027093 Al 1/2014 Cotsbak WO 2004/027093 Al 1/2014 Rajasskaran et al. WO 2005/014696 Al 2/2005 2014/0073511 Al 3/2014 Rajasskaran et al. WO 2008/01873 A2 2/2005 2014/0073511 Al 3/2014 Rajasskaran et al. WO 2008/18166 Al 2/2005 2016/018636 Al 5/2016 Estandyarpour et al. WO 2008/18166 Al 2/2005 2016/0186352 Al 6/2016 Estandyarpour et al. WO 2008/18166 Al 2/2005 2016/0186055 Al 6/2016 Estandyarpour et al. WO 2011/036153 Al 6/2010 2017/0192007 Al 7/2017 Rajasskaran et al. WO 2011/036153 Al 7/2017 2018/0106755 Al 8/2018 Paris et al. WO 2011/036053 Al 7/2017 Rajasskaran et al. WO 2011/036153 Al 5/2011 2019/01974745 Al 6/2017 Rajasskaran et al. WO 2011/036153 Al 5/2011 2019/01974745 Al 6/2017 Rajasskaran et al. WO 2011/	2010/0028559 A1					
2010/0222547 Al 9/2010 Ruing et al. JP 2011017711 A 1/2011 2010/0240555 Al 9/2010 Sundararajan et al. JP 2011519168 A 6/2011 2010/0240557 Al 9/2010 Chamarti et al. JP 20112510431 A 5/2012 2010/0304303 Al 12/2010 Maeda et al. JP 2012510431 A 5/2012 2011/0997762 Al 4/2011 Gao et al. JP 2012518294 A 8/2012 2011/0190210 Al 8/2011 Adini et al. JP 2012518294 A 8/2012 2011/0190210 Al 8/2011 Adini et al. JP 2012518294 A 8/2012 2011/0293644 Al 12/2011 Anderson et al. WO 1994/28075 Al 12/1994 2011/0293644 Al 12/2011 Shirazi et al. WO 98/12539 Al 3/1998 2011/0303027 Al 12/2011 Shirazi et al. WO 2000/16088 A2 3/2000 2012/0183981 Al 7/2012 Dal Farra et al. WO 2000/16088 A2 3/2000 2012/0183981 Al 7/2012 Norman et al. WO 2000/16088 A2 3/2003 2012/0245057 Al 9/2012 Albert et al. WO 2003/033803 A2 5/2003 2013/0084532 Al 4/2013 Wu et al. WO 2003/033803 A2 5/2003 2014/0031239 Al 1/2014 Kotsbak WO 2003/04273 A2 1/2004 2014/0073511 Al 3/2014 Wong et al. WO 2004/027093 Al 2/2005 2014/0073511 Al 3/2014 Wong et al. WO 2009/1038647 A2 4/2007 2014/0073688 Al 1/2015 Somoza et al. WO 2009/13323 Al 1/2006 2016/019368 Al 5/2016 Esami et al. WO 2009/133231 Al 1/2006 2016/019368 Al 5/2016 Esami et al. WO 2009/133231 Al 1/2006 2016/019368 Al 5/2016 Esami et al. WO 2010/06553 Al 2/2008 2016/0109368 Al 7/2017 Rajasekaran et al. WO 2010/06593 A2 8/2010 2016/019368 Al 7/2017 Rajasekaran et al. WO 2011/034620 Al 2/2008 2016/0103468 Al 7/2017 Rajasekaran et al. WO 2011/034620 Al 2/2010 2016/0193608 Al 7/2017 Rajasekaran et al. WO 2011/03450 Al 7/2010 2019/01074745 Al 6/2017 Rajasekaran et al. WO 2011/034620 Al 2/2010 2019/01074754 Al 7/2017 Rajasekaran						
2010/0240555 Al 9/2010 Sundararajan et al. JP 2011234723 A 11/2011 2010/0245057 Al 9/2010 Chamarti et al. JP 2011234723 A 11/2011 2010/0304303 Al 12/2010 Macda et al. JP 2012510431 A 5/2012 2011/0097762 Al 4/2011 Gao et al. JP 2012518394 A 8/2012 2011/0190210 Al 8/2011 Adini et al. WO 1994/28075 Al 12/1994 2011/0293644 Al 12/2011 Anderson et al. WO 1994/28075 Al 12/1994 2011/0293644 Al 12/2011 Anderson et al. WO 98/03872 A2 1/1998 2011/0303027 Al 12/2011 Shirazi et al. WO 1999/41007 A2 8/1999 2012/0172309 Al 7/2012 Dal Farra et al. WO 2000/16089 A2 3/2000 2012/0133981 Al 7/2012 Norman et al. WO 2001/43870 A2 6/2001 2012/0238477 Al 9/2012 Albert et al. WO 2003/023360 A2 3/2003 2013/0084532 Al 4/2013 Wu et al. WO 2003/038033 A2 5/2003 2014/0031239 Al 1/2014 Kotsbak WO 2003/0407373 Al 1/2014 Wong et al. WO 2005/014696 Al 2/2005 2014/0349888 Al 11/2014 Rajasekaran et al. WO 2000/07/038647 A2 4/2007 2015/0038373 Al 2/2015 Banyai et al. WO 2000/07/038647 A2 4/2007 2015/0038373 Al 1/2014 Rajasekaran et al. WO 2000/07/038647 Al 1/2006 2016/014368 Al 5/2016 Isami et al. WO 2000/07/03868 Al 7/2007 2016/0168625 Al 6/2016 Isami et al. WO 2000/08693 Al 2/2008 2016/0193608 Al 7/2016 Isami et al. WO 2000/086953 Al 8/2018 2016/0194745 Al 6/2017 Aghvanyan et al. WO 2011/03620 Al 3/2014 2016/0194745 Al 6/2017 Aghvanyan et al. WO 2011/036400 Al 3/2014 2016/0194745 Al 6/2017 Aghvanyan et al. WO 2011/03620 Al 3/2011 2019/0194745 Al 6/2019 Rajasekaran et al. WO 2011/036400 Al 3/2014 2019/0194745 Al 6/2019 Rajasekaran et al. WO 2011/034620 Al 3/2011 2019/0366291 Al 1/2018 Rajasekaran et al. WO 2011/034620 Al 3/2011 2019/0366291 Al 1/2018 Rajasekaran et al. WO 2011/034620 Al 3/2011 2019/0366291 Al 1/2018 Rajasekara						
2010/0245057 Al 9/2010 Chamarti et al. JP 2011251043 A 5/2012						
2011/0907762 A1						
2011/0097762 Al	2010/0304303 A1	12/2010	Maeda et al.			
2011/0281766 A1						
2011/0293644 A1						
2011/0303027 A1 12/2011 Shirazi et al. WO 1999/41007 A2 8/1999						
2012/0172309 A1						
2012/0183981 A1						- /
2012/0245057 A1 9/2012 Albert et al. WO 2003/023360 A2 3/2003 2013/0084532 A1 4/2013 Wu et al. WO 2003/038033 A2 5/2003 2014/00712963 A1 1/2014 Kotsbak WO 2004/027093 A1 4/2004 2014/0073511 A1 3/2014 Qin WO 2004/027093 A1 4/2004 2014/0349888 A1 11/2014 Rajasekaran et al. WO 2007/038647 A2 4/2007 2015/0038373 A1 2/2015 Banyai et al. WO 2008/0778868 A1 7/2007 2015/0246336 A1 9/2015 Somoza et al. WO 2008/118167 A1 10/2008 2016/0099737 A1 1/2016 Ikeda et al. WO 2008/151146 A2 12/2008 2016/0144368 A1 5/2016 Isami et al. WO 2009/132321 A1 10/2009 2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2010/060155 A1 6/2010 2017/0168047 A1 6/2017 Aghvanyan et al. WO 2010/086576 A1 7/2010 2016/0193608 A1 7/2016 Isami et al. WO 2010/086576 A1 7/2010 2017/0192007 A1						6/2001
2013/0084532 A1 4/2013 Wu et al. WO 2003/038033 A2 5/2003 2014/0031239 A1 1/2014 Kotsbak WO 2003/104273 A2 12/2003 2014/0072963 A1 3/2014 Qin WO 2005/014696 A1 2/2004 2014/0073511 A1 3/2014 Wong et al. WO 2005/014696 A1 2/2005 2014/0349888 A1 11/2014 Rajasekaran et al. WO 2007/078868 A1 7/2007 2015/0246336 A1 9/2015 Somoza et al. WO 2008/18167 A1 10/2007 2016/0099737 A1 1/2016 Ikeda et al. WO 2008/151146 A2 12/2008 2016/0144368 A1 5/2016 Isami et al. WO 2008/151146 A2 12/2008 2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2009/132321 A1 10/2009 2016/0193608 A1 7/2016 Isa						
2014/0031239 A1 1/2014 Kotsbak WO 2003/104273 A2 12/2003 2014/0072963 A1 3/2014 Qin WO 2004/027093 A1 4/2004 2014/0073511 A1 3/2014 Wong et al. WO 2007/038647 A2 4/2007 2014/0349888 A1 11/2014 Rajasekaran et al. WO 2007/078868 A1 7/2007 2015/0246336 A1 9/2015 Somoza et al. WO 2008/097370 A2 8/2008 2016/0009737 A1 1/2016 Ikeda et al. WO 2008/151146 A2 12/2008 2016/014368 A1 5/2016 Isami et al. WO 2009/132321 A1 10/2008 2016/0193608 A1 7/2016 Esfandyarpour et al. WO 2010/060155 A1 6/2010 2017/0168047 A1 6/2016 Esfandyarpour et al. WO 2010/085763 A1 7/2010 2017/0192007 A1 7/2016						
2014/0072963 A1 3/2014 Qin WO 2004/027093 A1 4/2004 2014/0072511 A1 3/2014 Wong et al. WO 2005/014696 A1 2/2005 2014/0349888 A1 11/2014 Rajasekaran et al. WO 2007/078868 A1 7/2007 2015/0038373 A1 2/2015 Banyai et al. WO 2008/097370 A2 8/2008 2015/0246336 A1 9/2015 Somoza et al. WO 2008/097370 A2 8/2008 2015/0246336 A1 9/2015 Somoza et al. WO 2008/118167 A1 10/2008 2016/0009737 A1 1/2016 Ikeda et al. WO 2008/151146 A2 12/2008 2016/0144368 A1 5/2016 Isami et al. WO 2008/151146 A2 12/2008 2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2010/060155 A1 6/2010 2016/0193608 A1 7/2016 Isami et al. WO 2010/085763 A1 7/2010 2017/0168047 A1 6/2017 Aghvanyan et al. WO 2010/096593 A2 8/2010 2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/0106795 A1 4/2018 Rajasekaran et al. WO 2011/034620 A2 3/2011 2018/0218250 A1 8/2018 David et al. WO 2011/034620 A2 3/2011 2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0262794 A1 8/2019 Rajasekaran et al. WO 2012/122929 A1 9/2012 2019/0262794 A1 8/2019 Rajasekaran et al. WO 2012/154594 A1 11/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran et al. WO 2013/119845 A1 8/2013						
2014/0073511 A1 3/2014 Wong et al. WO 2005/014696 A1 2/2005 2014/0349888 A1 11/2014 Rajasekaran et al. WO 2007/038647 A2 4/2007 2015/0246336 A1 2/2015 Banyai et al. WO 2008/097370 A2 8/2008 2015/0246336 A1 9/2015 Somoza et al. WO 2008/18167 A1 10/2008 2016/0009737 A1 1/2016 Ikeda et al. WO 2008/151146 A2 12/2008 2016/0144368 A1 5/2016 Isami et al. WO 2009/132321 A1 10/2009 2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2010/060155 A1 6/2010 2016/0193608 A1 7/2016 Isami et al. WO 2010/085763 A1 7/2010 2017/018007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/016795 A1 4/2018<						
2014/0349888 A1 11/2014 Rajasekaran et al. WO 2007/038647 A2 4/2007 2015/038373 A1 2/2015 Banyai et al. WO 2008/097370 A2 8/2008 2015/0246336 A1 9/2015 Somoza et al. WO 2008/118167 A1 10/2008 2016/0009737 A1 1/2016 Ikeda et al. WO 2008/151146 A2 12/2008 2016/0144368 A1 5/2016 Isami et al. WO 2009/132321 A1 10/2009 2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2010/060155 A1 6/2010 2017/0186047 A1 6/2016 Isami et al. WO 2010/085763 A1 7/2010 2017/0188047 A1 6/2017 Aghvanyan et al. WO 2010/096593 A2 8/2010 2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/019675 A1 4						
2015/0038373 A1						
2015/0246336 A1 9/2015 Somoza et al. WO 2008/151146 A2 12/2008 2016/0009737 A1 1/2016 Ikeda et al. WO 2008/151146 A2 12/2008 2016/0144368 A1 5/2016 Isami et al. WO 2009/132321 A1 10/2009 2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2010/060155 A1 6/2010 2016/0193608 A1 7/2016 Isami et al. WO 2010/085763 A1 7/2010 2017/0168047 A1 6/2017 Aghvanyan et al. WO 2010/096593 A2 8/2010 2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/0106795 A1 4/2018 Rajasekaran et al. WO 2011/034620 A2 3/2011 2018/0218250 A1 8/2018 David et al. WO 2011/058136 A1 5/2011 2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0262794 A1 8/2019 Rajasekaran WO 2012/124594 A1 11/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013	2015/0038373 A1					
2016/0144368 A1 5/2016 Isami et al. WO 2008/13140 A2 12/2008 2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2010/060155 A1 10/2009 2016/0193608 A1 7/2016 Isami et al. WO 2010/085763 A1 7/2010 2017/0168047 A1 6/2017 Aghvanyan et al. WO 2010/096593 A2 8/2010 2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/0106795 A1 4/2018 Rajasekaran et al. WO 2011/034620 A2 3/2011 2018/0218250 A1 8/2018 David et al. WO 2011/058136 A1 5/2011 2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0227704 A1 7/2019 Tschanz WO 2012/12559 A1 9/2012 2019/0366291 A1 12/2019 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
2016/0186252 A1 6/2016 Esfandyarpour et al. WO 2010/060155 A1 6/2010 2016/0193608 A1 7/2016 Isami et al. WO 2010/085763 A1 7/2010 2017/0168047 A1 6/2017 Aghvanyan et al. WO 2010/096593 A2 8/2010 2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/0106795 A1 4/2018 Rajasekaran et al. WO 2011/034620 A2 3/2011 2018/0218250 A1 8/2018 David et al. WO 2011/058136 A1 5/2011 2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0217704 A1 7/2019 Tschanz WO 2012/12599 A1 9/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 11/2012 2020/0095635 A1 3/20						
2016/0193608 A1 7/2016 Isami et al. WO 2010/085763 A1 7/2010 2017/0168047 A1 6/2017 Aghvanyan et al. WO 2010/096593 A2 8/2010 2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/0106795 A1 4/2018 Rajasekaran et al. WO 2011/034620 A2 3/2011 2018/0218250 A1 8/2018 David et al. WO 2011/058136 A1 5/2011 2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0262794 A1 7/2019 Tschanz WO 2012/12599 A1 9/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 11/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013						
2017/0168047 A1 6/2017 Aghvanyan et al. WO 2010/096593 A2 8/2010 2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/0106795 A1 4/2018 Rajasekaran et al. WO 2011/034620 A2 3/2011 2018/0218250 A1 8/2018 David et al. WO 2011/058136 A1 5/2011 2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0217704 A1 7/2019 Tschanz WO 2012/122959 A1 9/2012 2019/0366291 A1 8/2019 Rajasekaran WO 2012/154594 A1 11/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013			<i>J</i> 1			
2017/0192007 A1 7/2017 Rajasekaran et al. WO 2011/027048 A1 3/2011 2018/0106795 A1 4/2018 Rajasekaran et al. WO 2011/034620 A2 3/2011 2018/0218250 A1 8/2018 David et al. WO 2011/058136 A1 5/2011 2019/019/4745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0217704 A1 7/2019 Tschanz WO 2012/122959 A1 9/2012 2019/0262794 A1 8/2019 Rajasekaran WO 2012/154594 A1 11/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013						
2018/0218250 A1 8/2018 David et al. WO 2011/058136 A1 5/2011 2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0217704 A1 7/2019 Tschanz WO 2012/122959 A1 9/2012 2019/0262794 A1 8/2019 Rajasekaran WO 2012/154594 A1 11/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013				WO	2011/027048 A1	3/2011
2019/0194745 A1 6/2019 Rajasekaran WO 2012/122929 A1 9/2012 2019/0217704 A1 7/2019 Tschanz WO 2012/122959 A1 9/2012 2019/0262794 A1 8/2019 Rajasekaran WO 2012/154594 A1 11/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013						
2019/0217704 A1 7/2019 Tschanz WO 2012/122959 A1 9/2012 2019/0262794 A1 8/2019 Rajasekaran WO 2012/154594 A1 11/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013						
2019/0262794 A1 8/2019 Rajasekaran WO 2012/154594 A1 11/2012 2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013						
2019/0366291 A1 12/2019 Rajasekaran et al. WO 2012/174479 A1 12/2012 2020/0095635 A1 3/2020 Rajasekaran WO 2013/119845 A1 8/2013						
2021/0380629 A1 12/2021 Rajasekaran et al. WO 2014/052989 A2 4/2014						
	2021/0380629 A1	12/2021	Kajasekaran et al.	WO	2014/052989 A2	4/2014

(56)	References Cited
	FOREIGN PATENT DOCUMENTS
WO WO WO WO WO	2014/078606 A2 5/2014 2014/127328 A2 8/2014 2014/150851 A1 9/2014 2015/016315 A1 2/2015 2015/029691 A1 3/2015 2015/127409 A1 8/2015
WO WO WO	2016145434 A1 9/2016 2017/117292 A1 7/2017 2018218250 11/2018 2019217704 A1 11/2019

OTHER PUBLICATIONS

Zivic et al, Recent Advances and Challenges in the Design of Organic Photoacid and Photobase Generators for Polymerizations, 2019, Angew. Chem. Int. Ed. 2019, 58, 10410-10422. (Year: 2019).* Nielsen, P. et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide," Science, vol. 254, Iss. 5037, Dec. 6, 1991, pp. 1497-1500.

PCT/US2016/069017—International Search Report and Written Opinion, Apr. 21, 2017, 14 pages.

Seo et al., Four-color DNA sequencing by synthesis on a chip using photocleavable fluorescent nucleotides, 2005, PNAS, 102, 5926-5931.

Golubev, O. et al., "Formation of Mixed-Ligand Complexes of Pd2+ with Nucleoside 5'-Monophosphates and Some Metal-Ion-Binding Nucleoside Surrogates," Molecules, Oct. 22, 2014, vol. 19, No. 10, pp. 16976-16986.

PCT/US18/34939—International Search Report and Written Opinion, Nov. 15, 2018, 25 pages.

PCT/US18/34939—Invitation to Pay Additional Fees, Sep. 18, 2018, 2 pages.

Rothberg, J. et al., "An Integrated Semiconductor Device Enabling Non-Optical Genome Sequencing," Nature, vol. 475, Jul. 21, 2011, pp. 348-352.

Roy, B. et al., "Recent Trends in Nucleotide Synthesis," Chemical Reviews, 116(14), Jun. 20, 2016, pp. 7854-7897.

Shirai, M. et al., "Photoacid and Photobase Generators: Chemistry and Applications to Polymeric Materials," Progress in Polymer Science, vol. 21, Iss. 1, 1996, pp. 1-45.

Singh, Y. et al., "Recent Developments in Oligonucleotide Conjugation," Chemical Society Reviews, Iss. 6, Apr. 14, 2010, pp. 2054-2070.

Alawode, O. E. et al., "Clean Photodecomposition of 1-Methyl-4-Phenyl-1HTetrazole-5(4H)-Thiones to Carbodiimides Proceeds Via a Biradical," The Journal of Organic Chemistry, Jan. 7, 2011, pp. 216-222, vol. 76, No. 1.

Arimitsu K. et al., "Development of Highly Sensitive Photoreactive Materials Utilizing Photobase-generating Reactions and Base Proliferation Reactions", Journal Of Synthetic Organic Chemistry Japan, Jan. 1, 2012, pp. 508-516, vol. 70(5), Yuki Gosei Kagaku Kaokai, Tokyo, JP (with English Abstract).

Balakirev, M et al., "Photochemical Patterning of Biological Molecules Inside a Glass Capillary," Analytical Chemistry, vol. 77, No. 17, Sep. 1, 2005, pp. 5474-5479.

Ballew, J.T., "Antibody Biomarker Discovery Through in Vitro Directed Evolution of Consensus Recognition Epitopes," Proceedings of the National Academy of Sciences of the United States of America, Nov. 26, 2013, pp. 19330-19335, vol. 110, No. 48.

Beyer et al., "Combinatorial Synthesis of Peptide Arrays Onto a Microchip," Science, Dec. 21, 2007, p. 1888, vol. 318, 1 page and Sci. vol. 318 p. 1888 supporting online material, 6 pp.

Buus, S. et al., "High-Resolution Mapping of Linear Antibody Epitopes Using Ultrahigh-Density Peptide Microarrays," Molecular & Cellular Proteomics, Dec. 2012, pp. 1790-1800, vol. 11, No. 12. Camarero, J., "Recent Developments in the Site-Specific Immobilization of Proteins Onto Solid Supports," Biopolymers, 2008, pp. 450-458, vol. 90, No. 3.

Carra, C. et al., "Proton-Coupled Electron Transfer in a Model for Tyrosine Oxidation in Photosystem II," Journal of the American Chemical Society, 2003, pp. 10429-10436, vol. 125.

Chen, "Solid-Phase Peptide Synthesis (SPPS) and Applications of Synthetic Peptides," Proteomics 2010, Jan. 2010, 63 pages [Online] [Retrieved on Sep. 16, 2015] Retrieved from the Internet<URL:http:/bas.niu.edu.tw/download.php?filename=12155_cf09f16c.ppt&dir=communicty_forum/31&title=Topic+10-SPPS>.

Choung, R.S. et al., "Determination of B-Cell Epitopes in Patients with Celiac Disease: Peptide Microarrays," PLOS One, Jan. 29, 2016, e0147777, pp. 1-16, vol. 11, No. 1.

"Compound Summary for: CID 44140593, Tris(2,2'-bipyridine)ruthenium(II) dichloride," PubChem Compound, 2009 Retrieved from the Internet Jun. 29, 2014: http://pubchem.ncbi.nlm.gov.summary/summary.cgi?cid=44140593&loc=ec res>.

Fathalla, E., et al., "Efficient Synthesis of 1-Substituted-4-phenyl-1, 4-dihydro-SH-tetrazole-5-thione and (1-Phenyl-1H-tetrazol-5-yl)thiozcetyl Derivatives," Heteroatom Chemistry, 2007, vol. 18, No. 6, pp. 637-643.

Fan et al., Polyglutamine (PolyQ) diseases genetics to treatments Cell Transplant 23: 441-458, 2014.

Gomez-Zavaglia, A., et al., "Molecular structure, vibrational spectra and photochemistry of 5-mercapto-1-methyltetrazole," Journal of Molecular Structure, 2006, vol. 786, pp. 182-192.

Gunda, N. et al., "Micro-Spot with Integrated Pillars (MSIP) for Detection of Dengue Virus NS1," Biomed Microdevices, vol. 15, 2013, pp. 959-971.

Gundagola, A.S.V., Synthesis, Photochemistry, and DNA Photocleavage of Compounds Containing Tetrazolethione Scaffolds, Kansas State University, 2011, 3 pages, [Online] [Retrieved on May 1, 2015] Retrieved from the Internet <URL: http://krex.kstate.edu/dspace/handle/2097/12022>.ex.kstate.edu/dspace/handle/2097/12022>, 2 pages.

Han, S-Y. et al., "Recent Development of Peptide Coupling Reagents in Organic Synthesis," Tetrahedron, 2004, pp. 2447-2467, vol. 60. Lim, J-H. et al., "Direct-Write Dip-Pen Nanolithography of Proteins on Modified Silicon Oxide Surfaces," Angewandte Chemie International Edition, Wiley—VCH Verlag GmbH & Co., May 25, 2003, pp. 2309-2312, vol. 42, No. 20.

Lin et al., "Synthesis of Water Soluble Photoinitiators of Thioxanthone Derivatives III" Huadong Ligong Daxue Xuebao, Journal of East China University of Science and Technology, 2000, pp. 212-214, 220, vol. 26, No. 2 (with English abstract).

Meinl, E. et al., "Myelin Basic Protein-Specific T Lymphocyte Repertoire in Multiple Sclerosis, Complexity of the Response and Dominance of Nested Epitopes Due to Recruitment of Multiple T Cell Clones," The Journal of Clinical Investigation, Dec. 1993, pp. 2633-2643, vol. 92, No. 6.

Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," J Am. Chem. Soc., Jul. 20, 1963, pp. 2149-2154, vol. 85, No. 14.

Pellois, J.P. et al., "Individually Addressable Parallel Peptide Synthesis on Microchips". Nature Biotechnology, Sep. 2002, pp. 922-926, vol. 20, No. 9.

Piehler, J. et al., "Protein Interactions in Covalently Attached Dextran Layers," Colloid and Surfaces B: Biointerfaces 13 (1999), pp. 325-336.

Resch-Genger et al., "Quantum Dots Versus Organic Dyes as Fluorescent Labels," Nature Methods, Sep. 2008, pp. 763-775, vol. 5. No. 9.

Sardesai, N.P. et al., "A Microfluidic Electrochemiluminescent Device for Detecting Cancer Biomarker Proteins," Anal. Bioanal. Chem. Epub Jan. 11, 2013, pp. 3831-3138, vol. 405, No. 11.

Shin, D-S. et al., "Automated Maskless Photolithography System for Peptide Microarray Synthesis on a Chip," J. Comb. Chem., 2010, pp. 463-471, vol. 12.

Sun, X. et al., "Bicyclic Guanidinium Tetraphenylborate: A Photobase Generator and a Photocatalyst for Living Anionic Ring-Opening Polymerization and Cross-Linking of Polymeric Materials Containing Ester and Hydroxy Groups," Journal of the American Chemical Society, Jul. 2008, pp. 8130-8131, vol. 130, No. 26.

(56) References Cited

OTHER PUBLICATIONS

Suyama K. et al., "Photobase Generators: Recent Progress and Application Trend in Polymer Systems", Progress In Polymer Science, Feb. 1, 2009, pp. 194-209, vol. 34(2), Pergamon Press, Oxford, GB.

Tapia, V. et al., "Evaluating the Coupling Efficiency of Phosphorylated Amino Acids for Spot Synthesis," J. Peptide Sci., 2008, pp. 1309-1314, vol. 14, No. 12.

Takahashi et al., Polyglutamne diseases: Where does toxicity come from? What is Toxicity? Where are we going? (J Mol Cell Biol 2: 180-191, 2010.

Thermofisher Scientific, "Molecular ProbesTM Handbook: A Guide to Fluorescent Probes and Labeling Technologies," 11th edition, 2010, pp. 170-188.

Uddayasankar, U., "Towards a Surface Microarray Based Multiplexed Immunoassay on a Digital Microfluidics Platform," 2010, pp. 1-69, Master of Science Thesis. [Retrieved from the Internet Jun. 29, 2014: https://cipweb.cardinal-ip.com/PCTSRS/PCTSRS DAT A/PCT-US%2014-16737/PRIOR_ART PCTPCTUS14-16737 Uddayasankar Master Thesis 2010.pdf>.

Wagner, "Quality Control for Peptide Chip Array Production," PHD Thesis, 2011, 140 pages, [Online] [Retrieved on Jun. 14, 2013] Retrieved from the Internet<URL:http://archiv.ub.uni-heidelberg.de/volltextserver/12602/1/report.pdf>.

Wang et al, Microfluidic DNA microarray analysis: A review, 2011, Analytica Chimica Acta, 687, 12-27.

Wei, H. et al., "Electrochemiluminescence of tris(2, 2'-bipyridyl)ruthenium and Its Applications in Bioanalysis: A Review," Luminescence, Mar.-Apr. 2011, pp. 77-85, vol. 26, Issue 2.

Young, J.D. et al., "Coupling Efficiencies of Amino Acids in the Solid Phase Synthesis of Peptides," Peptide Research, Jul. 1990, pp. 194-200, vol. 3, No. 4.

Yuan et al., "Integrated Tyramide and Polymerization-Assisted Signal Amplification for a Highly-Sensitive Immunoassay," Anal. Chem., 2012, pp. 10737-10744, vol. 84, No. 24.

Zhao, Y. et al., "A Fluorescent Amino Acid Probe to Monitor Efficiency of Peptide Conjugation to Glass Surfaces for High Density Microarrays," Mol. Biosyst., Epub Jan. 13, 2012, pp. 879-887, vol. 8, No. 3.

U.S. Appl. No. 15/977,951—Office Action, dated Aug. 30, 2019, 21 pages.


U.S. Appl. No. 14/941,404—Office Action, Dec. 11, 2018, 9 pages. U.S. Appl. No. 15/120,452—Office Action, Sep. 18, 2017, 14 pages. U.S. Appl. No. 16/019,449—Office Action, Apr. 29, 2019, 7 pages. U.S. Appl. No. 16/287,968—Office Action, Jan. 6, 2020, 8 pages. PCT/US18/34939—International Preliminary Report on Patentability, Dec. 5, 2019, 15 pages.

Uhlmann E., "Peptide nucleic acids (PNA) and PNA-DNA chimeras: from high binding affinity towards biological function", Biol Chem, 1998, vol. 379, No. 8-9, pp. 1045-1052.

PCT/US2019/031555—International Preliminary Report on Patentability, Nov. 19, 2020, 10 pages.

Ucar, Ultraviolet (UV) Radiation, Center for Science Education, 2017, 1-3. (Year: 2017).

* cited by examiner



where n is 0-3 & X is OMe/ H/ photoactive group

Figure 1

Figure 2

Nov. 26, 2024




Figure 4

2-Position

Nov. 26, 2024

Figure 7




Figure 6A






Figure 6B

Nucleic Acid Binding



UV Light Exposure



(pH change according to its binding nucleic acid. $\Delta pH \propto \Delta I_d)$

Figure 7

ဗ ပ

Nov. 26, 2024

DNA Sequencing Result (detect one nucleotide at a time)





Figure 8






Figure 10




Figure 11




Figure 12







Figure 13







Primer	4	5,4	ph Reading	ading	Primer		24. A	ph Re	ph Reading
Extension	Sample	Cair Cair	WT Adapter MT Adapter	MT Adapter	Extension	Sample	Call	WT Adapter	MT Adapter
	Sample 1	Homozygous Wild	2.3	7.35		Sample 1	Homozygous Wild	12.21	7.33
	Sample 2	Homozygous Wild	2.36	7.4		Sample 2	Homozygous Wild	12.21	7.49
	Sample 3	Homozygous Wild	2.41	7.41		Sample 3	Homozygous Wild	12.27	7.46
	Sample 4	Homozygous Wild	2.49	7.34		Sample 4	Homozygous Wild	12.37	7.37
2	Sample 5	Hetrozygous	2.36	2.48	0,000	Sample 5	Hetrozygous	12.27	12.2
FEWIT	Sample 6	Hetrozygous	2.42	2.44	rcivio	Sample 6	Hetrozygous	12.27	12.29
	Sample 7	Hetrozygous	2.31	2.42		Sample 7	Hetrozygous	12.37	12.34
	Sample 8	Homozygous Mutant	7.47	2.39		Sample 8	Homozygous Mutant	7.49	12.25
	Sample 9	Homozygous Mutant	7.35	2.45		Sample 9	Homozygous Mutant	7.45	12.29
	Sample 10	Homozygous Mutant	7.35	2.46		Sample 10	Homozygous Mutant	7.35	12.38
Primer		2	ph Reading	ading	Primer	of the second of	200	ay dd	ph Reading
Extension	ခရေးမှင	Ç	WT Adapter MT Adapter	MT Adapter	Extension	aidilibc	-ca!!	WT Adapter	MT Adapter
	Sample 1	Homozygous Wild	3.81	7.48		Sample 1	Homozygous Wild	11	7.49
	Sample 2	Homozygous Wild	3.86	7.42		Sample 2	Homozygous Wild	11.06	7.49
	Sample 3	Homozygous Wild	3.9	7.39		Sample 3	Homozygous Wild	11.08	7.49
	Sample 4	Homozygous Wild	3.73	7.3		Sample 4	Homozygous Wild	10.92	7.4
DERAD	Sample 5	Hetrozygous	3.78	3.74	DEST	Sample 5	Hetrozygous	11.1	10.94
7.00	Sample 6	Hetrozygous	3.74	3.83	- C.IVI-7	Sample 6	Hetrozygous	11.05	11.06
	Sample 7	Hetrozygous	3.9	3.87		Sample 7	Hetrozygous	10.97	10.97
	Sample 8	Homozygous Mutant	7.43	3.81		Sample 8	Homozygous Mutant	7.37	11.06
	Sample 9	Homozygous Mutant	7.39	3.7		Sample 9	Homozygous Mutant	7.47	11.09
	Sample 10	Homozygous Mutant	7.4	3.87		Sample 10	Homozygous Mutant	7.49	11.06

Nov. 26, 2024

Figure 18





Figure 19B






Figure 19D

Figure 20

Figure 21

PM7

Figure 22

PM8

Figure 23

			pН		
Sample ID	Mutation	Original Result	Reading	HM Call	Calculated Result
MT1	rs1801133	Homozygous Wild C/C	2.71	HM5	Homozygous Wild C/C
MT2	rs1801133	Homozygous Wild C/C	2.75	HM5	Homozygous Wild C/C
MT3	rs1801133	Homozygous Wild C/C	2.87	HM5	Homozygous Wild C/C
MT12	rs1801133	Heterozygous C/T	6.84	HM5, HM7	Heterozygous C/T
MT13	rs1801133	Heterozygous C/T	6.79	HM5, HM7	Heterozygous C/T
MT14	rs1801133	Heterozygous C/T	6.855	HM5, HM7	Heterozygous C/T
MT15	rs1801133	Homozygous Mutant T/T	11.04	HM7	Homozygous Mutant T/T
MT16	rs1801133	Homozygous Mutant T/T	11.01	HM7	Homozygous Mutant T/T
MT17	rs1801133	Homozygous Mutant T/T	11.12	HM7	Homozygous Mutant T/T
No					
Template	rs1801133	No Template Control	7,34	None	No Template Control

Figure 24A

			ВH		
Sample ID	Mutation	Original Result	Reading	HM Call	Calculated Result
P91	rs10757274	Homozygous Wild A/A	3.92	НМ6	Homozygous Wild A/A
P92	rs10757274	Homozygous Wild A/A	3.93	нм6	Homozygous Wild A/A
P93	rs10757274	Homozygous Wild A/A	3.92	НМ6	Homozygous Wild A/A
P912	rs10757274	Heterozygous A/G	7.065	HM6, HM8	Heterozygous A/G
P913	rs10757274	Heterozygous A/G	7.05	HM6, HM8	Heterozygous A/G
P914	rs10757274	Heterozygous A/G	7.085	HM6, HM8	Heterozygous A/G
P915	rs10757274	Homozygous Mutant G/G	10.11	HM8	Homozygous Mutant G/G
P916	rs10757274	Homozygous Mutant G/G	10.1	HM8	Homozygous Mutant G/G
P917	rs10757274	Homozygous Mutant G/G	10.24	нм8	Homozygous Mutant G/G
No					
Template	rs10757274	No Template Control	7.38	None	No Template Control

Figure 24B

PHOTOACTIVE COMPOUNDS AND METHODS FOR BIOMOLECULE DETECTION AND SEQUENCING

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 16/709,423, filed Dec. 10, 2019, which application is a divisional of U.S. application Ser. No. 15/991,706, filed on May 29, 2018, which claims the benefit of U.S. Provisional Patent Application No. 62/511,786, filed May 26, 2017, each of which is incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 27, 2018, is named 40697US_CFR_sequencelisting.txt and is 6,997 bytes in size.

BACKGROUND

Microarray technologies can facilitate detection of many 25 features per square centimeter. This can include detection via probe binding methodologies to detect or accurately quantify the presence of biomolecules and to characterize these biomolecules, e.g., by determining a specific conformation or sequence. As more information continues to be 30 processed at faster rates, certain features start to become problematic as limiting to the amount of information that can be obtained. For example, many detection technologies, such as probe detection and sequencing rely on monitoring fluorophores and distinguishing fluorophores bound to 35 known probes. The use of fluorophore tags limits the size of the features on a chip due to the diffraction limit, and also can be difficult to detect at small concentrations. Alternative detection technologies exist, but they need further development to provide a suitable improvement to fluorophore- 40 based detection technologies. Therefore, what are needed are alternatives to fluorophore-based detection technologies to improve detection accuracy and facilitate a reduction of feature size for higher throughput and more efficient detec-

As one example, a typical solid support-based detection assay is generally comprised of probes that bind to biologically relevant or active molecules for example, RNA, DNA, or peptides. Probes that bind to target molecules or the target molecules themselves can be covalently attached to a solid 50 planar surface for example, glass, polymer (bead or even plastic composites), or most often, a silicon chip. Additionally, instruments are needed to handle samples (automated robotics), to read the reporter molecules (scanners) and analyze the data (bioinformatic tools). Recently, science has 55 moved toward a unitary machine to perform these much need analyses. In order to marry the chemistry and biology with electronics, silicon wafers are most often used as the solid support or substrate. The term "lab on a chip" has since been coined to describe such an arrangement.

Microarrays technology can facilitate monitoring of many probes per square centimeter. The advantages of using multiple probes include, but are not limited to, speed, adaptability, comprehensiveness and the relatively cheaper cost of high volume manufacturing. The uses of such an 65 array include, but are not limited to, diagnostic microbiology, including the detection and identification of pathogens,

2

investigation of anti-microbial resistance, epidemiological strain typing, investigation of oncogenes, analysis of microbial infections using host genomic expression, and polymorphism profiles.

Recent advances in genomics have culminated in sequencing of entire genomes of several organisms, including humans. Genomics alone, however, cannot provide a complete understanding of cellular processes that are involved in disease, development, and other biological phenomena; because such processes are often directly mediated by polypeptides. Given that huge numbers of polypeptides are encoded by the genome of an organism, the development of high throughput technologies for analyzing polypeptides, amongst many other diverse biomolecules, is of paramount is importance.

Peptide arrays with distinct analyte-detecting regions or probes can be assembled on a single substrate by techniques well known to one skilled in the art. A variety of methods are available for creating a peptide microarray. These methods include: (a) chemo selective immobilization methods; and (b) in situ parallel synthesis methods which can be further divided into (1) SPOT synthesis and (2) photolithographic synthesis. These methods are labor intensive and not suited for high throughput. These peptide arrays are expensive to manufacture, have low repeatability, may be unstable, require stringent storage conditions, take a long time to manufacture, and are limited in other ways. Further, while peptide-nucleic acid arrays are useful for identifying biomolecules, there is currently no way to deduce the binding strength or sequence.

What is needed therefore, are improved substrates or arrays and methods to elucidate and replicate biomolecule sequences and measure the binding of one or more biomolecules.

As another specific example, next generation sequencing technologies, including sequencing-by-synthesis, continue to pursue the goal of providing rapid sequencing data at a reasonable cost. This can be used to provide improved health care through individualized medicine and improved diagnostics. Despite many improvements in the past decades, this technology still has limitations in cost and throughput that prevent widespread use. Overcoming these limitations can provide a dramatic impact in several fields, including comparative genomics, high-throughput polymorphism detection, mutation screening, metagenomics, and transcriptome profiling.

Sequencing by synthesis of template DNA bound to a surface is commonly done using fluorophore-labeled, reversible terminator nucleotides. These nucleotides generate a signal corresponding to the sequence of a surface-bound template strand when incorporated into a complementary growing strand. For example, U.S. Pat. No. 7,622, 279 teaches a fluorescence-based method for sequencing four modified nucleotides with photocleavable fluorescence molecules bound to the side chain of the four nucleic acid bases.

However, optical detection methods have a limited minimum feature size due to diffraction limited detection of fluorophores. Furthermore, imaging of an array of signals and processing the image to generate discrete endpoints can take time and be computationally demanding. Thus, alternative methods of nucleotide identity detection, such as electronic detection are also being explored.

One such method of electronic detection, Ion Sensitive Field Effect Transistors (ISFET), is able to detect small changes in the pH of a reaction volume. Non-optical genome sequencing using ISFET has been performed by adding a

single nucleotide at a time to detect the release of an H+ ion upon incorporation of a correct base pair by a polymerase into a growing strand. However, this method is limited by the requirement of separate sequential addition of four individual nucleotides to determine the identity of the next onucleotide. Using ISFET detection, samples can be distributed on an array at the sub-micron level, and multiple arrays can be read simultaneously in a single device.

What is needed therefore, are improved methods, compositions, substrates and arrays for determining a polynucle-otide sequence based on electronic detection to allow reduce feature size on an array for increased information density with output that allows for more efficient analysis.

Furthermore, arrays comprising primers or probes to bind to target sequences to allow sequencing are also needed to enable efficient binding of target polynucleotides for to an array for subsequent sequencing. Also needed are methods and compositions for manufacturing arrays comprising the probes.

SUMMARY

According to some embodiments, provided herein is a ²⁵ probe capable of binding specifically to a target biomolecule, wherein said probe is bound to a photoactive group. In some embodiments, the photoactive group is a photoacid generator or a photobase generator.

In some embodiments, the photobase generator produces an organic compound having a pKa of 9 or higher, 10 or higher, 11 or higher, 12 or higher, 13 or higher, or 14 or higher upon exposure to an activating radiation. In some embodiments, the photoacid generator produces an organic compound having a pKa of 5 or lower, 4 or lower, 3 or lower, 2 or lower, or 1 or lower upon exposure to an activating radiation.

In some embodiments, the photoacid generator is selected from the group consisting of: an o-acyloxime, a benzoyloxycarbonyl derivative, a photoactive carbamates, an oxime ester compounds, an ammonium compound, a benzoin compound, a dimethoxybenzyl urethane compound, an orthonitrobenzyl urethane compound, an aromatic sulfonamide, an alpha-lactams, and an N-(2-arylethenyl) amide. In some embodiments, the photoacid generator is selected from: the photoactive group of PM1 and the photoactive group of PM2.

In some embodiments, the photobase generator is selected from the group consisting of: a 2-hydroxy-2-phenylaceto-phenone N-cyclohexyl carbamate, an o-nitrobenzyl N-cyclohexyl carbamate, an N-cyclohexyl-2-naphthalene sulfonamide, a 3,5-dimethoxybenzyl N-cyclohexyl carbamate, an N-cyclohexyl p-toluene sulfonamide; and a dibenzoin iso-phorone dicarbamate. In some embodiments, the photobase generator is selected from the group consisting of: the photoactive group of PM3 and the photoactive group of PM4.

In some embodiments, the photoactive group is cleaved upon exposure to an activating radiation. In some embodiments, the cleavage is homolytic cleavage. In some embodiments, the photoactive group initiates a downstream reaction upon exposure to an activating radiation.

In some embodiments, the photoactive group comprises 65 an ionic organic salt. In some embodiments, the photoactive group comprises an onium salt.

4

In some embodiments, the probe comprises a polypeptide. In some embodiments, the photoactive group is bound to said polypeptide. In some embodiments, the photoactive group is bound to a histidine side chain, a proline side chain, or a tyrosine side chain of said polypeptide.

In some embodiments, the probe is a polynucleotide or a single nucleotide. In some embodiments, the photoactive group is bound to a nucleobase of said polynucleotide or said single nucleotide. In some embodiments, the photoactive group is bound to a 2' or 5' carbon of said polynucleotide or said single nucleotide. In some embodiments, the single nucleotide comprises a removable blocking group. In some embodiments, the single nucleotide comprises a dideoxy terminator.

In some embodiments, the probe is selected from the group consisting of: a protein, a polypeptide, a glycoprotein, an oligosaccharide, and a glycolipid. In some embodiments, the probe is an antibody.

In some embodiments, provided herein is a composition comprising a nucleotide according to Formula I:

$$Z \longrightarrow [O_3P]_n \longrightarrow O \longrightarrow X$$

$$[PO_3]_n \longrightarrow Z$$

T

wherein

n is from 0-3;

X is selected from the group consisting of: H, OPg, and a photoactive group, where

Pg is a protecting group;

A is NH when

and A is N when

15

20

25

5

E is O when

and A is N when

and E is NHZ when

and

each Z is independently selected from the group consisting of: H, Me, and a photoactive group;

wherein at least one of said Z or X is said photoactive group.

In some embodiments, provided herein is a composition comprising a nucleotide according to Formula II:

$$Z \longrightarrow [O_3P]_n \longrightarrow O \longrightarrow N \longrightarrow N \longrightarrow Z$$

$$[PO_3]_n \longrightarrow Z$$

wherein

n is from 0-3;

X is selected from the group consisting of: H, OPg, and a photoactive group, where

Pg is a protecting group;

A is NH when

E is O when

6

and E is NHZ when

and

35

ΙΙ

each Z is independently selected from the group consisting of: H, Me, and a photoactive group;

wherein at least one of said Z or X is said photoactive group.

Also provided herein, according to some embodiments, is a composition comprising a modified nucleotide comprising a photoacid or photobase generator.

Also provided herein, according to some embodiments, is a composition comprising a modified nucleotide selected from the group consisting of: PM1, PM2, PM3, PM4, PM5, PM6, PM7, and PM8.

In some embodiments, the modified nucleotide is bound 45 to a removable blocking group. In some embodiments, the removable blocking group is a reversible terminator.

Also provided herein, according to some embodiments, is a polynucleotide comprising the modified nucleotide comprising a photoactive group provided herein.

Also provided herein, according to some embodiments, is an array comprising a one or more polynucleotides comprising the modified nucleotide comprising the photoactive group as provided herein, wherein the one or more polynucleotides are immobilized to the surface of the array. In some embodiments, the polynucleotide comprises PNA or LNA. In some embodiments, the array comprises a reaction area comprising said polynucleotide, wherein said reaction area comprises a set of electrodes for electronic monitoring of the pH of a solution. In some embodiments, the array comprises at least 100, at least 1,000, or at least 10,000 of said reaction areas.

Also provided herein, according to some embodiments, is a substrate comprising one or more compositions comprising the modified nucleotide comprising the photoactive group as provided herein, wherein the composition is immobilized to the surface of the substrate. In some embodiments, the substrate comprises an electrosensor capable of detecting

a signal from said probe. In some embodiments, the electrosensor is an ion-sensitive field effect transistor.

Also provided herein, according to some embodiments, is an array of probes comprising the modified nucleotide comprising the photoactive group as provided herein.

Also provided herein, according to some embodiments, is a system an array of probes comprising the modified nucleotide comprising the photoactive group as provided herein, wherein said array is in electronic communication with a reader configured to receive an electronic signal from said 10 set of electrodes.

Also provided herein, according to some embodiments, is a method for detecting a target biomolecule, comprising: providing probe capable of binding specifically to a target biomolecule, wherein said probe is bound to a photoacid 15 generator or a photobase generator; contacting a sample suspected of comprising said target biomolecule with said probe; removing unbound probes from said sample; exposing said sample to an wavelength of light capable of activating said photoacid generator or said photobase generator, 20 such that said probe, if bound to said target biomolecule, releases an acid or a base upon exposure to said wavelength of light; and detecting a concentration of ions in the sample, thereby identifying the presence or absence of said target analyte based on a change of said concentration of ions.

In some embodiments, the probe comprises a polynucleotide or a polypeptide. In some embodiments, the probe is an antibody.

In some embodiments, the concentration of ions is determined by measuring an ionic strength of the sample. In some 30 embodiments, the ionic strength is measured using an ionsensitive field effect transistor.

In some embodiments, the sample is immobilized on the surface of a substrate. In some embodiments, the substrate is an array. In some embodiments, the array comprises a 35 plurality of wells, wherein said wells each comprise a sensor for detecting an ionic strength of a solution in said wells. In some embodiments, the sensor is an ion-sensitive field effect transistor.

Also provided herein, according to some embodiments, is 40 a method of detecting a sequence identity of a target polynucleotide, comprising: providing a substrate comprising an immobilized target polynucleotide hybridized to a primer or probe; contacting said immobilized target polynucleotide with a solution comprising reagents for perform- 45 ing a polymerase extension reaction, said solution comprising a set of modified nucleotides comprising a photoactive group and a blocking group; exposing said substrate to conditions to promote incorporation of one of said modified nucleotides at the 3' end of said primer or probe; washing 50 said substrate to remove unbound modified nucleotides; exposing said immobilized target polynucleotide to a wavelength of light to induce said photoactive group to generate an acid or a base, thereby generating a detectable change in lized target polynucleotide if said modified nucleotide is incorporated into said target polynucleotide; detecting said change in ion concentration; and determining a sequence identity of said target polynucleotide from said detected change in ion concentration.

Also provided herein, according to some embodiments, is a method of determining a sequence of a target polynucle-otide, comprising: providing an array comprising a plurality of wells, wherein said wells comprise a target polynucle-otide to be sequenced bound to a surface of said well, and 65 wherein said plurality of wells each comprise a sensor for detecting an electronic signal from said wells; performing a

8

sequencing reaction comprising performing at least one cycle, each cycle comprising: contacting said wells with a solution comprising reagents for performing a polymerase extension reaction, said solution comprising a set of modified nucleotides comprising a photoactive group and a removable blocking group; exposing said well to conditions to promote incorporation of one of said modified nucleotides at the 3' end of a primer or probe hybridized to said single polynucleotide; washing said well to remove unbound modified nucleotides; exposing said well to a wavelength of light to induce said photoactive group to generate and acid or a base, thereby generating a detectable change in ion concentration; detecting the change in ion concentration with said sensor; and if another cycle of the sequencing reaction is to be performed, removing said terminator from said incorporated nucleotide.

In some embodiments, the electronic signal is specific to the identity of the base of the modified nucleotide added to the primer at each cycle. In some embodiments, the electronic signal represents the pH of a solution in said well. In some embodiments, the electronic signal is analyzed to determine a sequence of the target polynucleotide. In some embodiments, the sensor is an ion-sensitive field effect transistor.

In some embodiments, the photoactive group is photocleavable. In some embodiments, the photoactive group is a photoacid or photobase generator. In some embodiments, the removable blocking group is a reversible terminator. In some embodiments, the reversible terminator is photocleavable.

In some embodiments, the nucleotide set comprises only one of the group consisting of: nucleotides comprising adenine, nucleotides comprising guanine, nucleotides comprising thymine, nucleotides comprising cytosine, and nucleotides comprising uracil.

In some embodiments, the nucleotide set comprises nucleotides comprising adenine, guanine, cytosine, and thymine or uracil. In some embodiments, the solution comprises a plurality of random primers. In some embodiments, the reagents for performing a polymerase extension reaction comprise a primer capable of hybridizing to said single polynucleotide.

In some embodiments, if another cycle is to be performed, the method further includes neutralizing the solution in the wells

In some embodiments, the plurality of wells each comprise only a single target polynucleotide. In some embodiments, the plurality of wells each comprise a clonal population of a target polynucleotide.

BRIEF DESCRIPTION OF THE DRAWINGS

an acid or a base, thereby generating a detectable change in concentration in a solution surrounding said immobilized target polynucleotide if said modified nucleotide is change in ion concentration; and determining a sequence identity of said target polynucleotide from said detected change in ion concentration.

Also provided herein, according to some embodiments, is

FIG. 1 shows a general structure of a modified nucleotide comprising a photoactive group at the 2' carbon, according to some embodiments.

FIG. 2 shows embodiments of covalently bound attachment points of photoactive groups to different nucleobases to make a modified nucleotide.

- FIG. 3 shows examples of photoactive groups bound to a nucleobase with or without a linker.
- FIG. 4 shows examples of salts including photoactive groups bound to a nucleobase.
- FIG. 5 shows examples of photoactive groups bound at 5 the 2' or 5' position of the ribose component of a nucleotide.
- FIGS. **6**A and **6**B shows embodiments of a removable blocking group (e.g., a reversible terminator) bound to a 3' carbon of a sugar moiety on a nucleotide (FIG. **6**A) or to the base of a nucleotide (FIG. **6**B).
- FIG. 7 shows steps in a sequencing by synthesis reaction using the modified nucleotides comprising photobase or photoacid generators, according to an embodiment of the invention (SEQ ID NO: 27).
- FIG. **8** shows results of a DNA sequencing reaction using modified nucleotides described herein and detected by monitoring pH. The sequential cycled addition of nucleotides to a growing strand generates a sequence of signals which corresponds to the sequence of the synthesized oligonucleotide or the template strand (SEQ ID NO: 27).
- FIG. 9 provides an example of such an array comprising 20 a plurality of ISFET sensors arranged along a grid.
- FIG. 10 depicts an exemplary single nucleotide primer extension reaction to detect a sequence variant (SEQ ID NOS 28-29, respectively, in order of appearance).
- FIG. 11 shows a diagram of a system including a device 25 that interfaces with a chip or array as described herein to collect data from the chip and process it. Examples of mechanisms to obtain information from each of the multiple reaction areas on the array are shown.
- FIG. 12 shows a plate base contact to plate base readout ³⁰ stage and elements for UV exposure to induce photoactivation or photocleavage, according to an embodiment of the invention.
- FIG. 13 is a network diagram of an example system environment including the sequencing system in communication with one or more client devices and one or more servers via a network.
- FIG. **14** shows a pathway for synthesis of dCTP-PAG1 (PM1).
- FIG. **15** shows a pathway for synthesis of dATP-PAG2 40 (PM2).
- FIG. **16** shows a pathway for synthesis of dUTP-PBG1 (PM3).
- FIG. 17 shows a pathway for synthesis of dGTP-PBG2 (PM4).
- FIG. 18 shows a table of results of an assay to detect incorporation of each of the four modified nucleotides into a sequence.
- FIGS. 19A, 19B, 19C and 19D show a graph of results of an assay to detect incorporation of each of the four modified 50 nucleotides into a sequence.
- FIG. **20** shows the structure of modified nucleotide ddCTP-PAG1 (PM5).
- FIG. 21 shows the structure of modified nucleotide ddATP-PAG2 (PM6).
- FIG. **22** shows the structure of modified nucleotide ddUTP-PBG1 (PM7).
- FIG. 23 shows the structure of modified nucleotide ddGTP-PBG2 (PM8).
- FIGS. **24**A and **24**B show the results of detection of 60 incorporation and identity of a single modified nucleotide (for each of PM5-PM8) for sequencing.

DETAILED DESCRIPTION

The details of various embodiments of the invention are set forth in the description below. Other features, objects, 10

and advantages of the invention will be apparent from the description and the drawings, and from the claims.

Definitions

Terms used in the claims and specification are defined as set forth below unless otherwise specified.

As used herein, the term "photoactive group" refers to a functional group that undergoes a lysis reaction when exposed to electromagnetic radiation, heat, or an initiator species, thereby generating an acid or a base. Compounds or functional groups that generate an acid when exposed to electromagnetic radiation within a spectrum of wavelength and/or energy are referred to herein as photoacid generators. Compounds or functional groups that generate an acid when exposed to electromagnetic radiation within a spectrum of wavelength and/or energy are referred to herein as photobase generators. As used herein, photoactive groups can be bound to probes, such as antibodies, polynucleotides, or incoming pairing nucleotides during sequence-directed polymerization such that the compounds can be specifically detected due to the generation of an acid or a base when exposed to an activating radiation.

As used herein, the terms "photoactive compound" or "photoactive molecule" refer to an organic compound or molecule comprising a photoactive group. In some embodiments, an organic compound comprising a photoactive functional group undergoes a lysis reaction upon exposure to radiation to generate an acid or a base. In some embodiments, the lysis reaction is a homolysis reaction. In some embodiments, a photoactive group or compound converts electromagnetic radiation into chemical energy and may need an initiator to start the photochemical or otherwise homolysis reaction, i.e. a compound is added to the composition that initiates homolysis by reacting with the electromagnetic radiation, or even heat, to form an intermediate initiating species, e.g., free radicals or cations, that react further with the photoactive group. The radical product from an initiator need not react directly, or next in sequence with a photoactive group. The initiating species may react with another compound in a chain reaction to produce the desired chemical reaction with a photoactive group.

Photoactive compounds or groups include, for example, cationic photoinitiators such as photoacid generators (PAGs) 45 or photobase generators (PBGs), which generate a corresponding photoacid or photobase, respectively, when exposed to electromagnetic radiation. Examples of photoactive compounds are disclosed in the International Patent Publication No. WO/2014/078606, "Substrates, Systems, and Methods for Array Synthesis and Biomolecular Analysis," filed Nov. 14, 2013, which is incorporated herein in its entirety for all purposes. A photoinitiator is a compound especially added to a formulation to convert electromagnetic radiation into chemical energy in the form of initiating species, e.g., free radicals or cations. The acid, base, or other product of a photoactive compound exposed to electromagnetic radiation may then react with another compound in a chain reaction to produce a desired chemical reaction which can then be detected.

As used herein the terms "polypeptide," "peptide," or "protein" are used interchangeably to describe a chain or polymer of amino acids that are linked together by bonds. Accordingly, the term "peptide" as used herein includes a dipeptide, tripeptide, oligopeptide, and polypeptide. The term "peptide" is not limited to any particular number of amino acids. In some aspects, a peptide contains about 2 to about 50 amino acids, about 5 to about 40 amino acids, or

about 5 to about 20 amino acids. A molecule, such as a protein or polypeptide, including an enzyme, can be a "native" or "wild-type" molecule, meaning that it occurs naturally in nature; or it may be a "mutant," "variant," "derivative," or "modification," meaning that it has been 5 made, altered, derived, or is in some way different or changed from a native molecule or from another molecule such as a mutant.

11

As used herein the term "biomolecule" refers to any molecule(s) that occur naturally in a living organism. As such, the term biomolecules includes macromolecules such as, but certainly not limited to: proteins, carbohydrates, lipids and nucleic acids; and further also small molecules such as precursors and metabolites including, but not limited to: L-lysine, selenocysteine, isoprene, ATP and tocopherol.

As used herein, the term "probe molecules" refers to, but is not limited to, peptide nucleic acids ("PNA"), DNA binding sequences, oligonucleotides, nucleic acids, deoxyribonucleic acids (DNA), ribonucleic acids (RNA), nucleotide mimetics, chelates, side-chain modified peptide sequences, biomarkers and the like. As used herein, the term "feature" refers to a particular probe molecule that has been attached to a microarray. As used herein, the term "ligand" refers to a molecule, agent, analyte or compound of interest 25 that can bind to one or more features.

As used herein the term "linker molecule" or "spacer molecule" includes any molecule that does not add any functionality to the resulting biomolecule but spaces and extends out the biomolecule from the substrate, thus increasing the distance between the substrate surface and the growing peptide, nucleic, or in general the growing biomolecule. This generally reduces steric hindrance with the substrate for reactions involving the biomolecule (including uni-molecular folding reactions and multi-molecular binding reactions) and so improves performance of assays measuring one or more aspects of functionality.

As used herein, the terms "immunological binding" and "immunological binding properties" refer to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is a specific antibody/immunoglobulin molecule.

As used herein the term "antibody" or "immunoglobulin molecule" refers to a molecule naturally secreted by a particular type of cells of the immune system: B cells. There 45 are five different, naturally occurring isotypes of antibodies, namely: IgA, IgM, IgG, IgD, and IgE.

The term "antigen" as used herein refers to a molecule that triggers an immune response by the immune system of a subject, e.g., the production of an antibody by the immune 50 system. Antigens can be exogenous, endogenous or auto antigens. Exogenous antigens are those that have entered the body from outside through inhalation, ingestion or injection. Endogenous antigens are those that have been generated within previously-normal cells as a result of normal cell 55 metabolism, or because of viral or intracellular bacterial infection. Auto antigens are those that are normal protein or protein complex present in the host body but can stimulate an immune response.

As used herein the term "epitope" or "immunoactive 60 regions" refers to distinct molecular surface features of an antigen capable of being bound by component of the adaptive immune system, e.g., an antibody or T cell receptor. Antigenic molecules can present several surface features that can act as points of interaction for specific antibodies. 65 Any such distinct molecular feature can constitute an epitope. Therefore, antigens have the potential to be bound

12

by several distinct antibodies, each of which is specific to a particular epitope. biological sample

As used herein, the term "wafer" refers to a slice of semiconductor material, such as a silicon or a germanium crystal generally used in the fabrication of integrated circuits. Wafers can be in a variety of sizes from, e.g., 25.4 mm (1 inch) to 300 mm (11.8 inches) along one dimension with thickness from, e.g., 275 μ m to 775 μ m.

As used herein the term "microarray," "array," or "chip" refers to a substrate on which different probe molecules of protein or specific DNA binding sequences have been affixed at separate locations in an ordered manner thus forming a microscopic array. In some embodiments, specific PNA, RNA or DNA binding sequences have been affixed at separate locations in an ordered manner thus forming a microscopic array. Specific PNA, RNA or DNA binding sequences may be bound to the substrate of the chip through one or more different types of linker molecules. A "chip array" refers to a plate having a plurality of chips, for example, 24, 96, or 384 chips.

As used herein the term "microarray system" refers to a system usually comprised of bio molecular probes formatted on a solid planar surface like glass, plastic or silicon chip plus the instruments needed to handle samples (automated robotics), to read the reporter molecules (scanners) and analyze the data (bioinformatic tools).

As used herein the terms "substrate" and "solid support" are used interchangeably and refer to any insoluble, polymeric material. Such materials must have rigid or semi-rigid surface, where examples include, but are not limited to, natural polymeric materials such as glass or collagen, and synthetic polymers such as acrylamide, polyvinyl chordae, or silicon based arrays.

As used herein, the term "PNA-DNA chimera" refers to an oligomer, or oligomers, comprised of: (i) a contiguous moiety of PNA monomer units and (ii) a contiguous moiety of nucleotide monomer units with an enzymatically-extendable terminus

As used herein, the term "primer extension" refers to an enzymatic addition, i.e., polymerization, of monomeric nucleotide units to a primer while the primer is hybridized (annealed) to a template nucleic acid.

As used herein, the term "assay" refers to a type of biochemical test that measures the presence or concentration of a substance of interest in solutions that can contain a complex mixture of substances.

As used herein, the term "activating radiation" refers to electromagnetic radiation of a defined wavelength and energy sufficient to activate a photoactive group or compound to induce a reaction. In preferred embodiments, this reaction is the release of an acid or a base from a photoacid generator or a photobase generator, respectively.

As used herein, the term "blocking group" refers to a moiety bound to a monomer that prevents incorporation of a subsequent monomer in the synthesis of a polymer. A removable blocking group is one that can be removed to provide a binding site for incorporation of the next monomer. Removable blocking groups are commonly used for sequencing-by-synthesis reactions to control the stepwise addition of nucleotides during a template-directed polymerization reaction.

It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

Overview

Described herein, according to some embodiments, are methods and compositions for sensitive and specific detection of target biomolecules immobilized to the surface of a substrate using probes tagged with photoactive compounds. 5 As described herein, in some embodiments, the photoactive compounds are photoacid or photobase generators that generate a measureable change in the pH of the surrounding solution upon exposure to a wavelength of light. This change in pH is specific to the type of photobase or photoacid generator, such that multiple photoactive compounds can be distinguished. These probes comprising photoactive groups facilitate detection methods that provide a highly sensitive and specific detection that is not limited by the constraints of detection from light. In some embodiments, these methods 15 are performed on an array of ISFET detectors to measure the change in pH of the solution surrounding bound probes comprising a photoactive group. Synthesis of several embodiments of probes bound to photoactive groups and the use of the same for detection of target biomolecules, includ- 20 higher). ing for sequence discrimination and sequence determination, is provided herein.

Photoactive Compounds

Disclosed herein are photoactive groups, i.e. photoactive organic molecules or functional groups. In a most general 25 sense, photoactive groups or compounds are those which possess at least one chemical moiety that becomes reactive when exposed to radiation such as ultraviolet or visible light. Exposure of the photoactive compounds to electromagnetic radiation is a primary photochemical event that produces a 30 change in the pH of the surrounding microenvironment. This change is brought about by the acidic or basic chemical species that is produced due to photoactivation of the photoactive group or compound. One or more photoactive group or compound may react by an elimination, addition, or 35 rearrangement reaction; and may require an optional additive, or initiator, to kick-off the reaction reaction. In some embodiments, photoactivation generates a homolysis reaction to generate an acid or a base. In some embodiments, the photoactive groups or photoactive compounds are photoacid 40 generators or photobase generators that directly generate an acid or a base upon photoactivation, e.g., from a homolysis reaction. In some embodiments, the photoactive groups or photoactive compounds are photoinitiators that indirectly release an acid or a base, e.g., through release of a chemical 45 species that reacts downstream with another species to release an acid or a base.

Generally, the skilled artisan can easily identify a given functional group as a photoacid generator or a photobase generator since only those groups will form an organic acid 50 or base possessing a proton or heteroatom that is recognizable as an acidic or basic group upon homolysis of the bond attaching that group to the compound. In this regard, the skilled artisan quickly recognizes a photoacid generator or a photobase generator by working backwards (in a sense) in 55 identifying an acidic or basic functional group. For example, tertiary amine functional groups are recognized by organic chemists to be significantly basic because there is more electron density on the nitrogen atom of a tertiary amine, as opposed to say a secondary amine. Accordingly, a skilled 60 artisan would recognize that any compound that has a quaternary amine functional group that will, upon homolysis, form a tertiary amine functional group, is a photoactive compound or functional group of the present disclosure.

In some embodiments, photoactive compounds or func- 65 tional groups of the present disclosure will only include those which produce a compound having a pKa that is

significantly acidic or basic so that one skilled in the art would recognize that a veritable organic acid or base would be generated. To this end, in some embodiments, photoactive compounds or functional groups of the present disclosure produce an organic compound that has a pKa of 10 or

14

sure produce an organic compound that has a pKa of 10 or higher, 11 or higher, or 12 or higher. Photoactive compounds or functional groups of the present disclosure include acids or bases that are recognized in the art as "hard" or "soft".

In some aspects, photoactive compounds or functional groups of the present disclosure also have acidity or basicity according to the energy of their lowest unoccupied molecular orbital (LUMO) and/or energy of their highest unoccupied molecular orbital (HOMO). In some embodiments, the photoactive compounds or functional group produces a photoacid that has LUMO energy of -2.5 eV or lower (this is in terms of energy, so +1 would be lower). In some embodiments, the photoactive compounds or functional group produces a photobase that has HOMO energy of 1.7 eV or higher (this is in terms of energy, so -3 would be higher).

Photoactive compounds comprise at least one photoactive group to convert absorbed light energy, UV or visible light, into chemical energy in the form of initiating species, e.g., free radicals or cations. As such, in a general aspect, the photoactive groups or compounds of the present disclosure can be any organic functional group or compound that possesses one or groups that will absorb energy anywhere from 200 nm to 700 nm.

In general, photoactive compounds or functional groups are known to one skilled in the art. Examples of photoactive compounds or functional groups that are photoacid generators (PAG) include, but in no way are limited to: sulfonium salts, iodonium salts, sulfonyldiazomethane, N-sulfonyloxyimide, benzoinsulfonate, nitrobenzylsulfonate, sulfone, glyoxime derivatives, halogenated triazines, onium salts such as aryldiazonium salts and diaryl halonium salts, triaryl sulfonic salts, sulfonated esters, substituted hydroxyimides, substituted hydroxylimines, azides, naphthoquinones such as diazonaphthoquinones, diazo compounds, and many combinations thereof, nitrobenzyl esters, sulfones, phosphates, and the like. Examples of photoactive compounds or functional groups that are photobase generators (PBG) include, but in no way are limited to: o-acyloximes, benzoyloxycarbonyl derivatives, photoactive carbamates such as benzyl carbamates and benzoin carbamates, oxime ester compounds like o-carbamoyloximes, ammonium compounds like quaternary ammonium tetraphenyl borate salts, benzoin compounds, dimethoxybenzyl urethane compounds, orthonitrobenzyl urethane compounds, aromatic sulfonamides, alpha-lactams, N-(2-arylethenyl) amides, mixtures thereof, and the like. These compounds generally generate amine bases after irradiation. Photobase generators can also generate ammonia or hydroxy ions due to the action of light may also be used. These can be selected from, for example, N-substituted 4-(o-nitrophenyl)dihydroxypyridines, N-(2nitrobenzyloxycarbonyl)piperidine, 1,3-bis(N-(2-nitrobenzyloxycarbonyl)-4-piperidyl]propane, N,N'-bis(2-nitrobenzyloxycarbonyl)dihexylamine, and O-benzylcarbonyl-N-(1phenylethylidene)hydroxylamine. A good review of photoacid and photobase generators is found, for example, in Prog. Polym. Sci. vol. 21, 1-45, 1996, the entire contents and disclosure of which is incorporated herein by reference. Very specific examples of a suitable photobase generators include, but are not limited to: 2-hydroxy-2-phenylacetophenone N-cyclohexyl carbamate (i.e., C₆H₅C(=O)CH (C₆H₅)OC(=O)NHC₆H₁₁); o-nitrobenzyl N-cyclohexyl carbamate (i.e., o-NO₂C₆H₅CH₂C(=O)NHC₆H₁₁); N-cy-

clohexyl-2-naphthalene sulfonamide (i.e., $C_{10}H_7SO_2NHC_6H_{11}$); 3,5-dimethoxybenzyl N-cyclohexyl carbamate (i.e., $(CH_3O)_2C_6H_5CH_2C(=O)NHC_6H_{11}$); N-cyclohexyl p-toluene sulfonamide (i.e., p-CH $_3C_6H_5SO_2NHC_6H_{11}$); and dibenzoin isophorone dicarbamate. Finally, photoactive compound or functional group also includes any compounds or functional groups that behave as both photobases and photoacids. These compounds are described in the art as single component photoacid/photobase generators.

In some embodiments, a photoactive compound or group can be a photoacid generator (PAG) or a photobase generator (PBG). Photoacid generators (or PAGs) are cationic photoinitiators. A photoinitiator is a compound especially added to a formulation to convert absorbed light energy, UV or visible light, into chemical energy in the form of initiating species, e.g., free radicals or cations. Cationic photoinitiators are used extensively in optical lithography. The ability of some types of cationic photo initiators to serve as latent photochemical sources of very strong protonic or Lewis acids is generally the basis for their use in photo imaging applications.

In some embodiments, a photoacid generator is an iodonium salt, a polonium salt, or a sulfonium salt. In some 25 embodiments, a photoacid generator is (4-Methoxyphenyl) phenyliodonium or trifluoromethanesulfonate. In some embodiments, a photoacid generator is (2,4-dihydroxyphenyl)dimethylsulfonium triflate or (4 methoxyphenyl)dimethylsulfonium triflate, shown below:

In some embodiments, a photoacid generator is iodonium and sulfonium salts of triflates, phosphates and/or anti- 40 monates.

In some embodiments, a photobase generator is 1,3-Bis [(2-nitrobenzyl)oxycarbonyl-4-piperidyl]propane or 1,3-Bis [(1-(9-fluorenylmethoxycarbonyl)-4-piperidyl]propane. Conjugation of Photoactive Groups to Compounds

Generally the methods used to conjugate one or more photoactive molecule(s) or functional group(s) are known in the art. The skilled artisan will appreciate that various types of carbon-carbon and carbon-heteroatom bonds can be made that will attach a given photoactive molecule or functional 50 group to any such biomolecule of interest. Of course the skilled artisan will appreciate that any such attachment must not interfere with the binding, enzymatic and/or biological function of one or more biomolecule(s) described herein, i.e. the activity of the biomolecule it is attached to must not be 55 rendered inoperative nor shall the activity be rendered inoperative of other biomolecules such as DNA polymerase and the like that are otherwise present. To this end, one skilled in the art can refer to texts.

Further, once the photoactive compounds are synthesized, 60 the task of conjugating these compounds onto either the nitrogenous base, saccharide residue, or phosphate is within the purview of one skilled in the art of organic synthesis. There is much literature and even whole texts that are now that review and are able to instruct an organic chemist how 65 to perform the synthetic methods needed for "conjugating" a small organic molecule to an activated position on a

16

biomolecule or even incorporating a "conjugated" or "tagged" (fluorescent or otherwise) molecule into a biological process, such as enzymatic bond cleavage or construction. Such synthetic methods nowadays are routine to the trained organic or medicinal chemist. Relevant review articles, texts, and books include, but are not limited to: Hermanson, G. T., Bioconjugate Techniques, 3rd Ed., Academic Press, Oxford (2013); Sinh, Y. et al., "Recent developments in oligonucleotide conjugation" *Chem. Soc. Rev.*, 2010, 39, 2054-2070; and Roy, B. et al., "Recent Trends in Nucleotide Synthesis" *Chem. Rev.*, 2016, 116 (14), pp 7854-7897.

As a general guide, herein disclosed are representative syntheses to attach a photoactive molecule or functional group to a given biomolecule. As such, these synthetic techniques may not cover each and every way to conjugate a photoactive molecule and thus, are not meant to be limiting in any form since the skilled artisan will be able to use alternative synthetic reactions to conjugate or otherwise insert a photoactive molecule or functional group to a given biomolecule onto a biomolecule.

Photoactive Nucleotides

In some embodiments, the photoactive group is covalently or non-covalently attached to one or more nucleotides, or any combination thereof. In some embodiments, the photoactive group is covalently in a selective manner. For example, the photoactive group may be covalently attached to a guanine nucleobase/nucleotide, but not any other nucleobases/nucleotides. In another example, the photoactive group may be covalently attached to a thymine nucleobase/ nucleotide, but not any other nucleobases/nucleotides. In another example, the photoactive group may be covalently attached to any combination of two (2) of: cytosine, guanine, adenine, thymine and uracil (C, G, A, T, and U, respectively) nucleobases/nucleotides, but not any other nucleobases/ nucleotides. In another example, the photoactive group may be covalently attached to any combination of three (3) of: cytosine, guanine, adenine, thymine and uracil (C, G, A, T, and U, respectively) nucleobases/nucleotides, but not any other nucleobases/nucleotides. In another example, the photoactive group may be covalently attached to any combination of four (4) of: cytosine, guanine, adenine, thymine and uracil (C, G, A, T, and U, respectively) nucleobases/nucleotides, but not any other nucleobases/nucleotides.

In one embodiment, nucleotides of the present disclosure are tagged with a photoactive group. In one embodiment nucleotides of the present disclosure have a general structure according to FIG. 1. The photoactive group can be bound to the sugar, i.e., at the 2' C position. The photoactive group can also be bound to the nucleobase in a way that does not interfere with hydrogen bonding to its cognate nucleobase.

In a general embodiment, the photoactive group is covalently attached to a nucleobase to make a modified nucleotide. In such an embodiment, the photoactive group may even be attached at a nitrogen atom of a nucleobase. Though it is preferable that the modification retain the biologically activity of the nucleotide, for example an enzyme such DNA polymerase I would still be capable of using the tagged nucleotide to create one or more complimentary strands of RNA or DNA or the like. In such embodiments, the tag, i.e. the photoactive group, may generally be covalently attached to the nucleobase according to the FIG. 2.

In some embodiments, the photoactive group is covalently attached to a nucleobase via a linker. The linker can be from 2-40 atoms in length and need not be restricted in terms of the identity of heteroatoms and carbon atoms that it comprises. More to this point, the identity of the particular

organic functional groups that comprise the linker is not crucial or limiting as long as one or more of the functional groups themselves are photoactive groups and do not react with other functional groups of the nucleotide(s) or other components in the system so as to render them inoperable, e.g. peptide side chain functional groups are not altered so as to impact a loss in biological activity or even an enzyme, present in the system/assay, perhaps DNA polymerase I is not affected so as its function is impaired. Additionally in some embodiments, the photoactive group is covalently attached to a nucleobase directly and without any functional group as a linker. Examples of these photoactive group tags covalently bonded to a nucleobase are shown in FIG. 3 and are not meant to be limiting in any way.

In other such embodiments, the tag may even be attached in such a way as to create an onium salt or any other ¹⁵ otherwise ionic organic salts that can release acidic or basic species upon homolysis. Examples of such salts include photoactive groups covalently bonded in FIG. 4.

In other embodiments, the photoactive group is covalently attached to the five carbon saccharide at the 2-position. The 20 photoactive group need not be covalently bonded thru an oxygen atom at the 2-position, rather a carbon-carbon, carbon-nitrogen, or even a carbon-sulfur bond may be constructed and the photoactive group tag may be covalently bonded on the substituent at that is connected at the 2-position. Some non-limiting examples of tags at the 2-position include those in FIG. 5.

In other embodiments, the photoactive group need not be covalently attached thru the nucleobase of a nucleotide and instead, can be covalently attached thru the 3' position, 30 covalently bonded to the hydroxyl or not, otherwise alternatively covalently bonded thru the carbon atom at the 3' position, on the saccharide residue or covalently attached to an oxygen atom on the phosphate group of a nucleotide. In other embodiments, the photoactive group is non-covalently 35 bonded to an oxygen atom on the phosphate group of a nucleotide

Alternatively, the photoactive group can be attached non-covalently thru a chelate to one or more non-terminal nucleotides. For instance if the nucleotide is modified to 40 have a linker functional group, say ethylene diamine, that forms an cooper (Cu) metal atom chelate, a photoactive group may be non-covalently attached to the nucleotide via the metal chelate.

Nucleotides can be modified to attach a photoactive 45 molecule or functional group on either a carbon atom or a nitrogen atom of the nitrogenous base (so long as the covalent bond to the nitrogen atom does not adversely affect the biological activity, structural integrity, or recognition of the nucleotide). A couple of examples reactions bonding a 50 photoactive molecule to the nitrogenous base of a nucleotide follow.

-continued $[O_3P]_n - O \qquad N \qquad NH$ $[O_3P]_n - O \qquad NH_2$ $[O_3P]_n - O \qquad NH_2$ $[O_3P]_n - O \qquad NH_2$ $[PO_3]_n \qquad Where n is 0-3$

55

60

65

In one embodiment, a nucleotide is covalently bonded thru a linker to the photoactive group. In such an embodiment, the linker can be from one (1) to forty (40) atoms in length.

In some embodiments, the modified nucleotides described herein are incorporated into a polynucleotide probe that can bind specifically via hybridization to a target biomolecule comprising a polynucleotide sequence complementary to a portion of said polynucleotide probe. The photoactive group can be placed at a specific region of the polynucleotide probe. In some embodiments, the photoactive group is positioned at the end of the polynucleotide probe. In some embodiments, a polynucleotide probe comprises multiple photoactive groups placed at multiple positions along the nucleotide sequence.

Removable Blocking Groups

In some embodiments, the modified nucleotides comprise blocking groups that prevent addition of more than one 65 modified nucleotide during a reaction to polymerize a growing strand of an oligonucleotide. In some embodiments, the

blocking group is a fixed terminator group, such as a dideoxy terminator. In some embodiments, the blocking group is a removable blocking group, such as a reversible terminator. In some embodiment, the removable blocking group is photocleavable such that, upon exposure to light, it is removed to allow subsequent addition of nucleotides to the growing strand. In some embodiments, the modified nucleotide comprises a 3'-bound removable blocking group (FIG. 6A) where the blocking group —OR is linked to the oxygen atom of the 3'-OH of the pentose, while the photoactive group is linked to the base and is used for detection of the base attached. In some embodiments, the removable blocking group is the same group or bound to the same region of the nucleotide as the photoactive group.

In general, removable blocking groups can be used in sequencing-by-synthesis approaches that infer the sequence of a template by stepwise primer elongation. The sequencing process can involve (i) immobilizing the template and primers on the wafer; (ii) primer extension by one base and termination; (iii) obtaining the pH reading to identify the added nucleotide; (iv) removal of the blocking group that prevents the following polymerase addition; (v) washing and repeating the steps (ii-iv).

25 Peptides Comprising Photoactive Groups

Peptides can be modified to attach a photoactive molecule or functional group on the side chain. For example, the amine functional group on the side chain of a lysine amino acid residue in a given peptide sequence can be used in a nucleophilic displacement reaction with an electrophilic photoactive molecule. Such electrophilic species are easily prepared, for examples, aryl alkyl esters can be modified to the corresponding halo-aryl alkyl ester through an electrophilic aromatic substitution reaction. The halo-aryl alkyl ester is now an electrophile and can be used in an aromatic nucleophilic substitution reaction with the amine functional group of the lysine residue to create a covalent bond between the nitrogen atom on the side chain of lysine to the carbon atom (where the halogen resided) on the aromatic ring of the photoactive molecule.

Of course, covalent bonds are not the only means that are described herein to bond one or more photoactive molecule(s) or functional group(s). Ionic bonds, Van der Waals bonding and the like are also encompassed within the present disclosure. The skilled artisan will recognize the functional groups on a given biomolecule that can provide such bonding, e.g. a charged phosphonate group on, say, a nucleic acid may be used for an ionic bond or a terminal carboxylate on a peptide may be also be used (under basic conditions of course). The skilled artisan need only consult a text or literature reference to use a synthetic method to make these bonds.

As such, a given covalent bond on the biomolecule may be made to any carbon atom or heteroatom so long as that attachment does not alter the biological function of the biomolecule. For example, a covalent bond may attach a photoactive molecule or functional group to a nucleic acid. This bond may be attached thru say, a carbon atom on a guanine nitrogenous base to, for instance, an oxygen atom of the photoactive molecule or functional group. This type of conjugation is well within the parameters of the present disclosure as long as the nucleic acid does not lose biological activity, or perhaps the nucleic acid sequence readability with DNA polymerase.

An exemplary reaction scheme for binding a photoactive compound to a protein is shown below:

Synthesis of Photoactive Groups or Compounds

Photoactive compounds or functional groups (i.e. organic functional groups), are needed as small molecules in the present disclosure and can be purchased "off the shelf" from a petrochemical vendor such as Sigma Aldrich, VWR, 40 Fisher Scientific, etcetera or can be easily synthesized by the skilled artisan trained in classical organic syntheses. The breadth of small organic molecules (or functional groups) that are encompassed within the present disclosure is relatively large. However, one skilled in organic synthesis will 5 instantly identify numerous classical reactions that will produce the requisite molecule from readily available starting material. Apropos, many of the photoactive molecules (or functional groups), and the covalent bonds needed to synthesize them, are single step preparations or otherwise 50 relatively facile chemistry for those in the art.

The compounds described herein can be prepared by any of the applicable techniques of organic synthesis. Many such techniques are well known in the art. However, many of the known techniques are elaborated in Compendium of 55 Organic Synthetic Methods (John Wiley & Sons, New York) Vol. 1, Ian T. Harrison and Shuyen Harrison (1971); Vol. 2, Ian T. Harrison and Shuyen Harrison (1974); Vol. 3, Louis S. Hegedus and Leroy Wade (1977); Vol. 4, Leroy G. Wade Jr., (1980); Vol. 5, Leroy G. Wade Jr. (1984); and Vol. 6, 60 Michael B. Smith; as well as March, J., Advanced Organic Chemistry, 3rd Edition, John Wiley & Sons, New York (1985); Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry, In 9 Volumes, Barry M. Trost, Editor-in-Chief, Pergamon Press, 65 New York (1993); Advanced Organic Chemistry, Part B: Reactions and Synthesis, 4th Ed.; Carey and Sundberg;

Kluwer Academic/Plenum Publishers: New York (2001); Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, 2nd Edition, March, McGraw Hill (1977); Protecting Groups in Organic Synthesis, 2nd Edition, Greene, T. W., and Wutz, P. G. M., John Wiley & Sons, New York (1991); and Comprehensive Organic Transformations, 2nd Edition, Larock, R. C., John Wiley & Sons, New York (1999).

The skilled artisan can easily identify a given functional group as photoactive since only those groups will form an organic acid or base possessing a proton or heteroatom that is recognizable as an acidic or basic group upon homolysis of the bond attaching that group to the compound. In this regard, the skilled artisan quickly recognizes a photoactive group by working backward to identify functional groups in a sense. For example, tertiary amine compounds are recognized by organic chemists to be an organic base because there is more electron density on the nitrogen atom of a tertiary amine, as opposed to a secondary amine. Apropos, a skilled artisan would recognize that a compound that has a quaternary amine functional group that will, upon homolysis, form a tertiary amine functional group, is a photoactive compound or functional group of the present disclosure. Of course, most any functional group can be considered, to some extent, acidic or basic. Therefore, photoactive compounds or functional groups of the present disclosure will only include those which have a significant pKa so that one skilled in the art would instantly recognize that an organic acid or base would be generated. Thus, it is fair to generalize that the organic functional groups acidic or basic for photochemical use herein generally, though not always, include a bond to heteroatom. More specifically, the heteroatoms

22

that include oxygen, nitrogen, sulfur, and the halogens are especially attractive because homolysis of a compound containing these heteroatoms will produce a compound that is acidic having an oxygen-hydrogen or halogen-hydrogen bond; or will be basic having a lone pair of electrons on a 5 sulfur, oxygen, or nitrogen atom. Of course, these are not the extent of or entire list of heteroatoms that the skilled artisan will recognize as being potentially acidic or basic, but these are, generally, speaking the most common. Such organic functional groups produced from the homolysis of a moiety 10 having a covalent bond to a heteroatom include, but are not limited to: carboxylate esters (O-C bond homolysis forming the requisite carboxylic acid), α -halogenated ethers (O—C bond homolysis forming the requisite α -haloalcohol), α-nitro ethers (O—C bond homolysis forming the 15 requisite α-nitroalcohol), phenyl ethers (O—C bond homolysis forming the requisite phenol), sulfonate esters (O—C bond homolysis forming the requisite organic sulfonic acid), phosphonate esters (O—C bond homolysis forming the requisite organic phosphonic acid), and anhydride 20 (O—C bond homolysis forming the requisite organic carboxylic acid).

Of course, the skilled artisan will consult the relevant literature to synthesize the requisite covalent bonds to produce photoactive compounds or functional groups. Particu- 25 larly attractive review articles that are on point include: Shirai, M.; Tsunooka, M., "Photoacid and photobase generators: chemistry and applications to polymeric materials" Progress in Polymer Science 1996, 21(1), 1-45.; Shirai, M.; Suyama, K.; Okamura, H.; Tsunooka, M., "Development of 30 novel photosensitive polymer systems using photoacid and photobase generators" Journal of Photopolymer Science and Technology 2002, 15(5), 715-730; Houlihan, F. M.; Neenan, T. X.; Reichmanis, E.; Kometani, J. M.; Chin, T., "Design, synthesis, characterization, and use of all-organic, nonionic 35 photogenerators of acid" Chemistry of Materials 1991, 3(3), 462-71; Ahmad Hasan, Klaus-Peter Stengele, Heiner Giegrichl, Paul Cornwell, Kenneth R. Isham, Richard A. Sachleben, Wolfgang Pfleiderer, and Robert S. Foote, Photolabile Protecting Groups for Nucleosides: Synthesis and 40 Photodeprotection Rates, Tetrahedron, Vol. 53, No. 12, pp. 4247-4264, 1997; Serafinowski and Garland, J Am. Chem. Soc. 2003, 125, 962-965; Iwashima, C.; Imai, G.; Okamura, H.; Tsunooka, M.; Shirai, M., "Synthesis of i- and g-line sensitive photoacid generators and their application to pho- 45 topolymer systems" Journal of Photopolymer Science and Technology 2003, 16(1), 91-96; Okamura, Haruvuki; Sakai. Koichi; Tsunooka, Masahiro; Shirai, Masamitsu; Fujiki, Tsuyoshi; Kawasaki, Shinich; Yamada, Mitsuaki. I-line sensitive photoacid generators and their use for photocrosslink- 50 ing of polysilane/diepoxyfluorene blend. Journal of Photopolymer Science and Technology (2003), 16(1), 87-90; Okamura, Haruyuki; Sakai, Koichi; Tsunooka, Masahiro; Shirai, Masamitsu. Evaluation of quantum yields for decomposition of I-line sensitive photoacid generators. Journal of 55 Photopolymer Science and Technology (2003), 16(5), 701-706; and Okamura, Haruyuki; Matsumori, Ryosuke; Shirai, Masamitsu. I-line sensitive photoacid generators having thianthrene skeleton. Journal of Photopolymer Science and Technology (2004), 17(1), 131-134.

The skilled artisan can also consult literature and/or textbooks on organic syntheses involving carbon-heteroatom bond construction. Such texts include, but are not limited to: Yudin, A., Catalyzed Carbon-Heteroatom Bond Formation, Wiley-VCH Verlag, Weinheim, Germany (2011); Taber, D. and Lambert, T., Organic Synthesis: State of the Art 2011-2013, Oxford Press, Oxford, (2015); and

Wolfe, J., Synthesis of Heterocycles via Metal-Catalyzed Reactions that Generate One or More Carbon-Heteroatom Bonds Springer, New York, (2013).

Forthwith disclosed are some very general synthetic methods, known in the art, for constructing photoactive groups that include organic functional groups such as: alcohol, carboxylate esters, sulfonate esters, phosphonate esters, and ethers. Examples of these reactions or perhaps representative reaction schemes follow.

Such that \mathbb{R}^1 and \mathbb{R}^2 do not contain functional groups that are acidic, basic, nucleophilic or electphilic enough so as to affect the reaction described.

In one embodiment, one or more photoactive compounds or functional groups are covalently or non-covalently bonded to one or more biomolecules. In one embodiment, the biomolecule is an antibody. In one embodiment, the biomolecule is a peptide.

In one embodiment, the biomolecule is a nucleic acid. In one embodiment, the biomolecule is RNA. In one embodiment, the biomolecule is DNA.

In some aspects, one or more photoactive groups or compounds include biomolecules that have one or more photoactive groups conjugated to it, i.e. covalently attached, much like a tag. In some aspects, the one or more photoac-

tion; and g) determining a sequence identity of said target polynucleotide from said detected change in ion concentration.

26

tive groups are not covalently attached to the biomolecule but rather they are bound to it in a complex or by other means of chemical bonding such as by an ionic bond, a Van der Waals bond, or a hydrogen bond.

In a general aspect, additional components such as a solvent, reagents such as homolysis initiating compounds, whole biological cells, and/or additional photoactive compound(s) or biomolecules (e.g. additional antibodies) may be present or otherwise added to the substrate and/or biological molecule.

In one embodiment, the biomolecule is any combination of, or all of, one or more peptides and/or one more nucleotides having up to two photoactive groups on any given single peptide and/or nucleotide. In one embodiment, the biomolecule is a cell receptor antigen.

Methods of Use

The technology described herein related to modified probes and related methods, compositions, kits, and systems for binding probes modified to comprise a photoactive group 20 and specifically binding the probes to target biomolecules for detection via monitoring pH after exposure of the probes to an activating radiation.

In some embodiments, provided herein is a method for detecting a target biomolecule, comprising: a) providing 25 probe capable of binding specifically to a target biomolecule, wherein said probe is bound to a photoacid generator or a photobase generator; b) contacting a sample suspected of comprising said target biomolecule with said probe; c) removing unbound probes from said sample; d) exposing 30 said sample to an wavelength of light capable of activating said photoacid generator or said photobase generator, such that said probe, if bound to said target biomolecule, releases an acid or a base upon exposure to said wavelength of light; and e) detecting a concentration of ions in the sample, 35 thereby identifying the presence or absence of said target analyte based on a change of said concentration of ions.

In some embodiments, the probe comprises a polynucleotide or a polypeptide. In some embodiments, the probe is an antibody. In some embodiments, the concentration of ions is 40 determined by measuring an ionic strength of the sample. In some embodiments, the ionic strength is measured using an ion-sensitive field effect transistor. In some embodiments, the sample is immobilized on the surface of a substrate.

In some embodiments, the substrate is an array. In some 45 embodiments, the array comprises a plurality of wells, wherein said wells each comprise a sensor for detecting an ionic strength of a solution in said wells. In some embodiments, the sensor is an ion-sensitive field effect transistor.

In some embodiments, provided herein is a method of 50 detecting a sequence identity of a target polynucleotide, comprising: a) providing a substrate an immobilized target polynucleotide hybridized to a primer or probe; b) contacting said immobilized target polynucleotide with a solution comprising reagents for performing a polymerase extension 55 reaction, said solution comprising a set of modified nucleotides comprising a photoactive group and a blocking group; c) exposing said substrate to conditions to promote incorporation of one of said modified nucleotides at the 3' end of said primer or probe; d) washing said substrate to remove 60 unbound modified nucleotides; e) exposing said immobilized target polynucleotide to a wavelength of light to induce said photoactive group to generate an acid or a base, thereby generating a detectable change in ion concentration in a solution surrounding said immobilized target polynucleotide 65 if said modified nucleotide is incorporated into said target polynucleotide; f) detecting said change in ion concentra-

The technology described herein relates to modified nucleotides and related methods, compositions, kits, and systems for sequencing nucleic acids. Sequencing by synthesis relies on the incorporation of a nucleotide into a growing strand to form a correct cognate pair with a template strand. Either one nucleotide can be added at a time, and the incorporation of the correct nucleotide detected by various methods, or multiple nucleotides can be added, and the identity of the incorporated nucleotide for each growing strand identified by a detectable marker on the incorporated nucleotide after removal of all non-bound nucleotides. This type of reaction normally proceeds one nucleotide at a time, and thus the modified nucleotides additional comprise a removable blocking group, i.e., an element bound to the nucleotide that prevents incorporation of another nucleotide into the growing strand. This can be as simple as a dideoxy terminator, or can be a reversible terminator, allowing for subsequent polymerization of the growing strand for additional sequencing detection.

In many instances of sequencing by synthesis, a fluorophore is used as the detectable marker. However, imaging an array comprising millions of fluorophores and processing that image into useable data can take significant time and is computationally intensive. Furthermore, the use of fluorophores as a detectable marker introduces limitations on the minimum size of features on an array due to diffractionlimited sensing. Electronic detection, such as ISFET, can remove the diffraction-limited minimum size, and allow for simultaneous detection of a signal from millions of samples on multiple arrays. However, limitations on the availability of detectable markers to effectively distinguish between multiple nucleotides using electronic sensing is limited, and sensitivity needs to be improved. Therefore, provided herein are improved modified nucleotides to facilitate electronic detection to distinguish between at least four different nucleotides in a sequencing by synthesis reaction with high sensitivity and specificity.

The modified nucleotide provided herein can include photoactive groups capable of generating an ionic signal when cleaved by light. In some embodiments, the photoactive groups are photoacid generators that decrease the pH of a solution when exposed to light. In some embodiments, the photoactive groups are photobase generators that increase the pH of a solution when exposed to light. Thus, according to methods provided herein, a modified nucleotide comprising a photoactive group can be incorporated into a growing strand in a reaction chamber if it forms a complementary base pairing with the template strand, followed by removal of un-incorporated nucleotides from the reaction chamber. Then, the reaction chamber can be exposed to light sufficient to induce photocleavage of the photoactive group, and the pH of the solution can be monitored to determine the effect of the exposure to light on the reaction solution. A change in pH and its magnitude as detected by ISFET can be used to determine whether a nucleotide was incorporated, and if so, the identity of this nucleotide. Thus, in some embodiments, provided herein are novel methods and compositions for sequencing using modified nucleotides comprising photoactive groups capable of generating an ionic signal, e.g., through the release of an acid or a base, such as a photoacid or photobase generator.

In some embodiments, sequencing is performed by sequencing by synthesis of a clonal population of oligonucleotides, or by sequencing by synthesis of a single molecule. In some embodiments, a signal is generated to determine the identity of a nucleotide incorporated into the growing strand by electronic detection.

In previous generations of sequencing using electronic detection, one type of nucleic base at time added for 5 sequencing relays on weak H⁺ produced by each base. This not only limits the throughput of sequencing, but also requires a very sensitive Ion sensitive Field effective transistor which limits the feature size of the ion sensing GATE of the transistor, and therefore the diversity of sequencing 10 signals that can be generated by different nucleotides.

Herein we provide improved methods and compositions for electronic detection of nucleotide or base identity using sequencing by synthesis. Herein we provide modified nucleotides that do not rely on a weak H⁺ produced by 15 nucleic base addition, but instead can be detected by a strong H⁺ or OH⁻ produced by a non-interfering photo-energy to produce a desired ion strength for detection in a reaction area on an array. These compositions allow us to decouple ion production for sensing from the nucleic acid base coupling 20 to the growing strand. Since a strong H+ or OH– signal with varying ion strength can be generated by our modified nucleotides, then four nucleic acid bases can be simultaneously added at each coupling to sequence genome to generate a very high throughput. Furthermore, the strong elec-

tronic signal produced allows sensitive detection and specific discrimination among the four nucleotides to enhance the accuracy of sequencing information generated.

In some embodiments, the modified nucleotides comprise photoactive groups (i.e., photosensitive molecules) such as a photoacid or a photobase generator (i.e., a molecule capable of generating a Photogenerated acid or base), and can be referred to herein as a photosensitive molecule (PM). In some embodiments, the photosensitive molecule (PM) can be a molecule capable of producing a designed pH change when exposed UV light. In some embodiments, the photogenerated acid or base can be based on salt formulation, for example one photoactive positive or negative charged molecule and one base or acid molecule together form a salt. In some embodiments, the Photogenerated acid or base can be based on photo-cleavage, for example the PM comprises one photocleavage group (e.g., a linker) and one photoactive group covalently bonded to an acid or base which is released upon exposure to a light source.

Shown below is an example of a reaction of a nucleotide comprising a photoactive group and a removable blocking group (indicated as a "STOPPER") to control polymerization during sequencing by synthesis. The photoactive group is cleaved upon exposure to radiation to generate a detectable species.

In some embodiments, the modified nucleotides or photosensitive molecules comprising photoactive groups comprise a nucleotide molecule bound to a photocleavable linker bound to a photoinduced base or acid producing molecule. 20 In some embodiments, the modified nucleotides further comprise a removable blocking group to inhibit addition of more than one nucleotide to the end of the growing strand. Examples of removable blocking groups include dideoxy terminators and reversible terminators. The modified 25 nucleotide may also include a photoactive group that also acts as a removable blocking group, such that, when noninterfering photo-energy is applied to cleave photobase or photoacid generator, a signal for detection is generated and the growing strand is activated to allow coupling of the next 30 incoming nucleotide during the next cycle of nucleotide addition.

Sequencing can occur on an array to template strands bound to an array in a chamber for electronic or ionic detection. Examples of methods of electronic or ionic detec- 35 tion include ISFET, ChemFET, and MOSFET. An array can comprise a plurality of reaction chambers or areas each capable of detecting ionic changes to the solution in each of the reaction chambers or areas. Each reaction chamber or area can comprise a plurality of clonal oligonucleotides for 40 sequencing, or a single bound oligonucleotide for single molecule synthesis.

As provided herein, sequencing of oligonucleotides bound in an array can continue as follows: A mixture comprising reagents for amplification of primer extension, 45 e.g., a polymerase, a set of modified nucleotides and other reagents to facilitate the incorporation of the correct nucleotide into the growing strand hybridized to a template to be sequenced, is added to a reaction chamber (FIG. 7). The reaction is allowed to proceed to incorporate one comple- 50 mentary modified nucleotide into the growing strand. Then the reagents including unbound modified nucleotides are removed from the solution, e.g., by washing, leaving only the modified nucleotide (or nucleotides for clonal sequencing) incorporated into the growing strand in the reaction 55 chamber. The reaction chamber is exposed to light (e.g., UV light) (FIG. 7), which activates the photobase or photoacid generators to adjust the pH of the reaction chamber. This change in ionic conditions can then be detected by the sensors in the reaction chamber, e.g., ISFET. The pH of the 60 chamber is detected and can be used to determine the identity of the nucleotide incorporated into the growing strand in the preceding nucleotide addition cycle, which can then be used to determine the identity of the nucleotide base in the template strand.

In some embodiments, as shown in FIG. 7, the reagents for amplification include four modified nucleotides. These four modified nucleotides are each capable of adjusting the pH of the solution in the reaction chamber by a defined amount to provide information on the identity of the incorporated nucleotide. In some embodiments, as shown in FIG. 7, the four modified nucleotides can comprise photobase or photoacid generators. Two or more photobase generators can be used which have distinguishable ionic strengths to allow discrimination by unique pH levels in the reaction chamber after exposure to light. Two or more photoacid generators can be used which have distinguishable ionic strengths to allow discrimination by unique pH levels in the reaction chamber after exposure to light.

During the photoacid or photobase production, the ion level changes in the reaction chamber solution generated by the photoacid/photobase generation and detected by ionsensitive gate of field effective transistor can then be classified and analyzed according to the four types of nucleic acid bases (FIG. 8). In some embodiments, additional cycles of sequencing are perform to generate sequencing information for a stretch of oligonucleotides on the template strand. In this embodiment, the reaction chamber can be neutralized to revert the pH to 7 before proceeding with the next reaction. In addition, if a removable blocking group is still present on the modified nucleotide, it should be removed to allow addition of the next incoming modified nucleotide on the growing strand in the next cycle. Multiple cycles can be performed and analyzed as shown in FIG. 8 to detect a sequence of oligonucleotides.

Arrays

Methods of detection using photoactivated compounds is described herein using arrays. The arrays comprise multiple pH sensors, such as ion-sensitive field effect transistors (ISFET), which are sensitive to small perturbances in ionic strength and can be provided in miniaturized features on an array. Shown in FIG. 9 is an example of an array of wells each comprising a pH sensor, such as an ISFET sensor. Each well can have one or more target biomolecules bound therein, which can be detected or otherwise characterized, such as by sequencing, using the methods and photoactive compounds as described herein. Uses of the arrays disclosed herein can include research applications, therapeutic purposes, medical diagnostics, and/or stratifying one or more patients.

Any of the arrays described herein can be used as a research tool or in a research application. In one aspect, arrays can be used for high throughput screening assays. For example, substrates comprising immobilized probes comprising DNA (deoxyribonucleic acid), RNA (ribonucleic acid), PNA (peptide nucleic acid), LNA (locked nucleic acid), or hybrid combinations thereof can be tested by subjecting the array to a DNA or RNA molecule and

•

identifying the presence or absence of the complimentary DNA, RNA, or PNA molecule, e.g., by detecting at least one change among the features of the array. PNA-DNA chimeric substrates can be tested by subjecting the array to a complementary DNA molecule and performing a single nucleotide extension reaction to determine whether the substrate is biologically active, and to identify a SNP in a sample.

31

In some embodiments, an array can be used for detection of sequence variants in a sample, e.g., single nucleotide polymorphisms (SNPs). Detection of sequence variants can 10 occur through observing sequence-specific hybridization of labeled molecules to a probe on an array. Detection of sequence variants can also occur through binding of a sequence suspected of having a sequence variant to a probe on an array, followed by performing a polymerase extension 15 reaction with a labelled nucleotides. In preferred embodiments, PNA-DNA chimeric oligonucleotide probes are bound to the array and hybridize to nucleotide sequences from a sample suspected of comprising a sequence variant. The PNA-DNA chimeric oligonucleotides are enzymatically 20 active, i.e., they are capable of acting as a substrate for complementary nucleotide incorporation into a growing strand using a polymerase under preferred conditions for polymerization. FIG. 10 provides an exemplary scheme for detecting the identity of a sample oligonucleotide hybridized 25 to a PNA-DNA chimeric oligonucleotide covalently attached to the array using a polymerase-based single nucleotide extension reaction with a labeled nucleotide. Examples of PNA-DNA chimeric oligonucleotide-based methods for SNP detection are provided in U.S. Pat. No. 30 6,316,230, incorporated herein by reference in its entirety.

Arrays can also be used in screening assays for ligand binding, to determine substrate specificity, or for the identification of complimentary DNA, RNA, PNA molecule that are expressed in certain cells in vivo or in vitro. Labeling 35 techniques, protease assays, as well as binding assays useful for carrying out these methodologies are generally well-known to one of skill in the art.

In some embodiments, an array can be used to represent a predefined PNA chain as a sequence of overlapping PNA 40 sequences. For example, the PNA sequence of a known gene is divided into overlapping sequence segments of any length and of any suitable overlapping frame, and PNA chains corresponding to the respective sequence segments are insitu synthesized as disclosed herein. The individual PNA 45 segments so synthesized can be arranged starting from the amino terminus of the predefined PNA chain.

In some embodiments, a sample is applied to an array having a plurality of random PNA chains. The random PNA chains can be screened and BLASTed to determine homologous domains with, e.g., a 90% or more identity to a given nucleotide sequence. In some aspect, the whole PNA sequence can then be synthesized and used to identify potential markers and/or causes of a disease of interest.

In some embodiments, an array is used for high through- 55 put screening of one or more genetic factors. DNA or RNA expression associated with a gene can be investigated through PNA hybridization, which can then be used to estimate the relation between gene and a disease.

In another example, an array can be used to identify one 60 or more biomarkers. Biomarkers can be used for the diagnosis, prognosis, treatment, and management of diseases. Biomarkers may be expressed, or absent, or at a different level in an individual, depending on the disease condition, stage of the disease, and response to disease treatment. 65 Biomarkers can be, e.g., DNA, RNA, PNA, proteins (e.g., enzymes such as kinases), sugars, salts, fats, lipids, or ions.

32

Arrays can also be used for therapeutic purposes, e.g., identifying one or more bioactive agents. A method for identifying a bioactive agent can comprise applying a plurality of test compounds to an array and identifying at least one test compound as a bioactive agent. The test compounds can be small molecules, aptamers, oligonucleotides, chemicals, natural extracts, peptides, proteins, fragments of antibodies, antibody like molecules, or antibodies. In some embodiments, test compounds are hybridizing DNA, RNA or PNA sequences. The bioactive agent can be a therapeutic agent or modifier of therapeutic targets. Therapeutic targets can include phosphatases, proteases, ligases, signal transduction molecules, transcription factors, protein transporters, protein sorters, cell surface receptors, secreted factors, and cytoskeleton proteins.

In one aspect, also provided are arrays for use in medical diagnostics. An array can be used to determine a response to administration of drugs or vaccines. For example, an individual's response to a vaccine can be determined by detecting the gene expression levels of the individual by using an array with PNA chains or PNA-DNA chimeric oligonucleotide chains representing particular genes associated with the induced immune response. Another diagnostic use is to test an individual for the presence of biomarkers, wherein samples are taken from a subject and the sample is tested for the presence of one or more biomarkers.

Arrays can also be used to stratify patient populations based upon the presence or absence of a biomarker that indicates the likelihood a subject will respond to a therapeutic treatment. The arrays can be used to identify known biomarkers to determine the appropriate treatment group. For example, a sample from a subject with a condition can be applied to an array. Binding to the array may indicate the presence of a biomarker for a condition. Previous studies may indicate that the biomarker is associated with a positive outcome following a treatment, whereas absence of the biomarker is associated with a negative or neutral outcome following a treatment. Because the patient has the biomarker, a health care professional may stratify the patient into a group that receives the treatment.

In some embodiments, a method of detecting the presence or absence of a expressed gene of interest in a sample can include obtaining an array disclosed herein and contacted with a sample suspected of comprising the DNA or RNA sequence of a gene of interest; and determining whether the gene of interest is expressed in the sample by detecting the presence or absence of binding to one or more features of the array. In some embodiments, the DNA or RNA sequence of the gene of interest can be obtained from a bodily fluid, such as amniotic fluid, aqueous humour, vitreous humour, bile, blood serum, breast milk, cerebrospinal fluid, cerumen, chyle, endolymph, perilymph, feces, female ejaculate, gastric acid, gastric juice, lymph, mucus, peritoneal fluid, pleural fluid, pus, saliva, sebum, semen, sweat, synovial fluid, tears, vaginal secretion, vomit, or urine.

In some embodiments, a method of identifying a vaccine candidate can include obtaining an array disclosed herein contacted with a sample derived from a subject previously administered the vaccine candidate, wherein the sample comprises a plurality of DNA or RNA sequences; and determining the binding specificity of the plurality of DNA or RNA sequences to one or more features of the array. In some embodiments, the features comprise a plurality of distinct, nested, overlapping PNA chains comprising subsequences derived from a known nucleotide sequence.

In one embodiment, the two or more different photoactive groups are bound by the target biomolecules on the array or

substrate such that upon exposure to light, one group reacts and affects the pH selectively. In such embodiments, both of, or the plurality of, photoactive groups will affect the pH, however, one photoactive group will affect the pH significantly more. In some such embodiments, one photoactive 5 group will affect the pH at least half an order of magnitude more, viz. a measurable change in the pH of the surrounding environment is at least 0.5 units in magnitude different than what is predicted for the plurality of one or more photoactive groups to affect the pH. In some such embodiments, one photoactive group will affect the pH at least one order of magnitude more. In some such embodiments, one photoactive group will affect the pH at least two orders of magnitude more. In some such embodiments, two or more photoactive groups will each affect the pH at least half an order of 15 magnitude more than what is predicted for each one of the other one or more photoactive groups to affect the pH.

Herein also disclosed the inventors have contemplated that each and every embodiment and/or aspect may be used aspect. For examples, photoactive compounds or functional groups of the present disclosure can include any combination of the HOMO. LUMO, pKa, or absorbed light energy within the ranges set forth.

Substrates and arrays suitable for binding probes and 25 target biomolecules for use in detection of the photoactive groups and target biomolecules as described herein are disclosed at least in PCT Publication No. WO 2013/119845, PCT Publication No. WO 2014/052989, PCT Publication No. WO 2014/078606, PCT Publication No. WO 2014/ 30 127328, PCT Publication No. WO 2015/127409, PCT Publication No. WO 2016/145434, and PCT Publication No. WO 2017/117292, the entirety of which are each incorporated by reference.

Results Analysis and Information Storage

In some embodiments, the method of sequencing using modified nucleotides or the array comprising hybrid PNA/ DNA probe oligonucleotides is part of a system, such as a diagnostic or sequencing system or platform that provides highly-multiplexed sequencing results to users.

In some embodiments, provided herein is a sequencing system in which a sample is added to a sequencing array, and oligonucleotides from the sample are sequenced using the methods and compositions described herein. FIGS. 11 and 12 provide examples of systems that can be used to mount 45 an array provided herein and receive electrical signals from each well to perform a sequencing reaction. FIG. 11 shows a diagram of a system including a device that interfaces with a chip or array as described herein to collect data from the chip and process it. Examples of mechanisms to obtain 50 information from each of the multiple reaction areas on the array are shown. FIG. 12 shows a plate base contact to plate base readout stage and elements for UV exposure to induce photoactivation or photocleavage, according to an embodiment of the invention.

A reader can be used to read the sequencing array. For example, the sequencing array may be inserted into the reader, or placed on or inside the reader. In some embodiments, the reader provides an interface with the sequencing array to allow multiplexed electronic detection of sequenc- 60 ing, e.g., by detection of changes to pH such as through ISFET detection. The reader identifies electrical signals in each reaction area or well on an array from incorporated modified nucleotides after exposure to light to induce photoacid or photobase generation. The reader then reads the pH 65 of each reaction chamber, and determines the identity of the incorporated nucleotide. In some embodiments, the reader

includes a display, such as a screen, that allows it to display to the user the results of sequencing. In some embodiments, the confidence level of a nucleotide identification can also be determined and provided for display on the reader.

34

In some embodiments, a software program installed on the reader may compare one or more electronic signals from a reaction chamber with a reference electronic signal associated with a nucleotide. The program can perform this process through a number of cycles to generate a sequence of an oligonucleotide contained within a reaction area of the array. In some embodiments, the software program is a computer readable medium storing instructions on the reader that when executed by a processor within the reader cause the processor to perform certain actions, such as identifying the pH of a reaction area or storing certain data, such as sequencing data. In some embodiments, the software program comprises one or more software modules that perform each of the various functions described above for the reader.

FIG. 13 illustrates a system environment 101 including in any combination with any other embodiment and/or 20 the sequencing system 100 described above, according to an embodiment. The system environment 101 can further include one or more client devices 110, one or more servers 130, a database 105 accessible to the server 130, where all of these parties are connected through a network 120. In other embodiments, different and/or additional entities can be included in the system environment 101.

> The system environment 101 allows the results from the reader 140 to be shared via network 120 with one or more other users at their client devices 110, including being shared with family, friends, physicians or other medical personnel, schools, civil response teams, among others. Results can also be uploaded to the web.

> The network 120 facilitates communications between the components of the system environment 101. The network 120 may be any wired or wireless local area network (LAN) and/or wide area network (WAN), such as an intranet, an extranet, or the Internet. In various embodiments, the network 120 uses standard communication technologies and/or protocols. Examples of technologies used by the network 120 include Ethernet, 802.11, 3G, 4G, 802.16, or any other suitable communication technology. The network 120 may use wireless, wired, or a combination of wireless and wired communication technologies. Examples of networking protocols used for communicating via the network 120 include multiprotocol label switching (MPLS), transmission control protocol/Internet protocol (TCP/IP), hypertext transport protocol (HTTP), simple mail transfer protocol (SMTP), and file transfer protocol (FTP). Data exchanged over the network 120 may be represented using any suitable format, such as hypertext markup language (HTML) or extensible markup language (XML). In some embodiments, all or some of the communication links of the network 120 may be encrypted using any suitable technique or techniques.

The client device(s) 110 are computing devices capable of 55 receiving user input as well as transmitting and/or receiving data via the network 120. In one embodiment, a client device 110 is a conventional computer system, such as a desktop or laptop computer. Alternatively, a client device 110 may be a device having computer functionality, such as a personal digital assistant (PDA), a mobile telephone, a smartphone or another suitable device. A client device 110 is configured to communicate via the network 120.

In some embodiments, the system environment 101 may include one or more servers, for example where the sequencing system includes a service that is managed by an entity that communicates via the network 120 with the reader 140 and/or any of the client devices 110. The server 130 can store

data in database 105 and can access stored data in database 105. Database 105 may be an external database storing sequencing data, medical information, user or patient history data, etc. The server 130 may also store data in the cloud. In some embodiments, the server 130 may occasionally push updates to the reader 140, or may receive result data from the reader 140 and perform certain analyses on that result data and provide the analyzed data back to the reader 140 or to a client device 110.

In some embodiments, the reader **140** functionality can be ¹⁰ included in a client device **110**, such as a mobile phone, and can be operated via a mobile application installed on the phone. In these embodiments, a device may be attached to the phone that allows the phone to read the test strip, or the phone's own internal hardware (e.g., imaging hardware) can ¹⁵ be used to read the test strip. The mobile application stored on the phone can process the results read from the test strip and share the results with other devices **110** on the network **120**.

EQUIVALENTS AND SCOPE

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with 25 the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the appended claims.

In the claims, articles such as "a," "an," and "the" may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

It is also noted that the term "comprising" is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term "comprising" is 45 used herein, the term "consisting of" is thus also encompassed and disclosed.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

All cited sources, for example, references, publications, databases, database entries, and art cited herein, are incorporated into this application by reference, even if not expressly stated in the citation. In case of conflicting statements of a cited source and the instant application, the 60 statement in the instant application shall control.

Section and table headings are not intended to be limiting.

EXAMPLES

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for 36

illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, *Proteins: Structures and Molecular Properties* (W.H. Freeman and Company, 1993); A. L. Lehninger, *Biochemistry* (Worth Publishers, Inc., current addition); Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.); *Remington's Pharmaceutical Sciences*, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg *Advanced Organic Chemistry* 3rd Ed. (Plenum Press) Vols A and B (1992).

Example 1A: Synthesis of a PNA-DNA Probes on an Array

Synthesis of PNA Sequence

To generate a PNA-DNA chimera on the surface of an array, a PNA oligo of a desired sequence at a specific site was first synthesized on a chip according to the protocol provided below:

A location-specific PNA sequence synthesis is performed on an array as follows: A wafer is spin-coated at 2000-4000 rpm (preferably 2500-3000 rpm) for 10-180 seconds (preferably for 60-120 seconds) with a photoresist composition comprising a photobase generator as described above. The wafer and photoresist is exposed to 248 nm ultraviolet light in a deep ultra violet scanner tool according to a pattern defined by a photomask, wherein the locations exposed to ultraviolet light undergo base generation due to the presence of a photobase generator in the photoactive coupling solution in the photoresist. The expose energy can be from 1 mJ/cm² to 100 mJ/cm² (preferably 30-60 mJ/cm²).

After UV exposure, the surface of the wafer is post baked in a bake module. The post bake temperature can vary between 75° C. to 115° C., for a duration of at least 60 seconds (but not usually exceeding 180 seconds). The base generated at the UV-exposed regions removes a protection group on the amino groups. The photoresist is then stripped.

The free amino group is then coupled to activated R2-acetic acid by spin coating R2-acetic acid with activation agents and reacted in a bake module with the temperature varying from 55° C. to 115° C. for 60-240 seconds. Excess R2-acetic acid is removed.

Following addition of activated R2-acetic acid, a displacement reaction with a mono-amino protected ethylene-diamine is performed by addition of a displacement mixture onto the surface of the wafer. This displacement mixture is spin coated on the wafer and reacted in a bake module with the temperature varying from 55° C. to 115° C. for 30 seconds-300 seconds (preferably 120 seconds). In some embodiments, a mono-amino protection group can be any amino protection group as mentioned earlier.

Next, a coupling reaction is performed with the peptide nucleic acid monomer acetic acid. The displaced amine is coupled to the activated PNA monomer acetic acid by spin coating the activated PNA monomer acetic acid with activation agents and allowing to react for 90-300 seconds.

Optionally, a capping solution coat is applied on the surface to prevent any non-reacted amino groups on the substrate from reacting to the next coupling molecule. The capping solution includes a solvent, a polymer, and a coupling molecule. The capping solution is spin-coated on the wafer at 1500-3500 rpm for at least 30 seconds and reacted in a bake module with the temperature varying from 55° C. to 95° C. for 30 seconds-90 seconds (preferably 60 seconds) to complete one cycle.

This entire cycle can be repeated as desired with different nucleic acid monomers each time to obtain desired PNA sequences at specific sites on an array.

Part 2—Synthesis of PNA-DNA Chimera Step.

Addition of a sequence-specific DNA nucleotide to the end of a PNA sequence at specific locations on an array is performed as follows: The wafer comprising PNA sequences is spin-coated at 2000-4000 rpm (preferable 2500-3000 rpm) for 10-180 seconds preferably for 60-120 seconds with the photoresist and is exposed to 248 nm ultraviolet light in a 20 deep ultra violet scanner tool according to a pattern defined by a photomask, wherein the locations exposed to ultraviolet light undergo base generation due to the presence of a photobase generator in the photoactive coupling solution in the photoresist. The expose energy can be from 1 mJ/cm² to 25 100 mJ/cm² (preferably 30-60 mJ/cm²).

After UV exposure, the surface of the wafer is post baked in a bake module. The post bake temperature can vary between 75° C. to 115° C., for a duration of at least 60 seconds (but not usually exceeding 180 seconds). The generated base deprotects the protection of amino groups of the PNA sequences in the exposed regions. The photoresist is then stripped.

Reverse DNA amidites are activated with phosphoramidite activation solution (including e.g., a tetrazole catalyst) and then coupled to the free amine.

Optionally, a capping solution coat is applied on the surface to prevent any non-reacted amino groups on the substrate from reacting to the next coupling molecule. The 40 capping solution includes a solvent, a polymer, and a coupling molecule. The capping solution is spin-coated on the wafer at 1500-3500 rpm for at least 30 seconds and reacted in a bake module with the temperature varying from 55° C. to 95° C. for 30 seconds-90 seconds (preferably 60 seconds) 45 to complete one cycle. The phosphite-triester formed in the coupling step is then converted to a stable form which is achieved by iodine oxidation in the presence of water and pyridine.

Part 3—Reverse DNA Oligonucleotide Synthesis.

A location-specific DNA sequence reverse synthesis (5' to 3') is performed at the end of each PNA-DNA chimera on the array as follows: A wafer is spin-coated at 2000-4000 rpm (preferably 2500-3000 rpm) for 10-180 seconds (preferably for 60-120 seconds) with a photoresist composition comprising a photobase generator as described above. The wafer and photoresist is exposed to 248 nm ultraviolet light in a deep ultra violet scanner tool according to a pattern defined by a photomask, wherein the locations exposed to ultraviolet light undergo acid generation due to the presence of a 60 photoacid generator in the photoactive coupling solution. The expose energy can be from 1 mJ/cm² to 100 mJ/cm² (preferably 30-60 mJ/cm²).

After UV exposure, the surface of the wafer is post baked in a bake module. The post bake temperature can vary 65 between 75° C. to 115° C., for a duration of at least 60 seconds (but not usually exceeding 180 seconds). The acid

38

generated deprotects the protection of hydroxyl groups of the 3'-end of DNA sequence in the exposed regions. The photoresist is then stripped.

Reverse DNA amidites are activated with phosphoramidite activation solution (including e.g., a tetrazole catalyst) and then coupled to the free hydroxyl group.

Optionally, a capping solution coat is applied on the surface to prevent any non-reacted amino groups on the substrate from reacting to the next coupling molecule. The capping solution includes a solvent, a polymer, and a coupling molecule. The capping solution is spin-coated on the wafer at 1500-3500 rpm for at least 30 seconds and reacted in a bake module with the temperature varying from 55° C. to 95° C. for 30 seconds-90 seconds (preferably 60 seconds) to complete one cycle. The phosphite-triester formed in the coupling step is then converted to a stable form which is achieved by iodine oxidation in the presence of water and pyridine.

Example 2: Hybridization of PNA-DNA Chimera to Oligonucleotide DNA Sequence and Extension with Polymerase

To determine the biological activity of a PNA-DNA chimera sequence synthesized per the above protocol, a 34-mer length PNA-DNA chimera sequence 5'-GTG-GAAATTTGACATAGTCTCAGATGCCTAT(TAT)-3' (SEQ ID NO: 7) was synthesized according to Example 3 with (TAT) being the DNA oligomer portion of the PNA-DNA chimera. Four oligonucleotide DNA sequences complimentary to the sequence of the PNA-DNA chimera with one additional nucleotide were synthesized (IDT).

(SEQ ID NO: 8)
S1: CACCTTTAAACTGTATCAGAGTCTACGGATAATAA

(SEQ ID NO: 9)
S2: CACCTTTAAACTGTATCAGAGTCTACGGATAATAC

(SEQ ID NO: 10)
S3: CACCTTTAAACTGTATCAGAGTCTACGGATAATAG

(SEQ ID NO: 11)
S4: CACCTTTAAACTGTATCAGAGTCTACGGATAATAT

A primer extension reaction to detect incorporation of the correct complementary nucleotide in a primer extension reaction was performed. Alexa 405 ddATP, Alexa 488 ddCTP, Alexa 555 ddGTP, Alexa 647 ddTTP were synthesized by techniques well known to one skilled in the art. Hybridization and polymerase extension on each of the 4 chips were performed as follows. Oligomers S1, S2, S3 and S4 were diluted 1:1000 (100 nM) in 1xDNA Polymerase Buffer (Clontech), 20 nmol of MgCl2, 1 unit Titanium Taq DNA Polymerase (Clontech), and all 4 labelled ddNTPs labelled monomers (each 25 pmoles). Hybridization was done in a hybridization chamber at 55° C. for 30 minutes followed by washing the chips in 0.1× Ssarc buffer at 40° C. for 5 minutes twice followed by rinsing in DI Water. The chip was then scanned on a Nikon AIR confocal microscope which included the 4 wavelengths of the dyes used in the ddNTPs and results are depicted in Table 1.

TABLE 1

		ation and Exte		
Sequence	405 nm	488 nm	561 m	640 nm
S1 (a)	950.02	875.54	1047.8	65124.23
S2 (c)	1051.3	954.2	65531.25	875.6
S3 (g)	800.3	65014.78	802.5	1068.9
S4 (t)	65121.13	1012.98	946.6	780.9

Example 3: Genotyping Using PNA Sequence Hybridization

Testing of the PNA synthesis for a genotyping SNP-based application was performed. Genotyping of MTHFR region, with the well-known mutations, C677T and A1298C, were tested using 20 DNA samples. The DNA samples had a known genotyping result which were determined using Real-Time PCR.

PNA Sequences were as follows:

 $({\tt SEQ\ ID\ NO:\ 12})\\ {\tt GGAGAAGGTGTCTGCGGGAG\,(C)\,CGATTCATCATCACGCAGC,}$

 $({\tt SEQ\ ID\ NO:\ 13})$ GGAGAAGGTGTCTGCGGGAG(T) CGATTTCATCATCACGCAGC,

-continued

(SEQ ID NO: 14) GGAGGAGCTGACCAGTGAAG(A)AAGTGTCTTTGAAGTCTTCG,

 $({\tt SEQ\ ID\ NO:\ 15}) \\ {\tt GGAGGAGCTGACCAGTGAAG(C)AAGTGTCTTTGAAGTCTTTCG.}$

PNA sequences were synthesized on a chip using the methods given above. The location of the SNP is indicated in () region (surrounded by parentheses) and is synthesized in the middle of the sequence.

DNA were extracted from the samples (buccal swabs) using methods known to one skilled in the art. A standard PCR reaction using forward primer and biotin-labelled reverse primers was performed on the extracted DNA samples. Hybridization of the PCR product on the chip was performed with the PCR product (20 ul) diluted in hybridization buffer 0.1× Ssarc Buffer 60 mM sodium chloride (Sigma) (80 ul), 6 mM sodium citrate (Sigma), 0.72 weight % N-lauroylsarcosine sodium salt solution (Sigma). Hybridization was done in a hybridization chamber at 55° C. for 2 hours followed by washing the chips in 0.1× Ssarc buffer 40° C. for 5 minutes twice. This was followed by an incubation with 1 ng/ml Atto 488 Streptavidin (Rockland) diluted in PBS buffer, washing the chips in PBS Buffer twice and rinsing in DI Water. The chip was then scanned on a Nikon AIR confocal microscope and results are depicted in Table 2 and Table 3.

TABLE 2

		677C > T Mu	itation Results (PNA)	
Sample ID	Original Result	SEQ ID NO: 12 (C)	SEQ ID NO: 13 (T)	Ratio (C/T)	Calculated Result
MT1	Homozygous Wild C/C	65521.21	18343.16	3.571969606	Homozygous Wild C/C
MT2	Homozygous Wild C/C	65227.42	17390.41	3.750769533	Homozygous Wild C/C
MT3	Homozygous Wild C/C	65093.45	18262.83	3.564258661	Homozygous Wild C/C
MT4	Homozygous Wild C/C	65386.72	16498.11	3.963285491	Homozygous Wild C/C
MT5	Homozygous Wild C/C	65245.82	17957.35	3.633376862	Homozygous Wild C/C
MT6	Homozygous Wild C/C	65399.12	15087.35	4.334698937	Homozygous Wild C/C
MT7	Homozygous Wild C/C	65408.94	16166.17	4.046038115	Homozygous Wild C/C
MT8	Heterozygous C/T	32656.73	29003.56	1.125955917	Heterozygous C/T
МТ9	Heterozygous C/T	31140.4	28860.93	1.078981169	Heterozygous C/T
MT10	Heterozygous C/T	30317.09	27075.3	1.119732376	Heterozygous C/T
MT11	Heterozygous C/T	29953.05	30101.53	0.99506736	Heterozygous C/T
MT12	Heterozygous C/T	34884.62	32957.31	1.058478984	Heterozygous C/T
MT13	Heterozygous C/T	28468.43	30134.87	0.944700608	Heterozygous C/T
MT14	Heterozygous C/T	29909.26	26689.12	1.12065366	Heterozygous C/T
MT15	Homozygous Mutant T/T	16202.94	65103.75	0.248878751	Homozygous Mutant T/T
MT16	Homozygous Mutant T/T	16759.95	65465.38	0.256012415	Homozygous Mutant T/T
MT17	Homozygous Mutant T/T	18019.34	65327.52	0.275830768	Homozygous Mutant T/T
MT18	Homozygous Mutant T/T	15153.13	65116.35	0.232708529	Homozygous Mutant T/T
MT19	Homozygous Mutant T/T	16837.25	65198.8	0.258244784	Homozygous Mutant T/T

41

TABLE 2-continued

		677C > T Mu	tation Results (PNA)	
Sample ID	Original Result	SEQ ID NO: 12 (C)	SEQ ID NO: 13 (T)	Ratio (C/T)	Calculated Result
MT20	Homozygous Mutant T/T	16315.66	65431.64	0.249354288	Homozygous Mutant T/T
No Template	No Template Control	931.04	1010.87		No Template Control

TABLE 3

		1298A > C M	utation Results	(PNA)	
Sample ID	Original Result	SEQ ID NO: 14 (A)	SEQ ID NO: 15 (C)	Ratio (A/C)	Calculated Result
MT1	Homozygous Wild A/A	65379.46	18466.16	3.540501111	Homozygous Wild C/C
MT2	Homozygous Wild A/A	65471.94	15279.46	4.284964259	Homozygous Wild C/C
MT3	Homozygous Wild A/A	65031.65	16581.28	3.92199215	Homozygous Wild C/C
MT4	Homozygous Wild A/A	65219.55	17032.97	3.829018075	Homozygous Wild C/C
MT5	Homozygous Wild A/A	65122.87	15781.57	4.126514029	Homozygous Wild C/C
MT6	Homozygous Wild A/A	65211.42	16471.62	3.959016782	Homozygous Wild C/C
MT7	Homozygous Wild A/A	65284.01	16098.4	4.055310466	Homozygous Wild C/C
MT8	Heterozygous A/C	25864.99	26219.09	0.986494573	Heterozygous C/T
MT9	Heterozygous A/C	27535.6	33971.8	0.810542862	Heterozygous C/T
MT10	Heterozygous A/C	29798.31	25928.75	1.149238201	Heterozygous C/T
MT11	Heterozygous A/C	31306.14	30412.04	1.02939954	Heterozygous C/T
MT12	Heterozygous A/C	34735.37	26137.17	1.328964459	Heterozygous C/T
MT13	Heterozygous A/C	34293.84	32393	1.058680579	Heterozygous C/T
MT14	Heterozygous A/C	34029.48	29563.14	1.151077998	Heterozygous C/T
MT15	Homozygous Mutant C/C	17863.25	65072.67	0.274512326	Homozygous Mutant T/T
MT16	Homozygous Mutant C/C	15361.46	65400.42	0.234883201	Homozygous Mutant T/T
MT17	Homozygous Mutant C/C	16092.89	65285.28	0.246501049	Homozygous Mutant T/T
MT18	Homozygous Mutant C/C	16038.93	65184.73	0.246053485	Homozygous Mutant T/T
MT19	Homozygous Mutant C/C	16752.2	65398.01	0.256157641	Homozygous Mutant T/T
MT20	Homozygous Mutant C/C	16298.91	65253.44	0.249778556	Homozygous Mutant T/T
No Template	No Template Control	931.04	1010.87		No Template Control

In this method, the SNP location is ideally close to the center of the sequence synthesized.

Example 4: Genotyping Using PNA-DNA Chimera and Primer Extension

Testing of the PNA-DNA chimera for a genotyping SNP-based application was performed. Genotyping of MTHFR region, with the well-known mutations, C677T and A1298C, were tested using 20 DNA samples. The DNA samples had a known genotyping result which were determined using Real-Time PCR. 34-mer length PNA-DNA chimera primer 65 sequences 5'-CTGAAGCACTT-GAAGGAGAAGGTGTCTGCGG(GAG)-3' (SEQ ID NO:

16) for the 677C>T mutation and 5'-CTGAA 55 GATGTGGGGGGAGGAGCTGACCAGTG(AAG)-3' (SEQ ID NO: 17) for the 1298A>C mutation were synthesized according to the methods given above (with DNA nucleotide portion of the PNA-DNA chimera enclosed in parentheses).

DNA were extracted from the samples (buccal swabs) using methods known to one skilled in the art. A standard PCR reaction using forward and reverse primers was performed on the extracted DNA samples. Hybridization and polymerase extension on each of chips were performed as follows. The PCR product was mixed in 1×DNA Polymerase Buffer (Clontech), 20 nmol of MgCl₂, 1 unit Titanium Taq

DNA Polymerase (Clontech), and all 4 labelled ddNTPs labelled monomers (each at 25 pmol). Hybridization was done in a hybridization chamber at 55° C. for 30 minutes followed by washing the chips in 0.1× Ssarc buffer 40° C.

43

for 5 minutes twice followed by rinsing in DI Water. The chip was then scanned on a Nikon AIR confocal microscope which included the 4 wavelengths of the dyes used in the ddNTPs and results are depicted in Table 4 and Table 5.

44

TABLE 4

		677C>T I	Mutation Re	sults (PNA	A-DNA Chir	nera)	
Sample ID	Original Result	405 nm (A)	488 nm (C)	561 nm (G)	640 nm (T)	Ratio (C/T)	Calculated Result
MT1	Homozygous Wild C/C	987.88	65381.38	1068.03	1022.91	63.9170406	Homozygous Wild C/C
MT2	Homozygous Wild C/C	1079.22	65379.69	1003.71	1088.7	60.0529898	Homozygous Wild C/C
MT3	Homozygous Wild C/C	890.15	65426.33	1054.07	984.99	66.4233444	Homozygous Wild C/C
MT4	Homozygous Wild C/C	1019.28	65082.83	1072.37	1005.67	64.7158909	Homozygous Wild C/C
MT5	Homozygous Wild C/C	1054.92	65520.82	885.87	919.46	71.26010919	Homozygous Wild C/C
MT6	Homozygous Wild C/C	856.58	65086.76	1063	1081.46	60.18415845	Homozygous Wild C/C
MT7	Homozygous Wild C/C	1014.84	65048.37	1012.61	1020.77	63.72480578	Homozygous Wild C/C
MT8	Heterozygous C/T	1086.58	28940.21	916.77	25640.7	1.128682524	Heterozygous C/T
MT9	Heterozygous C/T	1045.85	34602.61	903.71	33874.1	1.021506402	Heterozygous C/T
MT10	Heterozygous C/T	920.14	30597.21	1085.44	32891.41	0.930249266	Heterozygous C/T
MT11	Heterozygous C/T	1065.78	26105.81	883.95	25875.75	1.00889095	Heterozygous C/T
MT12	Heterozygous C/T	1087.05	28716.64	1028.78	30765.41	0.933406706	Heterozygous C/T
MT13	Heterozygous C/T	1096.23	30296.19	1097.06	29260.09	1.035410007	Heterozygous C/T
MT14	Heterozygous C/T	999.32	31152.26	1083.28	28772.12	1.082723831	Heterozygous C/T
MT15	Homozygous Mutant T/T	959.46	920.49	983.83	65264.85	0.014103917	Homozygous Mutant T/T
MT16	Homozygous Mutant T/T	999.03	1017.52	1098.91	65228.95	0.015599209	Homozygous Mutant T/T
MT17	Homozygous Mutant T/T	908.97	1031.03	1083.42	65170.19	0.015820577	Homozygous Mutant T/T
MT18	Homozygous	1053.12	1000.45	961.54	65066.09	0.015375905	Homozygous
MT19		1070.32	1075.46	1009.19	65326.99	0.016462721	Mutant T/T Homozygous
MT20	Mutant T/T Homozygous Mutant T/T	1059.73	915.48	854.63	65287.66	0.014022252	Mutant T/T Homozygous Mutant T/T
No Template		1005.16	931.04	1018.61	1010.87		No Template Control

TABLE 5

	1298 A>C Mutation Results (PNA-DNA Chimera)						
Sample ID	Original Result	405 nm (A)	488 nm (C)	561 nm (G)	640 nm (T)	Ratio (A/C)	Calculated Result
MT1	Homozygous Wild A/A	65488.6	860.42	898.56	1053.57	76.11236373	Homozygous Wild A/A
MT2	Homozygous Wild A/A	65344.12	942.87	1005.5	859.47	69.30342465	Homozygous Wild A/A
MT3	Homozygous Wild A/A	65439.64	943	1040.81	1048.08	69.39516437	Homozygous Wild A/A
MT4	Homozygous Wild A/A	65352.13	1015.9	850.32	978.43	64.32929422	Homozygous Wild A/A
MTS	Homozygous Wild A/A	65258.17	1047.97	999.32	858.43	62.27102875	Homozygous Wild A/A
MT6	Homozygous Wild A/A	65327.7	871.43	984.33	971.42	74.96609022	Homozygous Wild A/A
MT7	Homozygous Wild A/A	65222.79	1032.19	1093.43	894.49	63.18874432	Homozygous Wild A/A
MT8	Heterozygous A/C	32437.6	29322.89	851.72	897.02	1.106221113	Heterozygous A/C

5-continued
esults (PNA-DNA Chimera)

		1298 A>C I	Mutation Re	sults (PNA	A-DNA Ch	imera)	
Sample ID	Original Result	405 nm (A)	488 nm (C)	561 nm (G)	640 nm (T)	Ratio (A/C)	Calculated Result
МТ9	Heterozygous A/C	28901.78	32234.2	972.78	930.13	0.896618498	Heterozygous A/C
MT10	Heterozygous A/C	31930.24	34009.27	902.33	1072.67	0.938868726	Heterozygous A/C
MT11	Heterozygous A/C	31187.77	33959.45	1066.13	858.62	0.918382659	Heterozygous A/C
MT12	Heterozygous A/C	35160.88	34129.73	1085.9	978.16	1.030212662	Heterozygous A/C
MT13	Heterozygous A/C	26032.4	34987.94	980.73	1047.35	0.744039232	Heterozygous A/C
MT14	Heterozygous A/C	32902.79	33518.34	1024.53	998.06	0.981635427	Heterozygous A/C
MT15	Homozygous Mutant C/C	853.23	65405.7	866.06	1096.1	0.013045193	Homozygous Mutant C/C
MT16	Homozygous Mutant C/C	861.56	65469.41	1045.55	1093.83	0.013159734	Homozygous Mutant C/C
MT17	Homozygous Mutant C/C	948.8	65335.08	1094.53	1025.03	0.014522061	Homozygous Mutant C/C
MT18	Homozygous Mutant C/C	853.16	65190.22	964.72	901.27	0.013087239	Homozygous Mutant C/C
MT19	Homozygous Mutant C/C	1014.49	65003.94	1015.66	922.79	0.015606592	Homozygous Mutant C/C
MT20	Homozygous Mutant C/C	926.32	65437.85	945.85	1063.8	0.014155722	Homozygous Mutant C/C
No Template	No Template Control	1043.98	1043.85	986.73	1073.34		No Template Control

contains the region just before the SNP location, thereby enabling the polymerase to selectively add the matched oligomer corresponding to the SNP identity.

The PNA-DNA chimera was able to hybridize to the DNA sequence and extend accurately according to the corresponding match DNA monomer. The PNA-DNA chimera is able to obtain a high Match/Mismatch Ratio which would accurately identify SNP-based genotyping results. Ratio for Match/Mismatch sequence is 3.5-4 for PNA sequence while it is 65-70 or PNA-DNA chimera sequence. Thus, PNA-DNA chimera with high yield of the sequence and the ability to perform a polymerase extension step on chip due to the DNA oligomer present provides a high-throughput, high accuracy system for various genomics applications including, but not limited to, SNP-based genotyping and DNA sequencing.

Example 5: Synthesis of Photoactive Molecule 1 (PM1) (dCTP-PAG1)

We modified dCTP by adding a photoacid generator (PAG1) to generate dCTP-PAG1 (i.e., "Photoactive Molecule 1", or "PM1"). A reaction scheme for the synthesis of PM1 is shown in FIG. 14.

5-Methyl-2-nitrobenzoic acid, Thionyl Chloride, Magnesium turnings, Chlorobenzene, Carbon tetrachloride (CCl₄), Diethyl malonate, Sulfuric acid (H₂SO₄), Chloroform, Acetic acid (AcOH), Sodium carbonate (Na₂CO₃), N-bromosuccinimide, Benzoyl peroxide, Ethyl Acetate (EtOAc), Sodium sulfate (Na₂SO₄), Hexane, Methanol, Hydrogen Chloride (HCl), 1,4-dioxane, Sodium borohydride (NaBH₄), Tetrahydrofuran (THF), Triphenylphosphine (PPh₃), triphosgene, trimethylamine, N-hydroxysuccinimide, potassium hydroxide (KOH), trichloroacetic acid, and sodium 65 bisulfite (NaHSO₃) were obtained from Sigma Aldrich. Ethyl Alcohol, methanol, acetonitrile and Acetone were

In this method, the sequence synthesized on the chip 30 obtained from VWR. 5-Aminoallyl-2'-deoxycytidine-5'-Triphosphate was obtained from Trilink Biotechnologies.

46

Step 1: 5-Methyl-2-nitrobenzoic acid (27.6 mmol) was added in small portions to thionyl chloride (148 mmol) and the mixture was stirred at room temperature for 12 hours. Excess thionyl chloride was removed by vacuum.

Step 2: Next, a mixture of magnesium turnings (442 mmol), 6 mL absolute ethyl alcohol, 8 mL chlorobenzene, and 0.1 mL CCl₄ were refluxed until most of the magnesium reacted. A solution of diethyl malonate (4.82 g) in 10 mL chlorobenzene was added followed by the addition of 5-Methyl-2-nitrobenzoic acid chloride. The reaction was stirred for 1 hour and 1.7 mL H₂SO₄ in 17 mL water was added. The mixture was stirred for 20 minutes and 20 mL chloroform was added. The aqueous layer was extracted 3 times with 10 mL chloroform and were combined, dried and evaporated.

Step 3: The residue was dissolved in 8.25 mL AcOH in 5.4 mL water containing 1 mL H₂SO₄ and the mixture was 50 refluxed for 6 hours. The mixture was neutralized with aqueous Na₂CO₃, extracted 3 times with 20 mL chloroform, dried and concentrated. The residue was re-crystallized from 70% ethyl alcohol and isolated. This mixture is 5-Methyl-2-nitroacetophenone.

Step 4: 5-Bromomethyl-2-nitroacetophenone was obtained by the mixture of 5-Methyl-2-nitroacetophenone (19.6 mmol), N-bromosuccinimide (20.6 mmol) and benzoyl peroxide (0.01 meq) which were refluxed in 20 mL CCl₄ for 5 hours. The reaction mixture was filtered, concentrated, recrystallized in CCl₄ and isolated.

Step 5: The 5-Bromomethyl-2-nitroacetophenone (7.75 mmol) was dissolved in acetone: H₂O (5:1 by volume, 50 mL). Sodium azide (11.6 mmol) was added, and the mixture was heated to 75° C. overnight in a flask equipped with a reflux condenser. After acetone evaporation under reduced pressure, the aqueous phase was extracted with EtOAc, washed with brine, and dried with Na2SO4, and the solvent

was evaporated under reduced pressure. The mixture was purified by silica gel chromatography using a 10-20% gradient of EtOAc in hexane.

Step 6: The purified mixture from step 5 (6.81 mmol) was dissolved in MeOH: dioxane (3:2 by volume, 30 mL), and 5 NaBH₄ (10 mmol) was added slowly. After 30 min, water (50 mL) and 2 M HCl (1 mL) were added and the suspension was extracted twice with EtOAc, washed with brine, dried over Na₂SO₄, and evaporated under reduced pressure and light protection. The resulting brown oil was purified by silica gel chromatography using a 10-20% gradient of EtOAc in hexane.

Step 7: To a solution of compound (brown oil) from step 6, (4.54 mmol) in THF (30 mL), PPh₃ (5 mmol) and H₂O (0.5 mL) were added and the mixture was heated at 60° C. 15 for 4 h. Evaporation of the solvent under reduced pressure gave a residue that was dissolved in chloroform and purified by silica gel chromatography with 5-15% MeOH in Chloroform to give the compound 1-(5-(Aminomethyl)-2-nitrophenyl)ethanol.

Step 8: Triphosgene (1 mmol) and triethylamine (10 mmol) were added at 0° C. to the solution of the adipic acid monoethyl ester (2 mmol) in dichloromethane (10 mL). Then N-hydroxysuccinimide (2 mmol) was added to the reaction mixture. The reaction mixture was stirred for 40 25 concentrated H₂SO₄ (2.88 μL) and 1 mL of alcohol (EtOAc min at room temperature. After completion of the reaction, the reaction mixture was filtered by suction filtration. The product was formed by the removal of the filtrate by rotary evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate in hexane. The solution 30 was mixed with 1-(5-(Aminomethyl)-2-nitrophenyl)ethanol (3 mmol) in DMF (3 mL). The solution was stirred at room temperature overnight and evaporated in vacuum. The residue was dissolved in EtOAc, dried over Na2SO4, and evaporated under reduced pressure.

Step 9: To a stirring solution of the ester (1 equivalent) and methanol (5 mL), KOH (2 molar equivalents) was added at 35° C. The reaction was allowed to continue for 1 hour and then quenched by addition of water (20 mL). The aqueous layer was acidified and the resulting acid was 40 extracted from the aqueous layer by EtOAc.

Step 10: A mixture of Trichloroacetic acid (1.35 mmol), 4% concentrated H₂SO₄ (2.88 μl) and 1 mL of alcohol (EtOAc containing the resulting acid) from Step 9 were combined in microwave reaction vessel and irradiated for 20 45 minutes, during which the acid catalyst was loaded every 5 minutes. Once the reaction was complete, the solvent was evaporated under pressure, and the crude residue was dissolved in ethyl acetate. The organic layer was washed with NaHSO₃ and dried with anhydrous Na₂SO₄. The mixture 50 was then purified and concentrated in vacuum to give the ester product.

Step 11: Triphosgene (1 mmol) and triethylamine (10 mmol) were added at 0° C. to a stirred solution of the adipic acid monoethyl ester (2 mmol) in dichloromethane (10 mL). 55 Then N-hydroxysuccinimide (2 mmol) was added to the reaction mixture. The reaction mixture was stirred for 40 min at room temperature. After completion of the reaction, the reaction mixture was filtered by suction filtration. The product was formed by the removal of the filtrate by rotary 60 evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate in hexane. The solution was mixed with 1-(5-(Aminomethyl)-2-nitrophenyl)ethanol (3 mmol) in DMF (3 mL). The solution was stirred at room temperature overnight and evaporated in vacuum. The residue was dissolved in EtOAc, dried over Na2SO4, and evaporated under reduced pressure.

48

Step 12: The compound (residue) from step 11 was then dissolved in 2 mL of acetonitrile. DSC (0.75 mmol) dissolved in 3 mL of acetonitrile: ethyl acetate (5:1) solution, was then added, followed by triethylamine (0.75 mmol). 5-Aminoally1-2'-deoxycytidine-5'-Triphosphate (1 mmol) was then added to this mixture. After overnight reaction, cold diluted HCl was added and the product was extracted with ethyl acetate. The solution was washed three times with diluted HCl, dried over anhydrous sodium sulfate, and the solvent was removed by evaporation.

Example 6: Synthesis of Photoactive Molecule 2 (PM2) (dATP-PAG2)

We modified dATP by adding a photoacid generator (PAG2) to generate dCTP-PAG2 (i.e., "Photoactive Molecule 2" or "PM2"). A reaction scheme for the synthesis of PM2 is shown in FIG. 15. The synthesis was performed as

20 N6-(6-Amino) hexyl-2'-deoxyadenosine-5'-triphosphate was obtained from Jenabiosciences. Acetic acid was obtained from Sigma Aldrich.

Steps 1 through 9 are repeated as given in Example 5. Step 10: A mixture of Acetic acid (1.35 mmol), 4% containing the resulting acid) from Step 9 were combined in microwave reaction vessel and irradiated for 20 minutes, during which the acid catalyst was loaded every 5 minutes. Once the reaction was complete, the solvent was evaporated

under pressure, and the crude residue was dissolved in ethyl acetate. The organic layer was washed with NaHSO₃ and dried with anhydrous Na₂SO₄. The mixture was then purified and concentrated in vacuum to give the ester product.

Step 11 Triphosgene (1 mmol) and triethylamine (10 mmol) were added at 0° C. to the stirred solution from Step 9 (2 mmol) in dichloromethane (10 mL). Then N-hydroxysuccinimide (2 mmol) was added to the reaction mixture. The reaction mixture was stirred for 40 min at room temperature. After completion of the reaction, the reaction mixture was filtered by suction filtration. The product was formed by the removal of the filtrate by rotary evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate in hexane. The solution was mixed with 1-(5-(Aminomethyl)-2-nitrophenyl)ethanol (3 mmol) in DMF (3 mL). The solution was stirred at room temperature overnight and evaporated in vacuum. The residue was dissolved in EtOAc, dried over Na2SO4, and evaporated under reduced pressure.

Step 12: The resulting compound from Step 11 was dissolved in 2 mL of acetonitrile. DSC (0.75 mmol) dissolved in 3 mL of acetonitrile: ethyl acetate (5:1) solution, was then added, followed by triethylamine (0.75 mmol). N6-(6-Amino) hexyl-2'-deoxyadenosine-5'-triphosphate (1 mmol) was then added to this mixture. After overnight reaction, cold diluted HCl was added and the product was extracted with ethyl acetate. The solution was washed three times with diluted HCl, dried over anhydrous sodium sulfate, and the solvent was removed by evaporation.

Example 7: Synthesis of Photoactive Molecule 3 (PM3) (dUTP-PBG1)

We modified dUTP by adding a photobase generator (PBG1) to generate dUTP-PBG1 (i.e., "Photoactive Molecule 3" or "PM3"). A reaction scheme for the synthesis of PM3 is shown in FIG. 16. The synthesis was performed as follows:

3-bromo-2-iodo benzoic acid, sodium, 4-aminophenol, dimethyl sulfoxide, then tris (2-(2-methoxyethoxy) ethyl) amine, copper chloride (CuCl), 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, Palladium(II) acetate (Pd(OAc)₂), Cesium carbonate (Cs₂CO₃), diethyl malonate, 5 dioxane, Triazabicyclodecene, diisopropyl ether, and N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride were obtained from Sigma Aldrich. 5-Aminoallyl-dUTP was obtained from Biotium.

Step 1: 3-bromo-2-iodo benzoic acid (8 mmol) was dis- 10 solved in a KOH solution (9.5 mmol). The mixture was condensed under vacuum at 100° C. and the resultant solid was heated under vacuum at 100° C. for 12 h to yield a dried potassium salt. Metallic sodium (8.35 mmol) was dissolved in 100 mL of methanol, and 4-aminophenol (8.35 mmol) was added. The mixture was condensed and heated under vacuum at 100° C. for 12 h to yield a dried sodium salt. The sodium salt was dissolved in 15 mL of anhydrous dimethyl sulfoxide, and then tris (2-(2-methoxyethoxy) ethyl)amine (TDA-1, 1.0 mL) was added. The mixture was stirred to 20 reach homogeneity at room temperature under anhydrous conditions, and then CuCl (350 mg) and potassium salt powders of the compound were added. The resultant mixture was stirred at 85° C. for 4 h, cooled down to room temperature, washed with a NaOH, filtered with diatomite, and 25 acidified with 1 N HCl to pH value at 2-3. A semisolid precipitate was collected, washed with water, and dried to yield a crude product.

Step 2: The crude product from Step 1 (7.35 mmol) was added to a stirring sulfuric acid solution. The mixture was 30 allowed to react for 30 min at 90° C., and then cooled down to room temperature, diluted with 200 mL of ice water, and filtered. The resultant solid was washed with water, dried, and recrystallized from EtOAc/Methanol to yield a light yellow solid.

Step 3: The light yellow solid from from Step 2 (7.25 mmol), 1, 3-bi-(2,6-diisopropylphenyl)imidazole chloride (Ipr. HCl 2% by mole), Pd(OAc)2 (2% by mole), Cs₂CO₃ (4.7 g, 14.5 mmol), diethyl malonate (1.16 g, 7.25 mmol), and 20 mL of dioxane were mixed. The mixture was allowed 40 to react at 80° C. for 24 h, and then cooled down to room temperature, diluted with 100 mL of EtOAc, and filtered to yield a black precipitate. The filtrate was condensed and recrystallized from EtOAc/MeOH to yield a light yellow solid.

Step 4: The light yellow solid from Step 3 (0.3 mol), 350 mL of methanol, and a NaOH solution (0.6 mol) were mixed. The mixture was heated, stirred at 40° C., hydrolyzed completely, acidified with acetic acid to yield a white precipitate, filtered, and dried to yield a crude product.

Step 5: Triphosgene (1 mmol) and triethylamine (10 mmol) were added at 0° C. to a stirred solution of the adipic acid monoethyl ester (2 mmol) in dichloromethane (10 mL). Then N-hydroxysuccinimide (2 mmol) was added to the reaction mixture. The reaction mixture was stirred for 40 55 min at room temperature. After completion of the reaction, the reaction mixture was filtered by suction filtration. The product was formed by the removal of the filtrate by rotary evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate in hexane. The solution was mixed with Step 5 compound (3 mmol) in DMF (3 mL). The solution was stirred at room temperature overnight and evaporated in vacuum. The residue was dissolved in EtOAc, dried over Na₂SO₄, and evaporated under reduced pressure.

Step 6: 10 mmol of Triazabicyclodecene and 10 mmol of 65 the compound obtained in Step 5 were dissolved into 20 mL of acetone, and stirred at room temperature for 30 minutes.

50

After completion of the reaction, reaction solution was concentrated under reduced pressure, and the resulting residue was washed with diisopropyl ether, and then dried under reduced pressure.

Step 7: To a stirring solution of the ester from Step 6 (1 equivalent) and methanol (5 mL), KOH (2 molar equivalents) was added at 35° C. The reaction was allowed to continue for 1 hour and then quenched by addition of water (20 mL). The aqueous layer was acidified and the resulting acid was extracted from the aqueous layer by EtOAc.

Step 8: 2 mmol of the compound from Step 7 is mixed along with EDC (8 mmol) and N-hydroxysuccinimide (2 mmol) and the reaction mixture was stirred for 40 min at room temperature. The product was formed by the removal of the filtrate by rotary evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate in hexane. The solution was mixed with 5-Aminoallyl-dUTP (3 mmol) in DMF (3 mL). The solution was stirred at room temperature overnight and evaporated in vacuum. The residue was dissolved in EtOAc, dried over Na₂SO₄, and evaporated under reduced pressure.

Example 8: Synthesis of Photoactive Molecule 4 (PM4) (dGTP-PBG2)

We modified dGTP by adding a photobase generator (PBG2) to generate dUTP-PBG2 (i.e., "Photoactive Molecule 4" or "PM4"). A reaction scheme for the synthesis of PM4 is shown in FIG. 17. The synthesis was performed as follows:

1,8-Diazabicyclo[5.4.0]undec-7-ene was obtained from Sigma Aldrich. 7-Deaza-7-Propargylamino-2'-deoxyguanosine-5'-Triphosphate was obtained from Trilink Biotechnologies.

Steps 1 through 5 are repeated as given in Example 7. Step 6: 10 mmol of 1,8-Diazabicyclo[5.4.0]undec-7-ene and 10 mmol of the compound obtained in Step 5 were dissolved into 20 mL of acetone, and stirred at room temperature for 30 minutes. After completion of the reaction, reaction solution was concentrated under reduced pressure, and the resulting residue was washed with disopropyl

Step 7: To a stirring solution of the ester from Step 6 (1 equivalent) and methanol (5 mL), KOH (2 molar equivalents) was added at 35 C. The reaction was allowed to continue for 1 hour and then quenched by addition of water (20 mL). The aqueous layer was acidified and the resulting acid was extracted from the aqueous layer by EtOAc.

ether, and then dried under reduced pressure.

Step 8: 2 mmol of the compound from Step 7 is mixed along with EDC (8 mmol) and N-hydroxysuccinimide (2 mmol) and the reaction mixture was stirred for 40 min at room temperature. The product was formed by the removal of the filtrate by rotary evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate in hexane. The solution was mixed with 7-Deaza-7-Propargylamino-2'-deoxyguanosine-5'-Triphosphate (3 mmol) in DMF (3 mL). The solution was stirred at room temperature overnight and evaporated in vacuum. The residue was dissolved in EtOAc, dried over Na₂SO₄, and evaporated under reduced pressure.

Example 9: Testing of Performance of Photoactive Molecules

Photoactive molecules PM1-PM4 were tested for their performance in Polymerase Chain Reactions (PCR) and specifically genotyping application on the methylenetetra-

hydrofolate reductase (MTHFR) gene. The nucleotide polymorphism 677 C>T (rs1801133) is located within the region coding for the catalytic domain of MTHFR and results in an amino acid substitution from an alanine to a valine at codon position 222 (exon 4).

PNA sequences were synthesized on a Silicon wafer containing a microarray of sequences to be used as 'adapters' for allele specific primer extension reactions. Genomic DNA samples were obtained in-house from the Vibrant Genomics Labs and the mutations of 677 C>T were known 10 through ACGT, Inc. sequencing.

To amplify the region in the genomic DNA, PCR was performed in a 20 µL reaction volume as follows: 50 ng of the human genomic DNA was added to a PCR amplification reagent mixture comprising: 2.5 units of Titanium Taq DNA 15 polymerase (Clontech), 200 µM each dNTP (dATP, dTTP, dGTP, dCTP) (Thermofisher Scientific), 10x PCR Buffer with 1.5 mM MgCI2 (Thermofisher Scientific), 20 pmol sense primer (5'-CCTATTGGCAGGTTACCCCA-3') (SEQ ID NO: 22) (IDT), and 20 pmol antisense primer (5'- 20 GGCAAGTGATGCCCATGTCG-3') (SEQ ID NO: 23) (IDT). The PCR reaction mixture was then pre-denatured at 94° C. for 5 minutes, followed by 35 cycles of amplification, each cycle comprising 1) denaturation at 94° C. for 30 seconds, 2) annealing at 54° C. for 30 seconds, and 3) extension at 72° C. for 45 seconds. A final extension step at 72° C. for 10 minutes was performed.

Primer extension mixes were prepared using extension primers specific to alleles. In this particular assay, ATGGCTAG-GAAGGTGTCTGCGGGAGC (SEQ ID NO: 30 1) and CGCGATTG-GAAGGTGTCTGCGGGAGT (SEQ ID NO: 2) (IDT) were used and represented as Adapter-Primer with the former being the primer specific to Wild-Type allele ('C') and the latter being the primer specific to the Mutant-Type allele ('T') of the MTHFR gene. The 35 microarray contains sequences complimentary to the above adapters to detect the performance of individual primers.

To test the performance of individual photoactive molecules, 4 different primer extension mixes were used. Primer Extension Mix 1 (PEM1) comprised of 20 µL reaction 40 Example 7. dUTP is replaced by ddUTP in this molecule. volume with 2.5 units of Titanium Taq DNA polymerase, 50 μM each dNTP (dATP, dTTP, dGTP, dCTP) and 10 μM of PM1, 10×PCR Buffer with 1.5 mM MgCl₂ (Thermofisher Scientific), and 20 pmol primer extension mix containing primers for both wild-type (SEQ ID NO: 1) and mutant-type 45 (SEQ ID NO: 2) allele specific primers.

Primer Extension Mix 2 (PEM2) comprised of 20 uL reaction volume with 2.5 units of Titanium Taq DNA polymerase, $50 \mu M$ each dNTP (dATP, dTTP, dGTP, dCTP) and 10 µM of PM2, 10×PCR Buffer with 1.5 mM MgCl₂ 50 (Thermofisher Scientific), 20 pmol primer extension mix containing primers for both wild-type (SEQ ID NO: 1) and mutant-type (SEQ ID NO: 2) allele specific primers.

Primer Extension Mix 3 (PEM3) comprised of 20 µL reaction volume with 2.5 units of Titanium Taq DNA 55 polymerase, 50 µM each dNTP (dATP, dTTP, dGTP, dCTP) and 10 µM of PM3, 10×PCR Buffer with 1.5 mM MgCl₂ (Thermofisher Scientific), 20 pmol primer extension mix containing primers for both wild-type (SEQ ID NO: 1) and mutant-type (SEQ ID NO: 2) allele specific primers.

Primer Extension Mix 4 (PEM4) comprised of 20 μL reaction volume with 2.5 units of Titanium Taq DNA polymerase, 50 µM each dNTP (dATP, dTTP, dGTP, dCTP) and 10 µM of PM4, 10×PCR Buffer with 1.5 mM MgCl₂ (Thermofisher Scientific), 20 pmol primer extension mix 65 containing primers for both wild-type (SEQ ID NO: 1) and mutant-type (SEQ ID NO: 2) allele specific primers.

52

Primer Extension reaction was done by adding 20 nt of primer extension mix to the amplified reaction mix and performed 40 cycles of PCR, with a pre-denaturation at 94° C. for 5 minutes and each cycle comprising of denaturation at 94° C. for 30 seconds, annealing/extension at 54° C. for 30 seconds, were carried out, followed by a final postdenaturation at 94° C. for 5 minutes.

After the completion of primer extension reaction, 60 µl of hybridization buffer (1×PBS buffer with 1% fish gelatin and 0.1 mg/mL salmon sperm DNA) was added and the pillar plate was kept in a hybridization chamber at 45° C. for 2 hours. This was followed by 2 wash steps of PBS with the first wash being at 39° C. for 5 minutes followed by a wash at room temperature for 10 minutes. The chips were then rinsed with DI water and dried under a stream of nitrogen.

The chips were then exposed using 365 nm bulb stratalinker for 15 minutes and mixed with 30 µl of DI water. Lastly, the pH of the solution was read using an ISFET pH sensor (Sentron). The results obtained are shown in FIGS. 18, 19A, 19B, 19C and 19D.

Example 10: Synthesis of Photoactive Molecule 5 (PM5) (ddCTP-PAG1)

Photoactive molecule PM5 is synthesized as given in Example 5. dCTP is replaced by ddCTP in this molecule. The structure of PM5 is shown in FIG. 20.

Example 11: Synthesis of Photoactive Molecule 6 (PM6) (ddATP-PAG2)

Photoactive molecule PM6 is synthesized as given in Example 6. dATP is replaced by ddATP in this molecule. The structure of PM6 is shown in FIG. 21.

Example 12: Synthesis of Photoactive Molecule 7 (PM7) (ddUTP-PBG1)

Photoactive molecule PM7 is synthesized as given in The structure of PM7 is shown in FIG. 22.

Example 13: Synthesis of Photoactive Molecule 8 (PM8) (ddGTP-PBG2)

Photoactive molecule PM8 is synthesized as given in Example 8. dGTP is replaced by ddGTP in this molecule. The structure of PM8 is shown in FIG. 23.

> Example 14: Testing the Performance of Photoactive Molecules (HM 5-8)

Photoactive molecules were tested for their performance in Polymerase Chain Reactions (PCR) and specifically genotyping application on the methylenetetrahydrofolate reductase (MTHFR) and 9p21 gene. The nucleotide polymorphism 677 C>T (rs1801133) is located within the region coding for the catalytic domain of MTHFR and results in an amino acid substitution from an alanine to a valine at codon position 222 (exon 4). The polymorphism rs10757274 (A;G) is a SNP located in chromosomal region 9p21.

Genotyping of MTHFR and 9p21 regions, with the wellknown mutations, rs1801133 and rs10757274, were tested using 20 DNA samples. The DNA samples had a known genotyping result which were determined using Real-Time PCR. 34-mer length PNA-DNA chimera primer sequences 5'-CTGAAGCACTTGAAGGAGAAGGTGTCTGCGG

(GAG)-3' (SEQ ID NO: 16) for the rs1801133 mutation and CCCGTGGGTCAAATCTAAGC (TTG)-3' (SEQ ID NO: 24) for the rs10757274 mutation were synthesized according to the methods given above.

DNA were extracted from the samples (buccal swabs) 5 using methods known to one skilled in the art. A standard PCR reaction using forward and reverse primers was performed on the extracted DNA samples. Hybridization and polymerase extension on each of chips were performed as follows. The PCR product was mixed in 1×DNA Polymerase 10 Buffer (Clontech), 20 nmol of MgCl₂, 1 unit Titanium Taq DNA Polymerase (Clontech), and all 4 photoactive molecules (PM5, PM6, PM7, PM8) (each 20 pmoles). Hybridization is done in a hybridization chamber at 55° C. for 30 minutes followed by washing the chips in 0.1× Ssarc buffer 15 40° C. for 5 minutes twice followed by rinsing in DI Water. The chips were then exposed using 365 nm bulb strata-linker for 15 minutes and mixed with 30 µl of DI water. Lastly, the pH of the solution was read using an ISFET pH sensor (Sentron). The results obtained are shown in FIGS. 24A and 20

Example 15: Synthesis of Anti-p53 Bound to PBG1

3-bromo-2-iodo benzoic acid, sodium, 4-aminophenol, 25 dimethyl sulfoxide, then tris (2-(2-methoxyethoxy) ethyl) amine, copper chloride (CuCl), 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, Palladium(II) acetate (Pd(OAc) 2), Cesium carbonate (Cs2CO3), diethyl malonate, dioxane, Triazabicyclodecene, diisopropyl ether, and N-(3-Dimethyl- 30 aminopropyl)-N'-ethylcarbodiimide hydrochloride obtained from Sigma Aldrich.

Step 1: 3-bromo-2-iodo benzoic acid (8 mmol) was dissolved in a KOH solution (9.5 mmol). The mixture was condensed under vacuum at 100° C. and the resultant solid 35 was heated under vacuum at 100° C. for 12 h to yield a dried potassium salt. Metallic sodium (8.35 mmol) was dissolved in 100 mL of methanol, and 4-aminophenol (8.35 mmol) was added. The mixture was condensed and heated under vacuum at 100° C. for 12 h to yield a dried sodium salt. The 40 sodium salt was dissolved in 15 mL of anhydrous dimethyl sulfoxide, and then tris (2-(2-methoxyethoxy) ethyl)amine (TDA-1, 1.0 mL) was added. The mixture was stirred to reach homogeneity at room temperature under anhydrous conditions, and then CuCl (350 mg) and potassium salt 45 powders of the compound were added. The resultant mixture was stirred at 85° C. for 4 h, cooled down to room temperature, washed with a NaOH, filtered with diatomite, and acidified with 1 N HCl to pH value at 2-3. A semisolid precipitate was collected, washed with water, and dried to 50 diimide and 2 weight % for N-Hydroxysuccinimide (NHS) yield a crude product.

Step 2: The crude product from Step 1 (7.35 mmol) was added to a stirring sulfuric acid solution. The mixture was allowed to react for 30 min at 90° C., and then cooled down to room temperature, diluted with 200 mL of ice water, and 55 filtered. The resultant solid was washed with water, dried, and recrystallized from EtOAc/Methanol to yield a light yellow solid.

Step 3: The compound from Step 2 (7.25 mmol), 1, 3-bi-(2,6-diisopropylphenyl)imidazole chloride (Ipr. HCl 60 2% by mole), Pd(OAc)2 (2% by mole), Cs2CO3 (4.7 g, 14.5 mmol), diethyl malonate (1.16 g, 7.25 mmol), and 20 mL of dioxane were mixed. The mixture was allowed to react at 80° C. for 24 h, and then cooled down to room temperature, diluted with 100 mL of EtOAc, and filtered to yield a black 65 precipitate. The filtrate was condensed and recrystallized from EtOAc/MeOH to yield a light yellow solid.

54

Step 4: The compound from Step 3 (0.3 mol), 350 mL of methanol, and a NaOH solution (0.6 mol) were mixed. The mixture was heated, stirred at 40° C., hydrolyzed completely, acidified with acetic acid to yield a white precipitate, filtered, and dried to yield a crude product.

Step 5: Triphosgene (1 mmol) and triethylamine (10 mmol) were added at OC to a stirred solution of the adipic acid monoethyl ester (2 mmol) in dichloromethane (10 ml). Then N-hydroxysuccinimide (2 mmol) was added to the reaction mixture. The reaction mixture was stirred for 40 min at room temperature. After completion of the reaction, the reaction mixture was filtered by suction filtration. The product was formed by the removal of the filtrate by rotary evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate in hexane. The solution was mixed with Step 5 compound (3 mmol) in DMF (3 ml). The solution was stirred at room temperature overnight and evaporated in vacuum. The residue was dissolved in EtOAc, dried over Na2SO4, and evaporated under reduced pressure.

Step 6: 10 mmol of Triazabicyclodecene and 10 mmol of the compound obtained in Step 5 were dissolved into 20 mL of acetone, and stirred at room temperature for 30 minutes. After completion of the reaction, reaction solution was concentrated under reduced pressure, and the resulting residue was washed with diisopropyl ether, and then dried under reduced pressure.

Step 7: To a stirring solution of the ester from Step 6 (1) equivalent) and methanol (5 mL), KOH (2 molar equivalents) was added at 35 C. The reaction was allowed to continue for 1 hour and then quenched by addition of water (20 mL). The aqueous layer was acidified and the resulting acid was extracted from the aqueous layer by EtOAc.

Step 8: 2 mmol of the compound from Step 7 is mixed along with EDC (8 mmol) and N-hydroxysuccinimide (2 mmol) and the reaction mixture was stirred for 40 min at room temperature. The product was formed by the removal of the filtrate by rotary evaporation followed by short-path silica-gel column chromatography using 20% ethyl acetate

Step 9: The solution was mixed with Anti-p53 antibody (3 mmol) in water (3 ml). The reaction was carried out at room temperature overnight and purified using a spin column.

Example 16: Testing Detection of the Photoactive Molecule Anti-p53 Bound to PBG1

Wafers with COOH are prepared as described previously. 4 weight % for 1-ethyl-3-(3-dimethylaminopropyl) carbowere added in 94 weight % DI water as reagents to activate the COOH substrate. Wafer substrate is activated by spinning the wafer with this reagent wash solution and then washed away with water.

All Fmoc based amino acids required for p53 validation on the wafer are obtained from Anaspec. The amino acids obtained are Leucine (Leu), Lysine (Lys), Tryptophan (Trp), Aspartic Acid (Asp), Serine (Ser), Phenylalanine (Phe), Threonine (Thr), Glutamic acid (Glu), Glutamine (Gln), Arginine (Arg) and Histidine (His). Ethanolamine is obtained from Sigma Aldrich.

Validation of the wafer by p53 coupling is done by coupling 2 sequences—natural and mutated sequence for p53 antibody. The natural sequence grown is Leu-Lys-Trp-Leu-Asp-Ser-Phe-Thr-Glu-Gln (SEQ ID NO: 25) and mutated sequence grown is Leu-Lys-Trp-Leu-Arg-His-Phe-Thr-Glu-Gln (SEQ ID NO: 26).

Amino acid coupling is done as follows—A Photobase coupling solution containing a polymer, amino acid and photobase is spin coated onto a wafer at 3000 rpm and baked at 65 c for 1 min. in a hot plate. Now the wafer is exposed using a reticle at 80 mj/cm2. and then hard baked at 85 c for 50 sec in a hot plate. Fmoc is deprotected only in the region where it is exposed and the amino acid is coupled simultaneously.

1M Ethanolamine is used for capping the activated COOH which have not been coupled. This is done by spin coating a mixture of polymer+1M Ethanolamine+DI Water and baked at 65 C for 90 secs. Wafer is then stripped with Acetone and IPA and the same process is repeated for coupling the next layer of amino acid.

Natural sequence starts with coupling Leu and is completed by coupling Gln. This sequence is grown on the wafer using a specific mask. Another independent mask is used to grow the mutated sequence similarly. The wafer is diced into chips and bioassay is done to verify p53 sequence assay sensitivity comparing 2 methods of detection. The first 20 method is using fluorescence and the second method is using pH sensing.

Anti-p53 Antibody and Atto 488 Goat ani-mouse IgG are obtained from ABCAM. TBS Buffer, PBST Buffer and BSA are obtained from VWR. The bioassay process is done as 25 follows:

Fluorescence detection: The chip is washed with methanol for 5 mins followed by washing with TBS Buffer for 5 mins. Primary antibody containing PBST+1% BSA+Antip53 Antibody is incubation is done on the chip at 37 C for 30 1 hr. The chip is washed with PBST for 5 mins thrice. This is followed by secondary antibody incubation at 37 C for 1 hr. Secondary antibody contains PBST+1% BSA+Goat Anti-mouse IgG. The chip is washed with PBST for 5 mins thrice. This is followed by DI water washing for 5 mins 35 twice. The chips are dried and scanned under a 488 nm laser scanner.

pH detection: The chip is washed with methanol for 5 mins followed by washing with TBS Buffer for 5 mins. Primary antibody containing PBST+1% BSA+Anti-p53 40 Antibody photoactive molecule (PBG1-p53) is incubation is done on the chip at 37 C for 1 hr. The chip is washed with PBST for 5 mins thrice. This is followed by DI water washing for 5 mins twice. The chips were then dried and exposed using 365 nm bulb strata-linker for 15 minutes and 45 mixed with 30 ul of DI water and the pH of the solution was read using an ISFET pH sensor (Sentron).

The results are shown in Table 6 below:

TABLE 6

Results of ionic vs. fluorescent detection of antibody binding							
Det	ection Method:	Fluoresce	nce	Dete	ection Method:	Fluore	scence
ID	p53 Antibody	Signal	De- tected	ID	p53 Antibody	pН	De- tected
	On	Natural s	sequence	synt	hesized		
S1	1 ng/ml	65535	Y	S1	1 ng/ml	12.3	Y
S2	100 pg/ml	12478	Y	S2	100 pg/ml	11.2	Y
S3	10 pg/ml	2645	Y	S3	10 pg/ml	9.9	Y
S4	1 pg/ml	856	N	S4	1 pg/ml	8.4	Y
S5	0 pg/ml	800	N	S5	0 pg/ml	7.23	N
	On	Mutant s	equence	synt	hesized		
S1	1 ng/ml	756	N	S1	1 ng/ml	7.31	N
S2	100 pg/ml	745	N	S2	100 pg/ml	7.38	N
S3	10 pg/ml	700	N	S3	10 pg/ml	7.47	N

TABLE 6-continued

	Results of ionic v	s. fluores	scent de	tectic	n of antibody b	oinding	ζ
De	tection Method: 1	Fluoresce	nce	Dete	ection Method:	Fluore	scence
ID	p53 Antibody	Signal	De- tected	ID	p53 Antibody	рН	De- tected
S4 S5	1 pg/ml 0 pg/ml	536 275	N N	S4 S5	1 pg/ml 0 pg/ml		N N

The results indicate that the photoactive molecules concept can be incorporated into protein/antibody detection and has a higher sensitivity of <1 pg/ml compared to 10 pg/ml (for fluorescence detection). This may be attributed to that the fact the fluorescence detection includes excitation which leads to higher noise compared to pH sensing. The pH sensing model can be utilized for protein and antibody detection assays.

Example 17: Sequencing

Photoactive sequencing molecules PM 9 (NPPOC-3'-dCTP-PAG1), PM10 (NPPOC-3'-dATP-PAG2), PM11 (NPPOC-3'-dUTP-PBG1) and PM 12 (NPPOC-3'-dGTP-PBG2) are synthesized as given in Examples 5, 6, 7 and 8 by replacing the dNTP's with 3'-NPPOC blocked nucleotides. The NPPOC blocking protects the nucleotide extension until the group is removed (i.e., is a removable blocker). Photoactive sequencing molecules PM9-PM12 are tested for their performance of sequencing on the methylenetetrahydrofolate reductase (MTHFR) gene.

A PNA-DNA chimera sequence 5'-ATGCACCGA-CATGGGC-3' (SEQ ID NO: 18) is synthesized on a Silicon wafer with ISFET wells according to the methods previously described. Genomic DNA samples are obtained in-house from the Vibrant Genomics Labs and sequenced using a commercial synthesizer to determine the sequence of the region of interest. The sequence to be synthesized is 5'-ATGCACCGACATGGGC ATCACTTG-3' (SEQ ID NO: 19), with the sequencing by synthesis component in bold.

A standard PCR reaction using forward and reverse primers is performed on the extracted DNA samples to amplify the MTHFR gene. Hybridization of the amplification product to the PNA-DNA probes and polymerase extension for sequencing by synthesis is performed. The PCR product is mixed in 1×DNA Polymerase Buffer (Clontech), 20 nmol of MgCl₂, 1 unit Titanium Taq DNA Polymerase (Clontech), and all 4 photoactive molecules (PM9, PM10, PM11, PM12) (each 20 pmoles).

Hybridization is done in a hybridization chamber at 55° C. for 30 minutes followed by washing the chips in $0.1\times$ Ssarc buffer 40° C. for 5 minutes twice followed by rinsing in DI Water.

The chips are then exposed using 365 nm bulb stratalinker for 15 minutes and mixed with 30 μ l of DI water. The pH of the solution is read using an ISFET pH sensor (Sentron).

The exposure to 365 nm light also simultaneously unblocks the NPPOC protection on the 3' end to enable continuation of the polymerization reaction and sequencing by synthesis. This hybridization and extension cycle are repeated multiple times to generate and detect the sequence of the region of interest. The results anticipated are shown in Table 7:

57 TABLE 7

	TT	TI Decide								
Cycle	pH Reading	PM Call	Detected nucleotide							
Cycle 1	3.84	PM10	A							
Cycle 2	11.2	PM11	T							
Cycle 3	2.68	PM9	C							
Cycle 4	3.98	PM10	A							
Cycle 5	2.66	PM9	C							
Cycle 6	11.02	PM11	T							
Cycle 7	11.1	PM11	T							
Cycle 8	10.15	PM12	G							

As shown, the detected nucleotide sequence will be 15'-ATCACTTG-3' (SEQ ID NO: 20), corresponding with the amplification product from the MTHFR amplicon sequence 5'-CAAGTGAT-3' (SEQ ID NO: 21)

Thus, the photoactive sequencing molecules described herein can be utilized to determine the sequence of a 20 polynucleotide using reversible terminator and a photoactive compound attached to the mononucleotides.

58 OTHER EMBODIMENTS

It is to be understood that the words which have been used are words of description rather than limitation, and that 5 changes may be made within the purview of the appended claims without departing from the true scope and spirit of the invention in its broader aspects.

While the present invention has been described at some length and with some particularity with respect to the several described embodiments, it is not intended that it should be limited to any such particulars or embodiments or any particular embodiment, but it is to be construed with references to the appended claims so as to provide the broadest possible interpretation of such claims in view of the prior art and, therefore, to effectively encompass the intended scope of the invention.

All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, section headings, the materials, methods, and examples are illustrative only and not intended to be limiting.

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 29
<210> SEQ ID NO 1
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     primer
<400> SEQUENCE: 1
                                                                        26
atggctagga aggtgtctgc gggagc
<210> SEQ ID NO 2
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer
<400> SEQUENCE: 2
cgcgattgga aggtgtctgc gggagt
                                                                        2.6
<210> SEQ ID NO 3
<400> SEOUENCE: 3
000
<210> SEQ ID NO 4
<400> SEQUENCE: 4
000
<210> SEQ ID NO 5
<400> SEQUENCE: 5
<210> SEQ ID NO 6
```

```
<400> SEQUENCE: 6
000
<210> SEQ ID NO 7
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1) .. (31)
<223 > OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 7
gtggaaattt gacatagtct cagatgccta ttat
<210> SEQ ID NO 8
<211> LENGTH: 35
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<400> SEOUENCE: 8
                                                                       35
aataataggc atctgagact atgtcaaatt tccac
<210> SEQ ID NO 9
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<400> SEQUENCE: 9
cataataggc atctgagact atgtcaaatt tccac
                                                                       35
<210> SEQ ID NO 10
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<400> SEQUENCE: 10
                                                                       35
gataataggc atctgagact atgtcaaatt tccac
<210> SEQ ID NO 11
<211> LENGTH: 35
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<400> SEQUENCE: 11
tataataggc atctgagact atgtcaaatt tccac
                                                                       35
<210> SEQ ID NO 12
<211> LENGTH: 41
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
```

```
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(41)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 12
ggagaaggtg tctgcgggag ccgatttcat catcacgcag c
                                                                       41
<210> SEQ ID NO 13
<211> LENGTH: 41
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1) .. (41)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 13
ggagaaggtg tctgcgggag tcgatttcat catcacgcag c
                                                                       41
<210> SEO ID NO 14
<211> LENGTH: 41
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(41)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEOUENCE: 14
ggaggagctg accagtgaag aaagtgtctt tgaagtcttc g
                                                                       41
<210> SEQ ID NO 15
<211> LENGTH: 41
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(41)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 15
ggaggagetg accagtgaag caagtgtett tgaagtette g
                                                                       41
<210> SEQ ID NO 16
<211> LENGTH: 34
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(31)
<223 > OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 16
                                                                       34
ctgaagcact tgaaggagaa ggtgtctgcg ggag
```

```
<210> SEQ ID NO 17
<211> LENGTH: 34
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(31)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 17
ctgaagatgt ggggggagga gctgaccagt gaag
                                                                       34
<210> SEQ ID NO 18
<211> LENGTH: 16
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(16)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 18
                                                                       16
atgcaccgac atgggc
<210> SEQ ID NO 19
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(24)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 19
atgcaccgac atgggcatca cttg
                                                                       24
<210> SEQ ID NO 20
<211> LENGTH: 8
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<400> SEQUENCE: 20
atcacttg
<210> SEQ ID NO 21
<211> LENGTH: 8
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
<400> SEQUENCE: 21
caagtgat
                                                                        8
```

```
<210> SEQ ID NO 22
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 22
cctattggca ggttacccca
                                                                       20
<210> SEQ ID NO 23
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 23
                                                                       20
ggcaagtgat gcccatgtcg
<210> SEQ ID NO 24
<211> LENGTH: 33
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer <220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(30)
<223> OTHER INFORMATION: Peptide nucleic acid
<400> SEQUENCE: 24
ctccccgtg ggtcaaatct aagctgagtg ttg
                                                                       33
<210> SEQ ID NO 25
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      peptide
<400> SEQUENCE: 25
Leu Lys Trp Leu Asp Ser Phe Thr Glu Gln
<210> SEQ ID NO 26
<211> LENGTH: 10
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
<400> SEQUENCE: 26
Leu Lys Trp Leu Arg His Phe Thr Glu Gln
<210> SEQ ID NO 27
<211> LENGTH: 13
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide
```

-continued

<400> SEOUENCE: 27 taggggtagc gta 13 <210> SEQ ID NO 28 <211> LENGTH: 10 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide <400> SEQUENCE: 28 atacgattac 10 <210> SEQ ID NO 29 <211> LENGTH: 13 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide <400> SEOUENCE: 29 13 taggtaatcg tat

What is claimed is:

1. A polynucleotide comprising a nucleotide bound to a 30 active group comprises an onium salt. photoactive group, wherein said photoactive group comprises a photoacid generator or a photobase generator.

67

- 2. The polynucleotide of claim 1, wherein said photobase generator produces an organic compound having a pKA of 9 or higher, 10 or higher, 11 or higher, 12 or higher, 13 or 35 higher, or 14 or higher upon exposure to an activating radiation.
- 3. The polynucleotide of claim 1, wherein said photoacid generator produces an organic compound having a pKA of 5 or lower, 4 or lower, 3 or lower, 2 or lower, or 1 or lower ⁴⁰ upon exposure to an activating radiation.
- 4. The polynucleotide of claim 1, wherein said photoacid generator is selected from the group consisting of: an o-acyloxime, a benzoyloxycarbonyl derivative, a photoactive carbamates, an oxime ester compounds, an ammonium compound, a benzoin compound, a dimethoxybenzyl urethane compound, an orthonitrobenzyl urethane compound, an aromatic sulfonamide, an alpha-lactams, and an N-(2arylethenyl) amide.
- 5. The polynucleotide of claim 1, wherein said photobase generator is selected from the group consisting of: a 2-hydroxy-2-phenylacetophenone N-cyclohexyl carbamate, an o-nitrobenzyl N-cyclohexyl carbamate, an N-cyclohexyl-2naphthalene sulfonamide, a 3,5-dimethoxybenzyl N-cyclo- 55 hexyl carbamate, an N-cyclohexyl p-toluene sulfonamide; and a dibenzoin isophorone dicarbamate.
- 6. The polynucleotide of claim 1, wherein said photoactive group is photocleavable.
- 7. The polynucleotide of claim 6, wherein said photoactive group is cleaved via homolytic cleavage.
- 8. The polynucleotide of claim 1, wherein said photoactive group initiates a downstream reaction upon exposure to an activating radiation.
- 9. The polynucleotide of claim 1, wherein said photoactive group comprises an ionic organic salt.

10. The polynucleotide of claim 1, wherein said photo-

68

- 11. The polynucleotide of claim 1, wherein said photoactive group is bound to a nucleobase of said nucleotide.
- 12. The polynucleotide of claim 1, wherein said photoactive group is bound to a 2' or 5' carbon of said nucleotide.
- 13. The polynucleotide of claim 1, wherein said nucleotide is bound to a removable blocking group.
- 14. The polynucleotide of claim 13, wherein said removable blocking group is a reversible terminator.
- 15. A polynucleotide comprising a nucleotide bound to a photoactive group, wherein said nucleotide is according to Formula I:

I

wherein

n is from 0-3;

X is selected from the group consisting of: H, OPg, and a photoactive group, where Pg is a protecting group;

A is NH when

and A is N when

E is O when

and E is NHZ when

and each Z is independently selected from the group consisting of: H, Me, and a photoactive group; and

wherein at least one of said Z or X is said photoactive group.

16. A polynucleotide comprising a nucleotide bound to a photoactive group, wherein said nucleotide is according to 50 Formula II:

$$Z \longrightarrow [O_3P]_n \longrightarrow O \longrightarrow X$$

$$O \longrightarrow X$$

$$O \longrightarrow X$$

$$PO_2I_n \longrightarrow Z$$

wherein

n is from 0-3;

X is selected from the group consisting of: H, OPg, and a photoactive group, where Pg is a protecting group; A is NH when

10

15

5

and A is N when

25

30

E is O when

35

40

and E is NHZ when

and

60

Π 55

> each Z is independently selected from the group consisting of: H, Me, and a photoactive group; and

wherein at least one of said Z or X is said photoactive group.

17. A polynucleotide comprising a nucleotide bound to a photoactive group, wherein said nucleotide is selected from the group consisting of:

-continued

18. The polynucleotide of claim 17, wherein said modified nucleotide is bound to a removable blocking group.

19. The polynucleotide of claim 18, wherein said removable blocking group is a reversible terminator.

20. A polynucleotide comprising a nucleotide bound to a 50 photoactive group, wherein said photoactive group comprises an ionic organic salt.

21. A polynucleotide comprising a nucleotide bound to a photoactive group, wherein said photoactive group comprises an onium salt.

22. A polynucleotide comprising a nucleotide bound to a photoactive group, wherein said photoactive group is bound to a 2' or 5' carbon of said polynucleotide or said single nucleotide.

23. An array comprising a plurality of polynucleotides 60 immobilized to the surface of the array, wherein at least one polynucleotide comprises a nucleotide bound to a photoactive group.

24. The array of claim 23, wherein said photoactive group comprises a photoacid generator or a photobase generator. 65

25. The array of claim 23, wherein said nucleotide is according to Formula I:

-[O₃P]_n- $[PO_3]_n$ —Z Ι

wherein

n is from 0-3;

X is selected from the group consisting of: H, OPg, and a photoactive group, where Pg is a protecting group;

10

15

25

30

35

40

A is NH when

and A is N when

E is O when

and E is NHZ when

and

each Z is independently selected from the group consisting of: H, Me, and a photoactive group; and wherein at least one of said Z or X is said photoactive

26. The array of claim 23, wherein said nucleotide is 50 according to Formula II:

$$Z \longrightarrow [O_3P]_n \longrightarrow O \longrightarrow N \longrightarrow N$$

$$V \longrightarrow N$$

$$[PO_3]_n \longrightarrow Z$$

wherein

n is from 0-3;

X is selected from the group consisting of: H, OPg, and a photoactive group, where Pg is a protecting group; A is NH when

20 and A is N when

E is O when

and E is NHZ when

60 and

65

II 55

each Z is independently selected from the group consisting of: H, Me, and a photoactive group; and wherein at least one of said Z or X is said photoactive group.

27. The array of claim 23, wherein said nucleotide is selected from the group consisting of:

28. The array of claim 27, wherein said modified nucleotide is bound to a removable blocking group.
29. The array of claim 28, wherein said removable blocking group is a reversible terminator.